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During the past decades, molecular imaging of infectious processes has 
enormously contributed to new insights in clinical practice, for diagnostic 
purpose as well as for prognostic loading and treatment decision making. 
Such strengthening relies on the ability of molecular imaging to pinpoint 
singular phase of disease onset besides the pure morphological anomalies, 
generally depicted by the majority of radiological imaging procedures. In 
fact, morphologic techniques (i.e. computed tomography, CT and 
ultrasonography, US) are extremely useful for treatment management once 
macroscopic changes are present. However, they may suffer from limitations 
in the early phase of infectious processes, when indistinctive sings of disease 
are manifested and when foreign bodies, implants, prosthesis are present. 
 
Cardiac infections  
 
Cardiac infections can occur in different tissues like the heart muscle, the 
pericardium or the endocardial surface of the heart. Infections can extend to 
prosthetic material or the electrocatether (leads) in case of the implantation of 
devices. Despite their relative low incidence, these infections, that are 
associated with high morbidity and mortality, involve a relevant burden of 
diagnostic workup. Moreover, the number of patients with suspected cardiac 
infections is progressively rising because of the increased use of prosthetic 
valve and cardiovascular electronic device implants. Early diagnosis is 
crucial for adequate patient treatment management, as early treatment 
improves the prognosis. Unfortunately, the clinical manifestations are often 
nonspecific. 
 Accurate diagnosis typically requires the correlation of imaging data 
with laboratory data. Echocardiography is always performed as a first line 
test, primarily to evaluate heart structures, wall thickness, wall motion, and 
cardiac function. Computed tomography (CT) and magnetic resonance 
imaging (MRI) are also being increasingly employed because of their 
possibility for tissue characterization. 
 Positron emission tomography with fluorine-18-fluorodeoxyglucose 
([18F]FDG PET) is a well-established imaging modality for the diagnosis and 
management of malignancies1, and evidence is also increasing regarding its 
value for assessing infectious and inflammatory diseases2. This introduction 
summarizes published evidence on the usefulness of [18F]FDG PET and 
radiolbelled leukocytes for the diagnosis of cardiac infections and vascular 
graft infections. Since the majority of such reports deal with endocarditis and 
cardiovascular device infections, these two conditions constitute the main 
5 
 
topic of this introduction. Nevertheless, the diagnostic potential of [18F]FDG 
PET in patients with pericarditis and myocarditis is also briefly reviewed, 
considering the most likely future advances and new perspectives that the use 




Infective endocarditis (IE) is an infection of the endocardial surface of the 
heart that can involve prosthetic material in case of valve replacements3. The 
incidence of IE is approximately 2-4 cases per 100,000 persons per year4. 
Although this overall value has not changed in the past 50 years, it is 
increasing in elderly subjects. At present, 25%-50% of the cases occur in 
patients older than 60 years5. An age-related pattern that implies several 
diagnostic and therapeutic challenges. Additionally, the clinical patterns of IE 
have changed significantly since the 1960s6. In particular, the increasing 
diffusion in the population of substance addiction (with intravenous self-
administration), growing and wider applications of invasive vascular 
procedures and massive use of antibiotics have multiplied the cases of IE 
linked to intravenous drug abuse7, prosthetic valve endocarditis8, and 
nosocomial IE9. The underlying valvular pathology in IE has also changed 
from rheumatic disease (that was predominant until about 30 years ago) to 
calcific aortic stenosis (now accounting for 50% of the cases in elderly 
patients)10. On the other hand, mitral valve prolapse is currently the most 
common predisposing condition for native valve endocarditis in young 
patients (about 30% of the cases)11. Less commonly, IE arises from artero-
venous fistulas used for hemodialysis12, central venous and pulmonary artery 
catheters, peritoneal-venous shunts for ascites, and ventriculo-atrial shunts 
for hydrocephalus, or as a complication of liver, heart, and heart-lung 
transplants13. IE may present itself as an acute, rapidly progressive infection, 
or else as a sub-acute or chronic disease with low grade fever and non-
specific symptoms which may prevent or confound initial assessment. 
Therefore, patients may be referred to a variety of specialists who may 
consider a range of alternative diagnoses.  
The diagnosis of IE is essentially clinical14 and should be suspected in 
all patients presenting with fever of unknown origin, particularly when fever 
(up to 90% of the cases) is associated with laboratory signs of infection, 
anemia, and microscopic haematuria, and when septic embolic manifestations 
are present (brain, lung or spleen, in about 30% of the cases)15,16. The main 
cardiac signs include heart murmur (up to 85% of the cases) and progressive 
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heart failure. Systemic signs, typically represented by spleen enlargement, 
glomerulonephritis, and peripheral stigmata, occur when IE remains 
undiagnosed for a long period. Vascular and immunological phenomena such 
as splinter haemorrhages and Roth spots are common. However, atypical 
symptoms may occur in elderly or immunocompromised patients17. 
Microbiological tests for germ characterization along with positive 
echocardiographic findings are necessary to establish a diagnosis according 
to the modified Dukes criteria18,19  (Table 1.1). Overall sensitivity of the 
Duke criteria is 80%20. However, in several instances blood culture and/or 
echocardiography are inconclusive, thus leading to a high proportion of 
unconfirmed cases of suspected IE. Indeed, up to 24% of the patients with 
pathologically proven endocarditis can be misclassified as "possible" IE 
based on Duke criteria alone20. The main reasons for the relatively low 
diagnostic accuracy of the Duke criteria are represented by either a negative 
blood culture or the failure to demonstrate vegetation at echocardiography. 
Negative blood cultures occur in 2.5-31% of IE patients, more 
commonly because of prior antibiotic administration21,22. Sub-acute right side 
endocarditis and mural endocarditis23, slow-growing and fastidious 
organisms as Coxiella burnetii, Brucella spp., Abiotrophia spp., HACEK 
group endocarditis, Listeria monocytogenes and fungi accounts for other 
causes of culture-negative endocarditis. A negative blood culture results in 
delayed diagnosis and therefore negatively impacts on treatment outcome22. 
Both transthoracic echocardiography (TTE) and transoesophageal 
echocardiography (TEE) may be used for detecting vegetations, with 
sensitivities ranging 40-63% and 90-100%, respectively. Three 
echocardiographic findings are major criteria in the diagnosis of IE: 
vegetation, abscess, and new dehiscence of a prosthetic valve. A negative 
TEE has a very high negative-predictive value for IE (86-97%)24. However, 
identification of vegetations may be difficult in the presence of pre-existing 
severe anatomic changes, especially in the early phases when vegetations are 
very small. Furthermore, several conditions may mimic vegetations, as 
occurs in degenerative valve disease, rheumatic disorders, valvular thrombus, 
chordal rupture, and with small intracardiac tumors3. Besides representing a 
crucial diagnostic aid for IE, echocardiography parameters are also useful for 
predicting the potential embolic burden, even though CT and MRI are 







Table 1.1: modifies Duke criteria18,19. 
Major criteria: 
A) Positive blood culture with typical IE microorganism, defined as one of the 
following: 
 Typical microorganism consistent with IE from 2 separate blood cultures, as noted 
below: 
• Viridans-group streptococci, or 
• S. bovis including nutritional variant strains, or 
• HACEK group, or 
• S. aureus, or 
• Community-acquired enterococci, in the absence of a primary focus 
     Microorganisms consistent with IE from persistently positive blood cultures 
defined as: 
• Two positive cultures of blood samples drawn >12 hours apart, or 
• All of 3 or a majority of 4 separate cultures of blood (with first and last 
sample drawn 1 hour apart) 
• Coxiella burnetii detected by at least one positive blood culture or 
antiphase I IgG antibody titer >1:800 
2. Evidence of endocardial involvement  
Echocardiographic findings positive for IE (TEE recommended in patients with 
prosthetic valves, rated at least possible IE by clinical criteria or complicated IE 
[paravalvular abscess]; TTE as first test in other patients), defined as follows: 
 Oscillating intracardiac mass on valve or supporting structures, in the path 
of regurgitant jets, or on implanted material in the absence of an alternative 
anatomic explanation, or 
 Abscess, or 
 New partial dehiscence of prosthetic valve or new valvular regurgitation 
(worsening or changing of pre-existing murmur not sufficient) 
Minor criteria: 
 Predisposition, predisposing heart condition, or intravenous drug use 
 Fever, temperature >38°C 
 Vascular phenomena, major arterial emboli, septic pulmonary infarcts, mycotic 
aneurysm, intracranial hemorrhage, conjunctival hemorrhages, and Janeway lesions  
 Immunologic phenomena: glomerulonephritis, Osler nodes, Roth spots, and 
rheumatoid factor 
 Positive blood culture (that doesn't meet a major criterion) or serologic evidence of 
infection with organism consistent with IE but not satisfying major criterion 
 Positive echocardiogram (that doesn't meet a major criterion)* 
 
Although attempts have been made to improve the diagnostic 
performance of the Duke criteria by proposing several additional clinical and 
microbiological parameters18, molecular imaging techniques (i.e., 
radionuclide imaging) could in principle be useful to integrate such 
traditional diagnostic criteria. Therefore, molecular imaging techniques might 
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fill uncertain gaps with information on the biochemical burden of the 
endocardial vegetations. However, during the last decades the use of 
radionuclide imaging for IE has been rather limited in daily clinical routine, 
because of the general perception of their relatively low diagnostic value. The 
introduction of hybrid equipment for both conventional nuclear medicine 
(e.g., SPECT/CT) and PET (e.g., PET/CT) has notably changed this scenario. 
In fact, thanks to a technology that allows the three-dimensional 
reconstruction of small regions of interest and precise localization of the 
site(s) of abnormal radiopharmaceutical accumulation, evidence is growing 
that SPECT and PET, performed with suitable infection imaging agents and 
co-registered with CT, improve the diagnosis of IE. SPECT/CT imaging 
relies on the use of autologous radiolabeled leukocytes that accumulate in a 
time-dependent fashion at the site of infection (difference between delayed 
images acquired at 3 hrs versus late image acquired at 20-24 hrs)26. PET/CT 
is generally performed using a single acquisition time-point (generally at 1 
hour) after administration of [18F]FDG, which is actively incorporated by 
activated leukocytes27, monocyte-macrophages28, and CD4+ T-lymphocytes29  
present at the site of infection. Less common PET/CT applications involve 
the use of autologous leukocytes labeled by in-vitro incubation with 
[18F]FDG, a more cumbersome procedure that is still in the phase of clinical 
validation30. 
The majority of the reports available in literature are based on the use 
of suboptimal radiopharmaceuticals for imaging infection (mostly [67Ga]-
citrate and 99mTc-labeled anti-granulocyte antibodies and just more recently 
[18F]FDG), combined with planar and/or stand-alone SPECT acquisitions. 
Scintigraphy with [67Ga]-citrate and 111In-labeled leukocytes has been used 
mainly for the detection of myocardial abscess31-34. Scintigraphy with99mTc-
labeled anti-granulocyte monoclonal antibodies, alone or associated with 
echocardiography is the technique with the highest accuracy for the detection 
of IE (100% sensitivity, 86% specificity, 92.2% overall accuracy, 89% 
positive predictive value) 35,36. However, these data have been produced 
before the introduction of SPECT/CT and PET/CT equipment, therefore 
limiting the correct evaluation of the heart region. Leukocyte scintigraphy 
can detect IE of native (Figure 1.1) and prosthetic valve infection origin 
(Figure 1.2). In the latter circumstance, both the attenuation-corrected images 
and the non-corrected CT images should be always inspected side by side, to 
minimize metal-related artefacts. It is reasonable to expect that, similarly as 
demonstrated for other infectious conditions37,38, the use of suitable infection-
specific agents and hybrid SPECT/CT or PET/CT equipment would 
9 
 
strengthen the diagnostic performance of molecular imaging of IE. In fact, 
SPECT/CT with 99mTc-HMPAO-WBC can accurately diagnose cardiac and 
additional unsuspected extra-cardiac sites of infection in up to 30% of IE 
patients and 23% of patients with CIED-related sepsis39, with limitations to 
be considered in case of small central nervous system embolism. Similarly, 
the use of 99mTc-HMPAO-WBC images allows to detect perivalvular abscess 
with 100% positive predictive value,  impacting on patients management in 
29% of patients40. Furthermore, whole-body images followed by additional 
planar imaging and SPECT/CT may allow to identify distant sites of septic 
embolism. Figure 1.3 represent some examples of the use of radiolabelled 
white blood cell (WBC) scans to detect septic embolisms. Table 1.2 
summarized all the studies with [67Ga]-citrate and 111In-labeled leukocytes 
and 99mTc-HMPAO-WBCs in patients with IE.  
Most of the published evidence concerning the use of [18F]FDG 
PET/CT in patients with suspected IE is represented by case reports or small 
series reports. The main findings of such reports are summarized in Table 
1.3. In particular, [18F]FDG PET/CT has been used to confirm the presence 
of IE involving either native valves IE (9 patients) or prosthetic valves IE (18 
patients). Suspicion of IE was based on clinical signs, laboratory tests and 
positive blood culture/serology (n=24), while echocardiography was negative 
or inconclusive in 17/24 cases (6/9 native valves and 11/18 prosthetic valve). 
In the remaining 3 patients negative blood culture was associated with either 
a negative echocardiography (n=2) or with the echocardiographic finding of 
paravalvular leak (n=1). Of interest, after a positive PET/CT a repeat 
echocardiography detected vegetations in 3 patients. [18F]FDG PET/CT 
confirmed the presence of IE in 8/9 patients with native valve infection and 
in 16/18 patients with prosthetic valve. In two patients with complex 
prosthesis of the aortic valve, the aortic root and the ascending aorta 
(Bentall's procedure), IE was excluded by [18F]FDG PET/CT, that localized 
infection at the aortic portion of the graft. Out of the 27 [18F]FDG PET/CT 
scans, one was false negative, in a patient with native valve IE sustained by 







Figure 1.1 - Example of radiolabelled leukocyte scintigraphy in a patient with native valve 
endocarditis (coronal images at upper panel and transaxial images at lower panel, SPECT at 







Figure 1.2 - Example of radiolabelled leukocyte scintigraphy in a patient with prosthetic 
mitral valve endocarditis (From left to right: transaxial SPECT, transaxial CT, SPECT/CT 
and transaxial non attenuated corrected SPECT images). The CT uncorrected CT image 







Figure 1.3 - Examples of the use of radiolabelled WBC scans to detect septic embolisms and 
metastatic sites of infection in patients with endocarditis. Lung embolisms (A), spleen 
embolisms (B), cholecystitis (C)  as well as vertebral (D) embolisms were detected.. (left 
column SPECT images and right column SPECT/CT images).  Images demonstrate the focal 
area of uptake at left upper lung lobe (A, and at cholecystis (C) while for spleen and 
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Table 1.3: Published evidence concerning the use of[18F]FDGPET/CT in patients with suspected infective endocarditis 
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Med Mol Imaging 
2008191 
47 y, F Fever >40°C + 
chills (6 d) 
Aortic  Staphylococcus aureus Valve + base of 
ascending aorta/ 
aortic wall/graft + 
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Negative Vind SH et al. J Nucl 
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56 y, M Fever, chills, night 
sweats (3 w) 
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Taken altogether, these data support the use of [18F]FDG PET/CT in 
association with echocardiography, to confirm or rule out IE in equivocal 
and/or difficult-to-explore situations, such as those due to artifacts caused by 
mechanical prosthesis or catheters. However, it should be noted that all the 
cases that have been reported so far investigated with [18F]FDG PET/CT 
represent patients with a high pre-test probability of IE. Therefore, the false 
positive rate of [18F]FDG PET/CT can be underestimated. In fact, some 
drawbacks in the use of [18F]FDG for the diagnosis of IE should be 
considered when interpreting the scan, avoiding false-positive findings in 
PET studies. Variable focal of diffuse physiologic [18F]FDG uptake is often 
observed in the normal myocardium of fasting nondiabetic patients (6-12 
hours to overnight) with normal glucose levels41. Accumulation of [18F]FDG 
is most notable in the left ventricular myocardium, which has a greater 
muscle mass than other cardiac chambers. Uptake in the wall of the right 
ventricle is typically equal to or less intense than that in the left ventricular 
myocardium; uptake in the wall of the right and left atria is usually not 
detected. Factors possibly influencing myocardial uptake of [18F]FDG 
include blood glucose levels, and a low-carbohydrate diet. In particular, 
while age and fasting time do not affect [18F]FDG uptake in the myocardium, 
blood glucose levels may have a nonlinear effect on myocardial uptake42. A 
low-carbohydrate diet43 and a very high-fat, low-carbohydrate, protein-
permitted meal followed by fasting for 3-6 hours44 before [18F]FDG injection 
might be adopted to decrease myocardial uptake. However, no specific 
protocol has yet been standardized and/or recommended to reduce the 
nonspecific myocardial uptake when assessing cardiac infection with 
[18F]FDG PET/CT. Another potential confounding factor for [18F]FDG 
PET/CT is represented by increased metabolic activity along the posterior 
aspect of the heart, where lipomatous hypertrophy of the interatrial septum 
may appear as a fat-containing mass with increased [18F]FDG uptake45. 
Furthermore, a number of pathological conditions can mimic the pattern of 
focally increased [18F]FDG uptake that is typically observed in IE, such as 
active thrombi41, soft atherosclerotic plaques46, vasculitis47, primary cardiac 
tumors48, cardiac metastasis from a non-cardiac tumor49, post-surgical 
inflammation50 and foreign body reactions (such as BioGlue, a surgical 
adhesive used to repair the aortic root) 51. Indeed, high specificity for IE using 
[18F]FDG can be achieved only by adopting accurate patient selection and 
inclusion criteria. On the contrary, the use of [18F]FDG PET/CT in patients 
with lower pre-test probability will rely on the high negative predictive value 
of this imaging procedure. Figure 1.4 shows examples of positive [18F]FDG 
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PET/CT scans in patients with IE. Figure1.5 shows an example of the use of 
[18F]FDG PET/CT to exclude the presence of IE in a patient with doubtful 




Figure 1.4: Examples of [18F]FDG uptake in patients with IE. A) Biological aortic prosthesis 
with linear focal uptake in the anteromedial portion. B) Mechanical aortic prosthesis with 
predominant uptake at the posterior and medial region of the aortic valve. C) Mechanical 
aortic prosthesis with predominant uptake at the posterior region of the valve. D) Mechanical 
aortic prosthesis with perivalvular abscess. E) Mechanical mitral valve IE with prevalent 
uptake at the posterolateral region of the valve.  
Left column: SPECT emission transaxial images, middle column: CT transaxial images, right 






Figure 1.5: [18F]FDG PET/CT excluding the presence of IE in a patient with fever and a 
doubtful echocardiographic positive finding. Images (left column: SPECT emission 
transaxial images, middle column: CT transaxial images, right column: transaxial 
superimposed PET/CT images) show absence of significant uptake at the region of the mitral 
mechanical valve. Transaxial images of the thorax at different levels (upper panel with 
mediastinal window, middle and lower panel using lung parenchyma window) show multiple 
sites of [18F]FDG uptake in both lungs, appearing to show the site of infection (pneumonia 













An additional advantage of [18F]FDG PET/CT imaging is its ability to 
reveal the concomitant presence of extra-cardiac infection sites as the 
consequence of septic embolisms, resulting from "metastatic" infections 
which originate from IE. According to literature reports, such embolisms 
were detected in a total of 11/27 patients evaluated for suspected IE. The sites 
of septic embolism were mainly localized at the lungs, bones, and spleen. 
Similarly, in a prospective study carried out in patients with definite IE, 
according to the modified Duke criteria prior to surgery, [18F]FDG PET/CT 
was able to detect at least one focus of peripheral embolization and/or 
metastatic infection in 11/24 patients (44%)52. These complications were 
detected even in patients without prior clinical suspicion and in patients 
without the typical echocardiographic findings considered as predictors of 
systemic embolism53. This unique whole-body exploring ability of PET/CT 
to detect multiple sites of disease with a single examination, can guide 
treatment management considering the optimal time window for surgical 
intervention. A limitation to the use of [18F]FDG PET/CT is localization of 
septic embolisms in the brain, due to the high physiological uptake of this 
tracer in the brain cortex and to the fact that metastatic infections are 
generally smaller than 5 mm, which is the spatial resolution threshold of the 
current PET/CT scanner. Figure 1.6 show examples of septic embolism and 
metastatic infections in patients with IE detected by [18F]FDG PET/CT. 
Finally, an additional promising role of [18F]FDG PET/CT considers 
patients with established IE, in whom it can be used to monitor response to 
antimicrobial treatment. In fact, considering the difficulties in the choice of 
the proper type, dose and duration of antimicrobial treatment, the possibility 
to distinguish patients who respond favorably to treatment from those who 
require intensified administration or alternative treatment options with 
PET/CT imaging is extremely attractive. Figure 1.7 shows an example of the 
use of [18F]FDG PET/CT to monitor response to antimicrobial treatment in a 
patient with IE.  
The possibility of efficient radiolabelling of autologous leukocytes 
with positron emitting radionuclides can be expected to change the whole 
scenario of PET imaging for patients with suspected IE. In this regard, 
intense [18F]FDG-WBC uptake at the site of valve infection has been 
described only for one patient with IE, reported up to now54. Unfortunately, 
the physical half-life of 18F is too short to encompass the whole kinetics of 
leukocyte migration into sites of infection, thus making the use of this 
procedure suboptimal for this purpose.  
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A new interesting radiopharmaceutical for PET imaging(64Cu-DTPA-
ProT) has been developed to tag prothrombin and therefore track its 
deposition to the fibrin-rich vegetations in Staphylococcus aureus’ 






Figure 1.6: Examples of septic embolism detection using [18F]FDG PET/CT. Upper panel:  
[18F]FDG PET/CT uptake in the lower posterior portion of the spleen in patients with aortic 
IE (left column: SPECT emission, middle column: CT, right column: PET/CT)  . Lower 
panel:  [18F]FDG PET/CT uptake in the spine, involving the inferior portion of the vertebral 
body of L3 and the superior portion of the vertebral body of L4 in patients with aortic IE, 







Figure 1.7: Example of the use of [18F]FDG PET/CT to monitor response to antimicrobial 
therapy. Upper panel: PET/CT images in a patient with IE at the mechanical aortic prosthesis 
at baseline condition show intense [18F]FDG uptake at the posterior part of the aortic 
prosthesis. Concomitant uptake at the left ventricle wall is also evident, making it difficult to 
interpret the images. Mild pleural effusion is evident in the CT images.  
Lower panel: A PET/CT performed 4 months after initiation of antimicrobial therapy shows 
normalization of the [18F]FDG uptake at the site of the mechanical valve. Increased pleural 
effusion is detected at the CT component of the scan, consistent with the worsening of the 
valve regurgitation as indicated by echocardiography. Therefore, prosthetic valve 
substitution was performed at this stage based on the PET/CT finding of significant reduction 
in infective burden. Left column: SPECT, middle column: CT, right column: PET/CT. 
 
Cardiovascular implantable electronic devices infections 
In the past few decades there has been an increase in the use of 
cardiovascular implantable electronic devices (CIED), mostly related to an 
increasing elderly population, both in the developed and in the developing 
countries. Worldwide there are approximately 3.25 million functioning 
pacemakers and 180,000 functioning implantable cardioverter defibrillators56. 
Infection rates for these devices range from 1% to 7%57-60. The majority of 
CIED infections are caused by either Staphylococcus aureus or coagulase-
negative staphylococci; a variety of other bacteria and fungi are less 
commonly identified as causes of CIED infection56,61,62. CIED-associated 
infections cause significant morbidity and high death rate, particularly 
regarding endovascular infection (20%)62. The incremental cost for managing 
CIED infection has been estimated to be about $ 28,676 to $ 53,34963,64. 
Nearly half of this amount being due to intensive care procedures65. 
Furthermore, device replacement procedures that are periodically necessary 
for battery depletion or for upgrading, are associated with infection rates 
higher than those occurring after initial implantation66,67.  
The interval between CIED implant or revision and the onset of 
infection varies widely, from days to years. The clinical presentation of CIED 
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infection depends on several factors, including the site of infection (e.g., 
generator's pocket versus intravascular leads or epicardial leads), the type of 
microorganism, and the origin of the infection (e.g., pocket erosion, localized 
infection of the generator's pocket, bacteremia from a remote site). Early 
infections, i.e. those occurring within a few months after implantation, 
manifest as acute or sub-acute infections of the pulse-generator's pocket. 
Bacteremia may occur even without clinical signs and symptoms. Fever is the 
most common finding and is the only sign in approximately 33% of the 
patients. Although some cases of CIED infection occur without obvious 
inflammatory changes of the skin, the diagnosis is most often (about 70% of 
cases) based on findings at the generator's pocket site, including local pain, 
swelling, redness, drainage, and skin and soft-tissue ulceration. The first sign 
of infection may be erosion through the skin at the site of the generator's 
pocket, with external exposure of the generator or the leads, with or without 
local inflammatory changes. Late infections occur up to several years after 
implantation or reimplantation and have much more subtle manifestations. 
Most often the transvenous or epicardial leads are involved. In the latter 
circumstance, complications such as pericarditis, mediastinitis and right-
sided endocarditis are often present.  
The diagnostic workup of CIED infections is problematic, since 
patients can present with a variety of manifestations including subtle signs of 
systemic or local infection. Final diagnosis of CIED infection is generally 
based on microbiological tests (blood cultures and culture of material from 
exposed sites of the device) and ultrasound evaluation of the cardiac region 
(either TTE or TEE) and of the venous pathway of the device. The above 
tests constitute the basis for defining the patients' likelihood to have CIED 
infection according to the Duke criteria68. However, in case of CIED 
infections the Duke criteria, originally developed for the diagnosis of IE, may 
be inadequate. Even with the addition of clinical parameters69,70 the 
possibility remains high of missing the presence and/or underestimating the 
extent of infection71. 
Blood cultures are recommended in all suspected cases of CIED 
infection, regardless of whether the patient is febrile or has other signs or 
symptoms of systemic infection. However, blood cultures may be negative 
despite CIED infection, particularly in patients with pocket-site infection and 
in those receiving antibiotics shortly before blood samples are drawn for 
culture. Moreover, positive blood cultures may be due to a source other than 
an infected CIED. The likelihood of CIED infection when blood cultures are 
positive varies according to the pathogen detected, the number and duration 
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of positive blood cultures, and the presence of other findings that suggest 
device-related infections72-77.  
TEE is recommended for patients with bacteremia, especially if the 
bloodstream infection is due to staphylococcal species or if the source is not 
identified. Also for patients with signs of systemic infection, regardless of the 
results of blood-culture TEE is recommended78. The main purpose of TEE is 
to identify complications such as valvular vegetations or myocardial or 
perivalvular abscesses. In adults, TEE is more sensitive than TTE for 
detecting signs of an intracardiac infection79,80. Vegetations on a lead are 
consistent with, but not diagnostic of, lead-related endocarditis. Bland 
(uninfected) clots on leads have been found on echocardiographic 
examination in 5% to 10% of patients with CIED despite the absence of 
infection81,82  and these mass lesions usually cannot be distinguished from 
infected vegetations. A negative TEE result does not rule out the possibility 
of lead infection83. Fever and/or a positive blood culture without 
identification of a primary source in patients with a CIED, represent device-
associated IE until proven otherwise. 
Several nuclear medicine imaging techniques have been applied to 
evaluate patients with suspected or ascertained CIED infection. In particular 
[67Ga]-citrate scintigraphy has been successfully employed in small series of 
patients with CIED infection84,85. The role of scintigraphy with 111In-oxime-
leukocytes or 99mTc-HMPAO-leukocytes has been tested in this clinical 
setting as well, demonstrating that this technique in some cases can define the 
presence of CIED infection and to evaluate its extension86,87, also in patients 
with implantation of left-ventricular-assist device (LVAD)88. In this study, 
leukocyte SPECT/CT was able to identify and define the precise anatomic 
location and extent of a suspected infection, improving patients’ treatment 
management88,89. Additionally, 99mTc-HMPAO-leukocyte SPECT/CT allows 
the detection of additional unsuspected extra-cardiac sites of infection in up 
to 23% of patients of device-related sepsis89, although with some limitations 
in case of small SNC embolism. Similar results have been published in one 
case of lead-associated infection using SPECT/CT with 99mTc-sulesomab90. 
Figure 1.8, Figure 1.9 and Figure 1.10 represent typical patterns of 
radiolabelled leukocyte scintigraphy in presence of CIED infections. Table 
1.4 summarized all the published evidence on the use of [67Ga]-citrate 
scintigraphy, 111In-oxime-leukocytes or 99mTc-HMPAO-leukocytes and 
99mTc-sulesomab. 
 The use of [18F]FDG PET/CT in CIED infections has been 
implemented to respond to specific clinical needs: i) confirming/excluding 
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the presence of infection in patients with equivocal echocardiographic 
findings or during febrile episodes without evidence of a primary source; ii) 
defining the extent of device involvement; iii) assisting in the decision 
whether to treat medically or to remove the device; iv) evaluating the 
response to antimicrobial therapy; v) selecting the optimal time to re-implant. 
Although the earliest reports on the use of [18F]FDG PET/CT for diagnosing 
CIED infection date back to 2006, original retrospective studies were 
published only in 2011 (Table 1.5). Overall, a total of 159 patients have been 
evaluated so far, including 54 controls. Based on these data, [18F]FDG 
PET/CT appears to provide useful information when added in the diagnostic 
workup of CIED infection, mostly because of its ability to confirm the 
presence of infection (70/78 total confirmed CIED-associated infections), to 
define the extent of device involvement, and to detect associated 
complications such as infectious endocarditis and septic embolism (occurring 





Figure 1.8 - Typical pattern of radiolabelled leukocyte scintigraphy in presence of CIED 
infections limited at the intracardiac portion of the lead. Planar images at both early and 
delayed time points seem negative (A upper panel, 30 minutes and lower panel 6 hrs.) while 
only using SPECT/CT (B upper panel coronal images and lower panel transaxial images, left 
column SPECT and right column SPECT/CT) it’s possible to demonstrate and localize a 
focal area of increased radiopharmaceutical uptake at the distal part of the intracardiac 







Figure 1.9 - Typical pattern of radiolabelled leukocyte scintigraphy in presence of CIED 
infections. SPECT/CT (transaxial SPECT left column, CT central column and SPECT/CT 
right column) demonstrate and localize a focal area of increased radiopharmaceutical uptake 
at the intravascular portion of the lead just behind the sternum, without any involvement of 
the other portion of the lead. However, in this patient the pocket is also infected (see below 







Figure 1.10 - Examples of SPECT/CT images acquired 6 hrs. after 99mTc-HMPAO 
administration (left panel: transaxial images of the attenuated corrected SPECT (left 
column), CT (central column) and SPECT/CT (right column)) demonstrate and localize a 
focal area of increased radiopharmaceutical uptake at the pocket site that is confirmed at non 
attenuated corrected images (right panel, transaxial image) in the first two cases (upper and 
middle panel) while in the last case (lower panel) the disappearance of uptake at the 




Table 1.4: Published evidence concerning the use of scintigraphy with 111In/99mTc-HMPAOradiolabelled leukocyte and99mTc-sulesomab in Cardiovascular 
Implantable Electronic Device infections. 
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CABG= coronary artery bypass graft, ICD= implantable cardia defribillator, LVAD= left-ventricular-assist device, CT=computed tomography, FUO=fever 




Table 1.5: Published evidence concerning the use of[18F]FDG PET/CT in Cardiovascular Implantable Electronic Device infections 
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Echocardiography Reference 
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replacement & PM 
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Vos FJ et al. Eur J Nucl 
Med Mol Imaging 
2006191 
 
80 y, M  Fever after PM  
replacement for 
infection (3 y 
previous)  
 






wire of PM 
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AICD, PM Pseudomonas spp. Old wire track in left 
axilla + lead + tip of 
lead at coronary sinus 
Unknown Khamaisi M et al. J 
Cardiovasc 
Electrophysiol 2008193 




to complete heart 




Staphylococcus aureus PM pocket +leads  
Lung embolism 
Initial TTE no 
vegetations.  
TEE post PET/CT: 
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valve annulus 
Abikhzer G et al. J 















Unknown Around PM, along 




Turpin S et al. Eur J 






>3 m previously  
  









TTE and TTE 
negative 
Ploux S et al. Heart 
Rhythm  201191  








Staphylococcus spp. (4) 















Bensimhon L et al. 
Clin Microbiol Infect 
2011196 
59 y, M 
 
Swelling over PM  
box (5 months 
previous), rigors & 
sweats (1 m). Prior 















shock of unknown 
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75 y, M  FUO (1 w); PM (8 
y previous) with 




Atrial lead Negative Amraoui S et al. Arch 
Cardiovasc Dis 2012199 
 




PM dependent for 
30 y with 7 leads 
ICD Staphylococcus 
epidermidis  
Intravascular lead Unk van Oostrom AJ et al. 
Europace 2012200 




PM Staphylococcus spp. 
(18) 












54.5% TEE positive 
 
Sarrazin JF et al.  
J Am Coll Cardiol 
2012201 
n=21  CIED infection PM Staphylococcus spp. 
(10) 
Streptococcus spp. (3) 
Propionibacterium 
acnes (3) 













(either TTE or 
TEE) 











Unk Left cutaneous 
retroauricular 
pedestal, thoracic 
internal cable, Left 
lung, normalized 
after treatment 
Unk Costo S et al. Clin Nucl 
Med 2011202 
 
FUO,  fever of unknown origin; lns, lymph nodes; PM, pacemaker; US, ultrasound. AICD = Automatic C; PPV = positive predictive value; NPV = 
negative predictive value;  ICD = implantable cardioverter-defibrillator; CABG = coronary artery bypass graft *Using maximum count rate device/mean 
count rate between right and left lung parenchyma >1.87  
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[18F]FDG PET/CT enabled to discriminate patients with isolated pocket 
infections (Figure 1.11) from patients with more severe and extended 
infection, involving the pocket and leads (Figure 1.12 and Figure 1.13). This 
also accounts for early device infection. In case of pocket infection [18F]FDG 
PET/CT sensitivity ranges from 86.7%-100% and specificity from 85-100%. 
However, in case of CIED infections, [18F]FDG specificity becomes 
particularly relevant when classifying patients with undetermined 
echocardiographic findings, e.g., bland clots adherent on leads detected on 
echocardiography without clear signs of infection. Therefore, in this 
circumstance and considering the high rate of false positive findings (up to 
8%) reported in asymptomatic patients with pacing systems 91, [18F]FDG 
PET/CT is of clinical value mostly because of its high negative predictive 
value.  
High diagnostic accuracy of [18F]FDG PET/CT was also reported for 
ruling out the involvement of devices during febrile episodes and for defining 
the embolic burden in patients with ascertained infection. A negative scan 
(negative predictive value from 75% to 100%) has consistently been 
associated with a favorable clinical outcome when antimicrobial therapy 
alone is initiated.  
A strong correlation between sites of infection identified by [18F]FDG 
PET/CT and outcome following various treatment regimens was also 
demonstrated. Therefore, [18F]FDG PET/CT has been suggested as a guide to 
clinicians for choosing the most suitable treatment, i.e., conservative 
treatment (antimicrobial agents alone, or removal of just the generator) versus 
full hardware extraction. This would be especially relevant considering the 
ongoing debate arising from the observation that novel antimicrobial agents 
can penetrate the bacteria-produced biofilm92, thus potentially decreasing the 
need of hardware removal in CIED infection93. However, the diagnostic 
accuracy of [18F]FDG PET/CT for cardiac device related IE has been recently 
questioned, based on the very low sensitivity (30.8%) and specificity (62.5%) 
reported by Cautela et al94. Previous antimicrobial therapy (that was ongoing 
in 9/13 patients with cardiac device related IE) and/or vegetation size could 
account for the poor sensitivity of [18F]FDG PET/CT in such report. 
Furthermore, [18F]FDG uptake in normal heart tissue may explain why low-
intensity lesions were undetected. Considering that the differential diagnosis 
between an infection limited at the skin/pocket and a more severe infection 
that involves the device over the pocket, remains the most important issue, 
which translates into a different patients’ management95 (from medical to 
surgical treatment). This issue requires further investigation before the 
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Figure 1.11: [18F]FDG PET/CT in patients with suspected infection of a  pacemaker. Left 
column: chest X-ray with delineation of the generator site (yellow) and the leads course 
(red). Right column: PET/CT (from left to right: SPECT image, CT l image and PET/CT 





Figure 1.12: [18F]FDG PET/CT in patients with suspected infection of a  pacemaker. 
Transaxial PET/CT images at different levels (: SPECT image, CT image and PET/CT 
image) show intense [18F]FDG uptake at the pocket site (upper panel) and all along the 







Figure 1.13: [18F]FDG PET/CT in patients with suspected infection of a  pacemaker. Left 
upper panel: chest X-ray with delineation of the generator site (yellow) and the leads course 
(red). PET/CT images (from left to right: emission images, CT images and superimposed 
PET/CT) in coronal views (right upper column) and transaxial views (lower panel) show 





Figure 1.14: [18F]FDG PET/CT images of patients with infection of unknown origin 
demonstrating sites of increased [18F]FDG uptake at the pericardium, finally diagnosed as 
CMV-related pericarditis. Upper panel: coronal PET/CT images (left column emission 
images, middle column CT images and right column superimposed PET/CT). Lower panel: 
transaxial PET/CT images (left column emission images, middle column CT images and 





Pericarditis is an inflammatory process that can be caused by localized or 
systemic diseases, including infection, connective tissue disorders, and 
uremia, or can occur after radiation therapy. Although dyspnea and pleuritic 
chest pain that changes with patient’s position are the typical signs of the 
disease, clinical manifestations can be more variable, depending on the extent 
of pericardial disease, the rate at which it develops, and its effect on cardiac 
function96. Additional signs include pericardial friction rub at physical 
examination and nonspecific S-T segment and T-wave changes on ECG.  
Discriminating pericarditis from myocardial disease or pulmonary 
infarction can be difficult on the basis of physical examination alone. 
Imaging may instead be helpful for distinguishing these different conditions.  
Echocardiography, CT, and MRI are frequently employed to identify 
and characterize the pericardium and pericardial space, their typical findings 
including pericardial thickening, pericardial enhancement and pericardial 
effusions97. However, echocardiographic assessment of pericardial thickening 
can be difficult, and the entire pericardium often cannot be fully evaluated 
because of the poor acoustic window. CT and MRI allow clearer 
characterization of the pericardium and pericardial space and can therefore 
help to distinguish between pericardial fluid effusion and thickening98. 
[18F]FDG PET/CT is generally employed as a complement to other 
imaging modalities, since the different pattern of [18F]FDG accumulation in 
the pericardium or in the pericardial fluid might help in distinguishing 
infectious/inflammatory conditions from neoplastic pericardial involvement. 
In fact, noninfectious and inflammatory processes involving the pericardium 
or pericardial space generally present a mild to moderate increase or no 
increase in [18F]FDG uptake, whereas neoplastic conditions generally present 
intense metabolic activity often associated with a focal soft-tissue mass. 
Incidental reports of cardiac infection or inflammation with increased 
[18F]FDG activity have been described in patients evaluated with [18F]FDG 
PET/CT for fever of unknown origin99. In patients with meningococcal sepsis 
and AIDS, intense pericardial uptake at [18F]FDG PET allowed to recognize 
infectious pericarditis100,101. Three cases of tuberculous pericarditis were 
diagnosed using [18F]FDG PET/CT, that identified either tuberculous 
pericardial involvement alone102,103  or associated with disease dissemination 
throughout the body103. A recent study exploited the ability of [18F]FDG 
PET/CT to distinguish acute tuberculous from idiopathic pericarditis104. 
Patients with acute tuberculous pericarditis showed a diffuse or multifocal 
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pattern of [18F]FDG uptake in the pericardium associated with mediastinal 
and supraclavicular lymph nodes with increased uptake. Significantly higher 
mean pericardial thickness (5.1 mm) and SUVmax at both pericardium and 
lymph-nodes was observed in tuberculous pericarditis (13.5 and 5.3, 
respectively) as compared with patients with acute idiopathic pericarditis (3.4 
mm, 3.0 and 2.8) who showed diffuse or regional [18F]FDG uptake. On the 
contrary, constrictive or effusive constrictive pericarditis, an uncommon 
complication of chemotherapy, can present with mild and diffuse pericardial 
[18F]FDG uptake105. Similarly, the lack of [18F]FDG accumulation in the 
pericardial space in a patient presenting with idiopathic pericarditis 
associated with striking hypermetabolism of the thoracic and abdominal 
aortic wall (highly suggestive of large vessel vasculitis) is consistent with 
pericarditis as the initial manifestation of giant cell arteritis106. Figure 1.14 





Myocarditis, or inflammation of the heart muscle, may present as an acute, 
sub-acute, or chronic illness. A large proportion of afflicted individuals may 
be asymptomatic. Because of such insidious nature of the disease, its 
epidemiology has been defined through post-mortem studies. Prospective and 
retrospective studies have identified myocardial inflammation in 1-9% of 
routine post-mortem examinations107-109. Myocarditis is a major cause of 
sudden, unexpected death (up to 20% of cases) in adults younger than 40 
years110. The causes of myocarditis include a variety of infectious or systemic 
diseases, toxins, and drugs. Viruses, especially enteroviruses, are the most 
important causes of myocarditis in developed countries. The enterovirus 
genome has been identified in the myocardium of patients with myocarditis 
or with dilated cardiomyopathy111-113. Since the early 1980s, endomyocardial 
biopsy has been used to evaluate patients with suspected myocarditis. In 
1986, the Dallas criteria for the histologic diagnosis of myocarditis were 
defined114, based on the identification of infiltrating lymphocytes and of 
myocytolysis. Patients with lymphocytic infiltration but without 
myocytolysis were classified as having sub-clinical  or ongoing myocarditis. 
However, less than 10% of the patients with suspected myocarditis had 
positive biopsies when assessed by the Dallas criteria115, thus raising the 
issue of low sensitivity and high inter-observer variability. A second  clinical 
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classification system was proposed in 1999116, but has not been widely 
accepted.  
Although there have not been major advances in the identification of 
the etiology of myocarditis in recent years, new molecular techniques such as 
polymerase chain reaction and genomic hybridization have allowed 
confirmation of the etiology in some cases which would have otherwise 
remained undiagnosed. The serum level of creatine kinase-MB (CK-MB) has 
high specificity, but limited sensitivity for the diagnosis of myocarditis. On 
the other hand, serum troponin I is more often elevated than CK-MB in 
patients with myocarditis117,118. Echocardiography performed in the setting of 
acute myocarditis may demonstrate either normal heart function, global 
hypokinesis or regional left ventricular hypokinesis, with an overall low 
reported sensitivity119. MRI allows discrimination of myocarditis from 
myocardial infarction by depicting scattered areas of hyper-enhancement 
with a nonvascular distribution (in midmyocardial or subepicardial locations) 
in case of myocarditis. These areas of hyper-enhancement correspond to 
inflammation and cell necrosis, and are most commonly seen in inferior and 
inferiolateral myocardial segments119-121.  
Diffuse, increased metabolic activity in the left wall with mild heterogeneity 
suggesting the occurrence of myocarditis have been observed at [18F]FDG 
PET/CT in a patient with chronic active EBV infection presenting with fever, 
dyspnea on exertion, general malaise, hepatosplenomegaly. The patient 
subsequently developed heart failure and myocarditis was confirmed by 
endomyocardial biopsy122. This condition must be discriminated from 
congestive heart failure, right ventricular strain, and hypertrophy due to 
elevated pulmonary artery pressure, which can also lead to increased 
[18F]FDG uptake in the right ventricular myocardium123.   
 
Vascular graft infection 
 
Vascular prosthetic infection (VPI) is a severe, late and most unwelcome 
complication following vascular surgery. It has a low frequency (between 
0.4% and 3.0%)124,125 but it is one of the most challenging issues for both 
diagnosis and treatment, and has a high morbidity and mortality rates (around 
50% and 25%-75%, respectively). Its severity depends also on the location of 
the graft, with 13% rate of infection in the inguinal region followed by aorto-
bifemoral bypass and femoro-popliteal bypass. Management of infected 
vascular grafts depends on several factors, including the position of the 
infected prosthesis, the extent of infection, and the underlying 
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microorganism126. Diagnosis is difficult, as there is no single diagnostic 
procedure that has 100% of accuracy. Therefore, a combination of physical 
examination, laboratory tests, and several imaging techniques is mandatory. 
In fact, patients may have a variety of clinically equivocal complaints and 
assessment of the extent of graft infection (one of the most difficult 
challenges) can be difficult. Furthermore, blood chemistry parameters can 
only show moderately elevated WBC counts, erythrocyte sedimentation rate 
and/or C-reactive-protein values, a common, non-specific finding. When 
clinical signs are minimal or absent because of low-grade infection, the 
diagnosis of vascular graft infection is uncertain. Nevertheless, it is critically 
important to avoid complications such as sepsis, aneurismatic ruptures, 
gastrointestinal bleeding and suture line disruption. Since risk factors for 
infection include removal of infected material by an aggressive surgical 
treatment, once a vascular graft infection is suspected, early and accurate 
detection is required for the correct choice of therapeutic procedures. Delay 
in treatment can lead to life-threatening sepsis and/or bleeding. 
The majority of VPI cases are due to Staphylococcus aureus, 
Escherichia coli and S. epidermidis whereas, Klebsiella spp, Pseudomonas 
spp, Enterobacter spp and Proteus spp account for most of the remaining 
infections127. Patients with suspected graft infection usually present with 
local pain, redness, a palpable lump, and/or secretion in the area of the 
surgical wound, associated with blood chemistry values consistent with 
infection. Microbiological cultures (obtained by a CT-guided needle 
aspiration, if technically feasible) may confirm the diagnosis. Success of 
surgical intervention is dependent on an early diagnosis and generally CT 
angiography is the technique of choice for both infection confirmation and 
complication detection. 
In case of a potentially infected vascular graft, the diagnostic 
approach can begin with imaging studies readily available in all healthcare 
institutions (mainly angio-CT and US) and radionuclide imaging studies are 
usually complementary to radiologic imaging 
Ultrasonography with color flow doppler is the first-line imaging 
procedure for diagnosing an infected prosthetic vascular graft. This non-
invasive technique does not involve any risk of contrast allergy and 
nephrotoxicity, does not expose the patient to ionizing radiation, and is in 
general highly cost-effective128. Unfortunately, especially in case of aortic 
grafts, its predictive value is limited both because of air content in the 
intestinal lumen and, sometimes, because of abundant subcutaneous fat of the 
patient. Computed Tomography (CT), is considered the gold standard 
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radiologic imaging technique. It has 94% sensitivity and 85% specificity129. 
Unfortunately, detection of gas bubbles around the graft, a diagnostic sign for 
infection, has good specificity but rather low sensitivity (about 50%). Despite 
several advantages (high specificity, guidance for needle aspiration, 
microbiological analysis, and speed of execution), CT imaging suffers from 
some limitations, such as low sensitivity in detecting low-grade and early 
post-surgical infections, and a significant radiation burden to patients130. 
The diagnostic role of Magnetic Resonance Imaging (MRI) in patients with 
suspected vascular graft infection is still unclear131,132.In particular, its 
sensitivity in the detection of peri-graft infection has not been thoroughly 
investigated, and is probably similar to that of CT. Furthermore, MRI suffers 
from the same limitations as CT imaging for the differential diagnosis of 
peri-prosthetic fluid accumulation in the first weeks after surgery. 
Nevertheless, this non-invasive imaging modality provides multiparametric 
information which is especially useful for tissue characterization. 
Nuclear medicine techniques are in general characterized by high accuracy in 
detecting graft infection in patients with aortic grafts and without specific 
signs of infection (low-grade phases), while in processes localized close to 
the prosthesis false positive results have occurred133,134. However, nuclear 
medicine procedures and MRI are limited to doubtful cases in which CT 
sensitivity is low (as in the cases of low-grade infection and early after 
surgery). Treatment of VPI is controversial: antimicrobial therapy may be the 
only option in high-risk patients. However, surgery and antimicrobial therapy 
remain the treatments of choice based on the patients’ clinical condition. The 
appropriate duration of antibiotic therapy both for patients treated with or 
without surgery is questioned135,136 and the decision to discontinue is 
clinically guided (absence of symptoms, fever and negative inflammatory 
markers)137.  
Radiolabeled autologous leukocytes (either with 99mTc or 111In) are most 
frequently used for scintigraphy imaging in VPI, but 67Ga-citrate, 
radiolabeled HIG and labeled anti-granulocyte antibodies have also been 
evaluated. A meta-analysis of the performance of nuclear medicine 
techniques for the diagnosis of prosthetic graft infection (37 papers published 
from 1980 to 2003)138 have shown a clear superiority of 99mTc-labeled 
autologous leukocytes (82-100% sensitivity and, 85-100% specificity) over 
the other methods including CT (specificity 56.6% and sensitivity 75%). 
When the abdominal region is included in the study and 99mTc-HMPAO 
WBC is used, methodological efforts are necessary to decrease false positive 
findings (i.e. adequate image acquisition time). This superiority over other 
45 
 
methods has increased with the introduction of SPECT/CT. In fact, fused 
images allow exclusion of false positive results (i.e. abdominal aspecific 
accumulation), accurate characterization of pathological foci site and 
extension, confirmation or rejection of graft involvement even in presence of 
post-surgical distortions and in complex anatomical sites139-141. High 
specificity is even maintained when scintigraphy is performed during the first 
month after surgery 142. A comparative study between MRI and 111In-WBC 
reported a similar performance of the two methods (positive and negative 
predictive value of 95% and 80% for MRI and 80% and 82% for 111In-
WBC)143. WBC scintigraphy may be used to determine the response to 
treatment, preventing the risk of adverse drug reactions related to long-lasting 
regimens as well as the acquisition of resistance in patients treated with long-
term suppressive antibiotic treatment144. Figure 1.15 show an example of  
99mTc-HMPAO WBC in VPI. 
99mTc-Fanolesomab was shown to diagnose prosthetic vascular graft infection 
with an accuracy of 95%145. Table 1.6 summarized the published evidence 
concerning the use of 67Ga-citrate, 111In-oxine WBCs, 99mTc-HMPAO WBC 
and 99mTc-Fanolesomab in VPI. 
[18F]FDG-PET and PET/CT may be considered an alternative valuable 
method for the evaluation of suspected vascular graft infections146. 
Sensitivity of 91% (versus 64% of CT) and specificity of 64% (versus 86% 
of CT) have been reported with significant improvement (sensitivity up to 
95%) when appropriate interpretation criteria are used (presence of focal 
[18F]FDG)147. In fact, inhomogeneous [18F]FDG uptake represents unspecific 
uptake, possibly related to very low grade infection, weak immune reaction, 
inflammation (i.e. vasculitis, atherosclerosis) or chronic aseptic inflammation 
and post-surgical scar tissue, which may persist for years after the 
implantation of the prosthesis148. More recently, the use of PET/CT allowed 
to increase sensitivity to 93% and specificity to 70-91%, with positive and 
negative predictive values of 82-88% and 88-96%149, mainly as a 
consequence of the better anatomical localization. Despite those favorable 
results, a high false positive rates may be an issue, as reported in a small 
series of patients using both semiquantitative [18F]FDG uptake and CT 
features (graft wall thickening, oedema, gas surrounding the graft or any 
other sights)150. Nevertheless, Spacek et al.151 identified the presence of focal 
[18F]FDG uptake and irregular graft boundary at CT images as an 
independent significant predictor of low-grade VPI with erroneous 
classification occurring in less than 5% in the majority of patients (75%). 
Table 1.7 summarized the published evidence concerning the use of[18F]FDG 
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PET and PET/CT in VPI. Figure 1.16 shows an example of [18F]FDG 
PET/CT imaging in patients with VPI.  
In conclusion, radiolabeled autologous leukocytes are considered the ‘gold 
standard’ for vascular graft infection diagnosis and treatment monitoring, 
since the high sensitivity and specificity of the method. The introduction of 
SPECT/CT increases the diagnostic accuracy. [18F]FDG-PET and PET/CT 
with appropriate criteria for imaging interpretation may provide a valid 
substitute. Still, no data on its use in the early phase after surgeryor for 









Figure 1.15 99mTc-HMPAO WBC transaxial  images of patients with suspected VPI showing 
very high uptake at the site of the vascular aotoiliac graft (left panel emission, middle panle 












Figure 1.16:  [18F]FDG PET/CT images of patients with suspected aneurysmatic dilatation 
of the abdominal aorta. Transaxial images (left panel emission, middle panle CT at right  
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modalities 
Reference 










Upper GE series, CT, 
endoscophy following 
scintigraphy  
Causey DA et al.  AJR 
Am J Roentgenol 1980203 
21 Unknown Unknown 111In-oxine WBCs Sensitivity 100%, 
Specificity 87% 
Unknown Lawrence P et al. J Vasc 
Surg 1985204 
21 Fever, suspected 
VPI 
Unknown 111In-oxine 
WBCs, planar 4 
and 24 hrs 
Sensitivity 100%, 
Specificity 88% 
CT (10): Sensitivity 
75%, Specificity 100% 
Williamson MR et al. 
AJR Am J Roentgenol 
1986205 
70 Suspected VPI Unknown 111In-oxine WBCs Sensitivity 100%, 
Specificity 85% 





Unknown 111In-oxine WBCs Abnormal scan for 
mean 114 daysa after 
surgery, rare in 
abdomen and most 
frequent in the groin. 




accuracy  53% 
na Sedwitz M et al. J Vasc 
Surg 1987207 
11 Suspected VPI Unknown 67Ga-citrate and 
99mTc-HMPAO 
WBC, planar and 
SPECT 
For 67Ga: Sensitivity 
100%, Specificity 
90% 
 For WBCs: 








32 Suspected VPI 
(23) and controls 
(9) 
Unknown 111In-oxine WBCs Sensitivity 82%, 
Specificity 83% 
Unknown Reilly DT et al. Eur J 








CT: Sensitivity 100%, 
Specificity 82%  
Johnson K, et al. AJR 
Am J Roentgenol 1990210 





Unknown Thomas P et al. Clin 
Nucle Med 1994211 







Escherichia coli,  
99mTc-HMPAO 
WBC 
High suspicion of 
VPI: Sensitivity and 
Specificity 100%. 







specificity 89%,   
CT: High suspicion of 
VPI: sensitivity and 
Specificity 100%. 
Low suspiscion of VPI: 
sensitivity 100%, 




 specificity 100%. 
Fiorani P et al. J Vasc 
Surg 1993212 
61 Suspected VPI 
(36) and controls 
(25) 







and planar 5-30 
min and 3-24 hrs  
Sensitivity and 
specificity 100% 
CT (12) Sensitivity 
67%, Specificity 100% 















Unknown Krznaric E et al. Nucl 













na Liberatore M et al. Eur J 
Vacs Endovasc Surgery 
1997215 
129 Aortofemoral and 
peripheral grafts 















and planar at 2 hrs 
Aortofemoral  
high suspicion: 
sensitivity 100% and 
specificity 92.5% 
low suspicion: 





na Liberatore M et al. J 






contributory in 67% 
cases 
Unknown Bar-Shalom R et al. J 
Nucl Med. 2006140 
50 
 
23 Serial scan 1 wk 
before and 1 wk 




No FP < 1 mth from 
surgery 
na Liberatore M et al. Med 
Sci Monit. 2006142 
40 Suspected 
infection 
Mixed  111In-oxine 
WBCs, planar 
Sensitivity = 73%, 
Specificity = 87% 
MRI: Sensitivity = 
68%, Specificity = 
97% 
Shahidi S et al. Ann 
Vasc Surg. 2007143 
18 Suspected VPI Unknown 99mTc-
Fanolesomab, 2-5 
and 18-30 hrs 
At 18-30 hrs images 
accuracy 95% 
na Tronco GG et al. Nucl 
Med Commun. 2007145 
73 y, F Fever and 
tenderness of 







Uptake around the 
vascular graft in the 
lateral chest wall 
CT: graft patency,  
small fluid collection 
around the graft at right 
axilla, saccular 
aneurysm of the aortic 
arch 
Lee A. et al. Clin Nucl 
Med. 2008217 
11 Suspected VPI  Mixed 99mTc-HMPAO 
WBC SPECT/CT 
Sensitivity = 86%, 
Specificity = 100% 
 Lou L et al. Nucl Med 
Commun. 2010141 









Specificity 100%  




CT: Sensitivity 88%,  
Specificity 50% 
Khaja MS et al. Clin 
Imaging 2013218 
 




Table 1.7: Published evidence concerning the use of[18F]FDG PET and PET/CT  in VPI 
. 






70 y, M Low grade fever and 
malaise 2 yrs after 





Linear uptake Aortic graft uptake, 
confirmed at surgery 
CT: abnormal 









54 y, M Fever 6 mts after 
femoropopliteal 
PTFE 




uptake linear + focal 
na US: reduced flow 
in the bypass, no 
exudate around 












some parts of the 
graft 
Stadler P et al. J 
Vasc Surg 
2004220 
75 y, M Spiking fever and 
malaise 15 yrs after 
Anaerobic gram 
positive bacilli 
Focal uptake at both 
limbs of the 
na CT: 
unconclusive,  
Tsunekawa T et 





prosthesis highest at 
the distal portion 
Endovasc Surg 
2007221 







Increased uptake All positive: 3/4 
confirmed at surgery; 1/4 
superficial infection 
confirmed at surgery; 1/4 
only moderate uptake 








79 y, M Recurrent fever, 
chills 6 yrs after 
vascular grafting 
Unknown Shaped uptake at 
proximal anastomosis 











Increased uptake at 
bifurcation  
na CT: small 
bubbles 
Tegler G et al. J 
Vasc Surg 
2007224 
72 y, M Infected pus 
secreting surgical 







Increased uptake Vascular graft + soft 
tissue abscess 
na Keidar Z et al. 
Mol Imaging Biol 
2003225 
33 Suspected advanced 
aortic graft infection 
(9), low-grade aortic 
graft infection with 
Unknown Positivity: focal 
uptake grade 3 
(<physiologic uptake 
by the bladder) or 4 
sensitivity 91%, 
specificity 95%, 
PPV 91%, NPV 93%, 




PPV 70%, NPV 














124 FUO (94) and post-
surgical infection 
(30) 
unspecified Unspecified 7 confirmed VPI na Jaruskova M et 
al. Eur J Nucl 
Med Mol 
Imaging 2006226 
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uptake with intensity 




91%, PPV 88%,  NPV 
96%. 
 
na Keidar Z et al. J 
Nucl Med 2007137 
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after aortic 
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Coxiella burnetii Increased uptake Uptake at vascular graft 
(99mTc-WBCs negative) 
negative after treatment 
TEE, US, CT 
negative 
Van Assen S et 
al. J Vasc Surg 
2007227 
16 Out of  2,045 pts  
examined by PET/CT 
for oncological 
indications 
unspecified 3-grade scale for 
high, low, or no 
uptake; SUVmean 
and TBR. 
CT: graft wall 
thickening, edema, or 
All pts positive, but very 
high 
SUVmax and TBR 
seems to be more 
specific for graft 
infection 
na Wassélius J et al. 






the graft or any other 
signs of graft 
infection. 
unk Abdominal pain, GE 
beelding  Increased 
inflammatory 
markers 7 wks after 
proximal type I 
endoleak repair   
na Increased uptake Uptake resulting FP at 
laparotomy 
na Zimmerman PM 
et al.  Vascular 
2008228 
76 suspected VPI based 
on clinical signs of 







blood culture) not 
requiring urgent 




irregular boundary of 
the prosthesis  
 
sensitivity 98.2%, 
specificity 75.6%, PPV 




boundary at CT : 
sensitivity 72.7%, 
specificity 85.7%, 
, PPV 88.9%, 
NPV 88.9%, 
accuracy 77.8% 
Spacek M et al. 




irregular boundary of the prosthesis  
+ intense focal FDG uptake = probability of 
VPI >96% 
75 y, M Swelling, pain and 
patchy erythema of 





Increased uptake Uptake at bypass graft US: negative 
MRI: edema, 
myositis 
Marion MD et al. 
J Vasc Surg 
2009229 
83 y, M Asyntomatic Unknown Increased uptake Uptake at aorto-iliac 
graft + fistula into bone 
causing osteomyelitis  
na Makis W et al. 




25 Suspected VPI: fever 
and/or pain 
 
Unknown Positivity: focal 
uptake grade 3 
(<physiologic uptake 
by the bladder) or 4 
(= physiologic 
urinary uptake by the 
bladder SUVmax and 
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sensitivity 93%, 
specificity 70%, PPV 
82%, NPV 88% 
CT: sensitivity 
56%, specificity 
57%, PPV 60%, 
NPV 58%, 
Bruggink JL et al. 
Eur J Vasc 
Endovasc Surg. 
2010149 
47 y, M Sepsis 6 mths after 
bypass betwenn 
thoracic descendent 




Increased uptake Uptake all along the 
vascular graft (99mTc-
WBCs negatve) 





70 y, M Abdominal and 




Coxiella burnetii Increased uptake Uptake at prosthesis, 




collection in lf 
psoas muscle, 
small cysts at L4 




57y M Intermittent pain for 
microemboli in 
claves, finger and 
feet 1 yrs after aortic 
arch prosthesis 
Candida albicans Increased uptake Focus of uptake at aortic 
prosthetic graft, negative 









Motloch L et al. 
Tex Heart Insti J 
2011233 
 
PTFE=polytetrafluoroethylene, na=not assessed; US=ultrasonography, CT=computed tomography, MRI=magnetic resonance imaging, VPI=vascular 
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Clinical performance of the Duke Endocarditis Service criteria to establish 
the diagnosis of infectious endocarditis (IE) can be improved through 
functional imaging procedures such as  radiolabeled leukocytes (99mTc-
HMPAO-WBC). Methods: We assessed the value of 99mTc-HMPAO-WBC 
scintigraphy including SPECT/CT acquisitions in a series of 131 consecutive 
patients with suspected IE. Patients with permanent cardiac devices were 
excluded. 99mTc-HMPAO-WBC scintigraphy results were correlated with 
transthoracic (TTE) or transesophageal (TEE) echocardiography, blood 
culture and the Duke criteria. Results: Scintigraphy was true positive in 46/51 
and false negative in 5/51 cases (90% sensitivity, 94% NPV, 100% 
specificity and PPV). No false positive results were found, even in patients 
with early IE evaluated within the first two months from the surgical 
procedure. In 24/51 patients with IE we also found extracardiac uptake, 
indicating septic embolism in 21/24. Despite septic embolism was found in 
11/18 cases of Duke “definite IE”, most of the added value from the 99mTc-
HMPAO-WBC scan for decision-making was seen in patients in whom the 
Duke criteria yielded "possible" IE. The scan was particularly valuable in 
patients with negative and/or difficult-to-interpret echocardiographic findings 
since it correctly classified 11/88 of these patients as having IE. Furthermore, 
3 patients were falsely positive at echocardiography but correctly negative at 
99mTc-HMPAO-WBC scintigraphy: these patients had marantic vegetations. 
Conclusions: Our results demonstrate 99mTc-HMPAO-WBC scintigraphy 
ability to reduce the rate of misdiagnosed IE when combined to the standard 
diagnostic tests (a) in patients with high clinical suspicion but inconclusive 
echocardiographic findings; (b) for the differential diagnosis between septic 
and sterile vegetations detected at echocardiography; (c) when 
echocardiographic, laboratory and clinical data are contradictory, as also to 
exclude valve involvement (especially of a prosthetic valve) during febrile 
episodes, sepsis or post-surgical infections.  
 






The incidence of infectious endocarditis (IE), is approximately 2-4 cases per 
100,000 persons/year (1). At present, 25-50% of the cases occur in patients 
older than 60 years (2). 
The diagnosis of IE, first suspected on clinical ground, is further supported 
either by detecting a vegetation at transthoracic (TTE) or transesophageal 
(TEE) echocardiography, and/or by positive blood culture (3). In most 
institutions the final diagnosis is established using the Duke Endocarditis 
Service criteria (4), which also entail echocardiographic findings. Overall 
sensitivity is about 80% (5). However, in some instances blood culture or 
echocardiography are inconclusive, thus leading to a high proportion of 
unconfirmed cases of suspected IE. Indeed, up to 24% of the patients with 
pathologically proven endocarditis were misclassified as "possible" IE based 
on Duke criteria alone (5). 
Attempts have been made at improving the diagnostic performance of the 
above criteria, and modifications that consider several additional clinical and 
microbiological parameters have been proposed (6). The so-called modified 
Duke criteria are now recommended for diagnostic classification (7). 
Traditional diagnostic criteria may also be integrated with information 
derived from radionuclide imaging, given the ability to localize functional 
hallmark of infection as represented by increased radiolabeled leukocytes 
recruitment. Using three-dimensional reconstruction of hybrid SPECT/CT or 
PET/CT images it’s possible to detect and precisely localized throughout the 
body all the sites of infections represented by areas of radiopharmaceutical 
uptake. In association with echocardiography, this imaging technique can be 
employed to confirm or rule out IE in equivocal and/or difficult-to-explore 
situations (i.e., marantic vegetations, artefacts caused by mechanical 
prosthesis). Furthermore, scintigraphy can also reveal the presence of extra-
cardiac infection sites as the consequence of septic embolism originated from 
IE (8). In this study we assessed the added value(s) of SPECT/CT with 99mTc-
HMPAO-labeled autologous leukocyte (99mT-HMPAO-WBC) in the 
characterization of patients with suspected or established IE, as defined 








Materials and methods 
 
Patient Population  
Between October 2005 and December 2010, a total of 185 consecutive 
patients were referred for scintigraphy with 99mT-HMPAO-WBC for 
suspected IE. Fifty-four of these patients were excluded from the present 
analysis because they were bearing permanent cardiac devices, a condition 
that might introduce confounding factors linked to the different mechanism 
of infection (9). Therefore, the population for the present work included the 
remaining 131 patients (45 women and 86 men, mean age 62.8±16.6 years), 
in whom IE was suspected, or established as definite according to the Duke 
criteria; in the latter case, scintigraphy was performed to exclude septic 
embolism. All patients had undergone clinical examination, blood tests 
including WBC counts, CRP, ESR, acute phase proteins, electrophoresis, 
urinalysis and echocardiography (either TTE, TEE or both). Three sets of 
blood cultures including at least one aerobic and one anaerobic from a 
peripheral vein were performed for all patients (10). The main clinical 
features and risk factors of the patients are summarized in Table 2.1.  
Final diagnosis of IE, or exclusion of this condition and identification 
of an alternative cause of disease was defined based on the final 
microbiological (n=20) or clinical diagnosis (n=31), with clinical follow-up 
of 12 months for all patients. Based on these combined parameters, IE was 
confirmed in 51 out of the 131 patients, that is, in 24/28, 25/55 and 2/48 of 
the cases in which IE had been classified as definite, possible, or rejected, 
respectively, according to Duke criteria. 
 In the 51 patients who were eventually diagnosed as having IE, 
infection involved more frequently the aortic valve and affected almost 
equally native valves either biological or mechanical prosthetic implants 
(Table 2). In patients with prosthetic valves early IE (< 2 months from valve 
replacement) was present in 9/35 patients, semi-late IE (between 2 and 12 
months) in 11/35 and late-onset IE in 15/35 (Table 2.2).  
Staphylococcus spp. was the microorganism more frequently 
responsible for the infection (24/51), followed by Enterococcus spp. (11/51), 
Streptococcus spp. (10/51), and P. aeruginosa (4/51). Haemophilus and 








Table 2.1: Main features of the 131 patients included in the study. 
 
Age (years) Mean ± SD Median Range  














































 28/131 55/131 48/131  
 
 
Table 2.2: Site of IE, type of valve and time of infection onset. 
 
Type of valve  Native Biological prosthesis Mechanical 
prosthesis 
 
 116/51 (31%) 19/51 (38%) 16/51 (31%)  
 








Aortic + mitral 
Native 9/30 (30%) 6/19 (32%) 1/1 (100%) - 
Biological prosthesis 10/30 (33%) 8/19 (42%) - 1/1 (100%) 
Mechanical prosthesis 11/30 (37%)   5/19 (26%)* - - 
 








 9/35 (26%) 11 (31%) 15 (43%)  
 












(*) including 2 patients with anuloplasty. 
  
Radiolabelling of Autologous Leukocytes and Image Acquisition 
Protocol 
Autologous radiolabeled WBCs were prepared according to the EANM 
Guidelines for the labeling of leukocytes with 99mTc-HMPAO (11,12). 
Radiolabelling efficiency was always between 70-85%, and viability of the 
radiolabeled leukocytes was always tested by the Tripan blue exclusion test 
before reinfusion. 
 Whole body and spot planar images were obtained after 30 minutes 
(early), then 4-6 and 20-24 hours (delayed images) after reinfusion of 370-
555 MBq of 99mTc-HMPAO-WBC. SPECT/CT of the chest was performed in 
all patients at 6 hours and repeated at 24 hours in case of negative or doubtful 
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imaging at 6 hours. Images were acquired using a dual-head, variable-angle 
SPECT/CT gamma camera (Hawkeye, GE Healthcare). The low-dose CT 
transmission scan was acquired for 16 seconds over 220° for each transaxial 
slice. The full FOV consisting of 40 slices was completed in 10 minutes. The 
transmission data were reconstructed using filtered back-projection to 
produce cross-sectional images. Resolution of the CT scan was 2.2 mm and 
localization images were produced with a 4.5-mm pixel size, similar to the 
nuclear medicine emission images. The CT scans were reconstructed into a 
256×256 matrix. The SPECT component of the same FOV was acquired 
using a 128×128 matrix, 360° rotation, 6° angle step, and 40/60-sec-per-
frame acquisition time at 6 and at 24 hours, respectively. Both CT-
attenuation corrected and non-corrected SPECT images were evaluated in the 
coronal, transaxial, and sagittal planes, as well as in tridimensional maximum 
intensity projection (MIP) cine mode. Matching pairs of x-ray transmission 
and radionuclide emission images were fused using the Xeleris software, and 
hybrid images of overlying transmission and emission data were generated. 
 
Interpretation Criteria 
Two experienced nuclear physicians aware of the patients’ clinical history 
and of the results of prior conventional imaging tests reviewed independently 
the planar scans and the SPECT/CT images, with regard to the presence and 
location of any focus of abnormal radioactivity accumulation indicating 
infection. Preliminary analysis of the SPECT/CT images included visual 
inspection to exclude misregistration between the SPECT and the CT 
components. 
 The scintigraphic studies were classified as negative when no sites of 
abnormal uptake were observed at SPECT/CT images, or positive for 
infection when at least one focus of abnormal uptake characterized by time-
dependent increase in radioactivity from early planar to delayed images was 
observed (13). This time-dependent pattern of uptake is especially relevant 
for the cardiac region, considering that physiologic accumulation of 
radiolabeled leukocytes in the bone marrow (as in the sternum, overlying the 
heart) early after reinfusion can interfere with interpretation of the planar 
images. When present, focal uptake indicating infection was further classified 
as pertaining to the heart and/or to extracardiac sites. 
 The contribution of SPECT/CT was considered with special attention 
to the possibility of anatomically localizing the exact site of infection, 
particularly for the heart region. In fact, neither the planar nor the stand-alone 
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SPECT images allow to localize areas of focal uptake of the radiolabeled 
leukocytes in the cardiac region as pertaining or not to endocardium.   
 
Data Analysis 
Results of 99mTc-HMPAO-WBC scintigraphy were correlated with those of 
TTE, TEE, blood culture and the Duke criteria. The ability to detect or to 
exclude the presence of IE was defined based on the final microbiological or 
clinical diagnosis. Furthermore, in patients with known IE the ability to 
identify septic emboli and metastatic sites of infection was considered, in 
order to assess the ability of 99mTc-HMPAO-WBC scintigraphy to define 
disease burden. 
 No comparative analysis was performed between the stand-alone 
SPECT and the SPECT/CT findings concerning intracardiac location of 
infection, because in case of focal uptake in the cardiac region no further 
topographic localization is possible with the former sets of images, 
considering that the mitral valve and, i.e., the aortic valve (the most frequent 
site of IE) are <1 cm apart one from each other. 
 
Statistical Analysis 





By adopting the interpretation criteria described above for scintigraphic 
detection of infection, it was possible to classify all the scans as either frankly 
positive or frankly negative, therefore without any equivocal result at 
scintigraphy. With these criteria, 99mTc-HMPAO-WBC scintigraphy was 
totally negative in 34/131 patients for either cardiac and/or extracardiac sites 
of focal uptake indicating infection, without any discordant results between 
planar and SPECT/CT acquisitions. At least one abnormal area with focal 
uptake of the radiolabeled leukocytes was detected in 97 out of the 131 
patients included in this study. When considering the 51 patients with final 
diagnosis of IE, the uptake was either limited to the heart only (n=23; Figures 
2.1, 2.2 and 2.3), both at the heart and at extracardiac sites (n=23), or at 
extracardiac sites only (1 case with septic embolism in the spleen, which was 
therefore considered as a false negative scan for IE).  
 
99mTc-HMPAO-WBC SPECT/CT was therefore true positive in 46/51 
and false negative in 5/51 cases. The 5 false negative findings for IE at 99mTc-
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HMPAO-WBC scintigraphy occurred in patients with small valve 
vegetations (<6 mm) and in the presence of infection from Enterococcus 
(n=4) or Candida (n=1); all such patients were under high-dose antimicrobial 
therapy at the time of scintigraphy. There were no false positive scans for 
infection of the cardiac valves. 
 Although both planar and stand-alone SPECT images were 
sufficiently accurate to detect the presence of infection involving the heart in 
the majority of the patients (there were in fact only 4 false negative planar 
scans due to accumulation of the radiolabeled leukocytes hidden by the 
sternum or the ribs), only after co-registration with CT it was possible to 
precisely discriminate the localization of 99mTc-HMPAO-WBC uptake (i.e. 
especially mitral versus aortic valves, given their proximity, metal devices, or 
surgical stitches/clips) from any non-cardiac site of infection in the 
mediastinal space. Out of the total 89 sites of increased 99mTc-HMPAO-WBC 
uptake in the chest, fused SPECT/CT imaging demonstrated heart valve 
localization in 44 cases, as opposed to non-cardiac-valve localizations due to 
infection of aortic graft (n=11), sternum osteomyelitis (n=13), mediastinitis 
(n=3), and lung infection (n=17). For areas with focal 99mTc-HMPAO-WBC 
uptake located outside the thorax, major impact of the SPECT/CT findings 
was observed for infection sites in the CNS and head-and-neck lesions, as 
well as to discriminate between bone infection and soft tissue infection. In 
particular, the exact sites of 99mTc-HMPAO-WBC accumulation were 
diagnosed as CNS, nasal and maxillary sinus infections (in 3 and 5 cases, 
respectively), spleen embolism (n=4) or bone, soft tissue or prosthetic joint 






Figure 2.1 - 99mTc-HMPAO-WBC scintigraphic images in a patient with aortic endocarditis. 
The MIP image (A) demonstrates focal increase of radiolabeled WBCs in the heart region. 
Transiaxial SPECT/CT images (panel B) show that such focal uptake is localized at the 
mechanical prosthesis of the aortic valve (CT section in left panel, fused SPECT/CT section 




Figure 2.2 - 99mTc-HMPAO-WBC SPECT/CT images obtained in a patient with positive 
blood culture and fever arose few months after substitution of the mitral valve with a 
mechanical prosthesis (coronal sections in upper panel, transaxial sections in lower panel; 
CT images in left panels, SPECT/CT images in central panels, SPECT images in right 
panels). SPECT images demonstrate a clear focus of uptake in the right heart, identified as 
endocarditis of the native tricuspid valve by the superimposed SPECT/CT images (central 
panels). Endocarditis of  the mechanical prosthesis, the expected site of infection before 






Figure 2.3 - 99mTc-HMPAO-WBC scintigraphy demonstrating the value of SPECT/CT for 
precisely localizing the site of infection. (A) Planar anterior and posterior views (anterior in 
left panel, posterior in right panel), where focal uptake of radiolabeled WBCs mimic sternal 
osteomyelitis. (B) Coronal, sagittal, and transaxial CT sections in left panels, fused 
SPECT/CT sections in middle panels and SPECT sections in right panels. The tomographic 
images correctly localize uptake of 99mTc-HMPAO-WBCs at the mitral valve prosthesis. 
 
 Septic embolism was detected in 41% of patients (Figure 2.4). Three 
cases interpreted as septic embolism at 99mTc-HMPAO-WBC scintigraphy 
were instead false-positive, due to active vasculitis of the aortic arch, an 
isolated vertebral metastasis from prostate cancer, and an osteoporotic 
vertebral crush, respectively. There were 8 false negative scans for 
extracardiac infection, due to kidney (n=3) or cerebral septic embolism (n=5) 
(all detected by the CT or MRI imaging). 
Table 2.3 correlates the SPECT/CT results and the Duke classification in the 
51 patients with final diagnosis of IE. Most of the added value from the 
99mTc-HMPAO-WBC scan for decision-making was seen in patients in whom 
the Duke criteria yielded "possible" IE. Furthermore, 3 patients were falsely 
positive at echocardiography but correctly negative at 99mTc-HMPAO-WBC 
scintigraphy: these patients had marantic vegetations.  
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Table 2.4 shows the correlation between echocardiographic and 99mTc-
HMPAO-WBC scintigraphic findings. The scan was particularly valuable in 
patients with negative and/or difficult-to-interpret echocardiographic findings 
due to several circumstances, such as mechanical valve implants or the 
presence of huge calcifications (in a diabetic patient undergoing dialysis). 
Table 2.5 correlates the results of 99mTc-HMPAO-WBC scintigraphy 
and blood culture. The most striking result was a positive scan observed in 
patients with negative blood culture; such high negative fraction of false-
negative result of the blood culture could be linked to high-dose antibiotic 
therapy. 
 
Table 2.3: Results of 99mTc-HMPAO-WBC scintigraphy in patients with final diagnosis of 

















Definite IE (24/51) 9 11* 0 4 
Possible IE (25/51) 13 11# 1* 0 
Rejected IE (2/51) 1 1* 0 0 
 
(*) with septic embolism consequent to IE 
(#) 8 patients with septic embolism, 1 with vasculitis, and two false-positive scans due to 
vertebral crush and metastasis from prostate cancer  
 
 
Table 2.4 - Results of 99mTc-HMPAO-WBC scintigraphy in patients with final diagnosis of 
IE, stratified according to echocardiography (ECHO). 
  
  
Positive scan Negative scan 
 
ECHO positive (40/51) 35 5 









Table 2.6 shows results of all the diagnostic procedures in patients without 
IE. Out of the 50/80 patients without IE who exhibited a positive 99mTc-
HMPAO-WBC scintigraphy (only at extracardiac sites), the scan correctly 
classified such patients as having either osteomyelitis (n=22), peripheral 
vascular graft infection (n=12), lung infection (n=7), mediastinitis (n=5), or 
cholecystitis (n=2). In 2 cases focal uptake of the radiolabeled leukocytes in 
the spine was falsely positive for infection, as it was due to vertebral crush 
caused by osteoporosis in one case, by metastasis from a melanoma with 
unknown primary site in the other case. 
 
 
Figure 2.4 - Examples of septic embolism at 
different sites as detected by 99mTc-HMPAO-
WBC SPECT/CT. (A) Patient with septic 
embolism in the left lung (coronal, sagittal 
and transaxial CT sections in left panels, 
fused SPECT/CT sections in middle panels, 
and SPECT sections in right panels). (B). 
Patient with spetic embolism in the spleen, 
where infection shows as a photopenic area 
in the splenic parenchyma (transaxial CT 
section in left panel, fused SPECT/CT 
section in center panel, SPECT in right 
panel). (C) Patient with septic embolism in 
the spine (coronal, sagittal and transaxial CT 
sections in left panels, fused SPECT/CT 
sections in middle panels, and SPECT 
sections in right panels). Similarly as in the 
case of the spleen, infection shows as a 
photopenic area which in this patient 




Table 2.5 - Results of 99mTc-HMPAO-WBC scintigraphy in patients with final diagnosis of 
IE, stratified according to blood culture. 
  
















 1 1 
 
(*) 11/14 with septic embolism consequent to IE and two false-positive scans due to 
vertebral crush 
(#) during antibiotic therapy in 44/64 patients  
(§) 8/9 with septic embolism consequent to IE and one false-positive scan due to vasculitis 
 





Positive scan*  Negative scan 
ECHO  positive (n = 3/80) 0 3 
 negative (n = 77/80) 0 77 
Blood culture positive (n = 35/80) 26 9 
 negative (n = 45/80) 24 21 
Dukes criteria 
Definitive IE (n = 4) 4 0 
Possible IE (n =30) 19 11 
Rejected IE (n =46) 27 19 




The diagnosis of IE is becoming progressively more challenging due to a 
variety of factors. These include the indiscriminate use of antimicrobial 
agents in some clinical settings, the increased proportion of individuals with 
predisposing and/or underlying conditions (i.e., frail and elderly, 
immunosuppressed persons), as well the increasing number of interventional 
cardiovascular procedures and placement of valve prosthesis, intravascular, 
or cardiac devices. Mortality of IE remains high when this condition is 
undiagnosed, therefore not adequately treated (14). Early diagnosis and 
prompt institution of appropriate antibiotic therapy reduce septic embolism 
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and mortality (15); therefore, the identification of patients at highest risk of 
death may offer the opportunity to change the course of the disease and 
improve prognosis.  
 Because of the ability to detect endocardial vegetations (16), abscess 
(17) as well as intra-cardiac complications (i.e., valve perforation and chordal 
rupture) (18), echocardiography is the indirect method of choice for 
investigating patients with clinical suspicion of IE (19,20). Furthermore, 
some echocardiographic features such as vegetation size (higher risk for 
lesions >10 mm in diameter and for vegetations that are increasing in size), 
number (multiple) and features (mobile but pedunculated, noncalcified, 
prolapsing) (20) may be also used to predict the potential embolic burden of 
IE. However, the presence of prosthetic valves consistently decreases 
sensitivity and specificity of echocardiography, to about 20% for TTE and 
around 90% (in the hands of an experienced operator) for TEE (8). In 
approximately 15% of the cases, echocardiography can be false positive 
(because thickened valves, nodules, or valvular calcifications are 
misinterpreted as vegetations) (4), while a similar proportion can be false 
negative (4). Thus, echocardiographic findings alone cannot always definitely 
confirm nor exclude the clinical suspicion of IE. Since echocardiography 
represent the backbone of Duke criteria, this suboptimal diagnostic accuracy 
translates into a relatively high proportion of the cases classified as "possible" 
IE; yet, about 24% of such cases are eventually diagnosed to have indeed IE 
(5). 
 Additional potentially misleading factors in the Duke's classification 
include some well-known pitfalls in blood culture (antimicrobial treatment, 
subacute right-sided and mural endocarditis (21), fungi, slow-growing and 
difficult to identify organisms) (22), and ambiguous symptoms without any 
of the classical stigmata of valvular infection. 
 A functional imaging modality such as radionuclide imaging, capable 
of characterizing specific features of the endocardial vegetations, may 
contribute to solve clinical dilemmas in such conditions. In our experience, 
when the results of 99mTc-HMPAO-WBC scintigraphy were associated with 
either a positive echocardiography or a positive blood culture no cases of IE 
went undiagnosed. In particular, the radiolabeled leukocyte scan facilitated 
the diagnosis of IE in challenging situations for echocardiography, as in the 
presence of mechanical prosthetic valve, anuloplasty rings, calcifications, 
and/or nonbacterial thrombotic vegetations. Furthermore, 99mTc-HMPAO-
WBC scintigraphy allowed to exclude valve infection in patients with 
concomitant risk factors, non-diagnostic echocardiographic findings, positive 
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blood cultures (37% of the cases in our series), or to identify other focal 
infections different from IE (as occurred in 38% of the overall 131 patients). 
99mTc-HMPAO-WBC scintigraphy can therefore be considered as the second-
line test of choice in patients with prosthetic valve/device, fever, positive 
blood cultures and equivocal TTE/TEE findings. 
 This study confirms that 99mTc-HMPAO-WBC scintigraphy is a 
crucial imaging modality also for localizing sites of infection in patients with 
symptoms and signs and laboratory findings of sepsis (increased ESR, CRP, 
and WBC count) (12) with either a positive or a negative blood culture. In 
these patients generally neither TEE nor TTE are used for screening purposes 
(4) and, therefore, the heart region should always be carefully evaluated when 
analysing the 99mTc-HMPAO-WBC scan. 
 The possibility of acquiring whole-body images and additional planar 
and SPECT/CT spot images constitutes an invaluable aid for detecting septic 
embolism and metastatic sites of infection, as observed in our patients 
population. In particular, septic embolism was detected even in the absence 
of the typical echocardiographic predictors of systemic embolism (8,20).  
 These results refer only to patients with IE arising on native and 
prosthetic valves since we intentionally excluded patients with device related 
infection.  In fact, we consider not possible to apply the same diagnostic 
algorithm intended for IE to this different clinical entity. 
 Specific methodology-related issues must be properly addressed in 
order to ensure adequate scintigraphic acquisitions. Images should be 
acquired in time-mode, compensating for isotope decay at each time point. In 
case of equivocal findings at 6 hours SPECT/CT imaging of the thorax, 
images should be repeated also at 24 hours. Images should be analysed using 
the same scale frame to easily identify any focal area of activity that increases 
over time or modifies its shape from early to late images. Both CT-
attenuation corrected and non-corrected images should be always inspected 
side by side, to minimise metal-related artefacts. Quantitative analysis of 
target/background (T/B) ratios was not necessary in these patients. 
SPECT/CT is mandatory to correctly interpret and localize sites and 
extension of radiolabeled leukocyte uptake indicating infection (23), to 
discriminate involvement of the heart valve or prosthesis from uptake around 
the prosthesis. Furthermore, in cases with positive scintigraphy in the cardiac 
region SPECT/CT imaging can discriminate endocardial infections from all 
other possible causes of post-surgical fever, i.e., mediastinitis, osteomyelytis 
of the sternum or ribs, wound infections. 
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No false positive findings were found, particularly in patients with 
early IE evaluated within the first two months from the surgical procedure, 
suggesting that adequate acquisition protocol and interpretation criteria can 
optimize specificity of the scan also in this clinical setting. On the other hand, 
the false negative scans observed in presence of IE sustained by Candida spp. 
or Enterococcus spp. may be explained by the ability of these micro-
organisms (as well as others such as S. epidermis) of forming a "biofilm" that 
results in resistance to antimicrobial treatment and escape from the host 
defence mechanisms (24). Additionally, altered neutrophil recruitment at the 
primary site of IE by E. faecalis extracellular proteases constitute a further 
mechanism of innate immune response impairment (25). Such mechanisms 
might reduce sensitivity of scintigraphy with radiolabeled leukocytes in 
patients with IE. However, in our experience the reduced sensitivity of 99mTc-





 Both false negative and false positive findings were also observed in 
our patients' group regarding distant septic embolism. In particular, the 
typical 99mTc-HMPAO-WBC scintigraphic pattern of spleen embolism and 
spondilodiscitis represented by a cold spot (26) may be also present in other 
benign or malignant conditions. Thus, despite highly suggestive for septic 
embolism, such finding in patients with IE should be confirmed with 
additional diagnostic imaging, as MRI. Finally, it is reasonable to assume that 
the availability of new generation SPECT/CT scanners with a more advanced 
CT component will further increase diagnostic accuracy, particularly when 
evaluating the CNS and bone. Alternatively, PET/CT imaging may be 
proposed to improve spatial resolution. In this regard, preliminary data have 
Figure 2.5 - False positive [18F]FDG 
PET/CT result in a patient with fever. The 
area of increased [18F]FDG uptake suspected 
for endocarditis at a mitral valve mechanical 
prosthesis (A, central panel fused transaxial 
PET/CT and right panel PET stand alone) 
turned out to be negative in the 99mTc-
HMPAO-WBC SPECT/CT (B; central panel 
fused transaxial SPECT/CT and right panel 
SPECT) clinical follow-up confirmed the 





demonstrated significant uptake of [18F]FDG both in infected endocardial 
vegetations and at metastatic sites of infection (27-30). However, [18F]FDG 
uptake is observed in a variety of benign and malignant conditions such as 
inflammation or tumours (31), thus reducing its specificity. Moreover, special 
caution should be employed when interpreting of [18F]FDG uptake in the 
cardiac region, due to the high number of possible causes other than IE for a 
positive scan: recent thrombi (32), soft atherosclerotic plaques (33), vasculitis 
(34), primary and metastatic cardiac tumors (35,36), or simply post-surgical 
inflammatory reaction (37). In the clinical routine, focal areas of [18F]FDG 
uptake at heart site in the absence of IE are quite commonly observed 
(unpublished data, see Figure 2.5). The possibility of efficient radiolabelling 
of autologous leukocytes with positron emitting radionuclides can be 
expected to change the whole scenario of PET imaging for patients with 
suspected IE. In this regard, intense [18F]FDG-WBC uptake at the valve site 
has been described for the only patient with IE ever reported up to now (38). 
Unfortunately, the physical half-life of 18F is too short to encompass the 
whole kinetics of leukocyte migration into sites of infection, thus making a 




In conclusion, our experience supports the use of scintigraphy with 99mTc-
HMPAO-WBC in patients with high clinical suspicion of IE, in order to 
confirm the diagnosis in doubtful circumstances and/or to detect sites of 
septic embolism. The rate of misdiagnosed IE can be reduced with the use of 
99mTc-HMPAO-WBC (a) in patients with high clinical suspicion but 
inconclusive echocardiographic findings; (b) for the differential diagnosis 
between septic and sterile vegetations detected at echocardiography; (c) when 
echocardiographic, laboratory and clinical data are contradictory, as also to 
exclude valve involvement (especially of a prosthetic valve) during febrile 
episodes, sepsis or post-surgical infections.  
SPECT/CT is necessary to demonstrate and localize 99mTc-HMPAO-WBCs 
at native or prosthetic valves, thus confirming the diagnosis of IE. 
Furthermore, whole-body images followed by additional planar and 
SPECT/CT spot images allow to detect distant sites of septic embolism, thus 
constituting an invaluable aid of this scintigraphic procedure. Negative 
results in presence of a typical echocardiographic pattern for IE should be 
carefully evaluated, since false negative findings due to limited spatial 
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Objectives: We investigated the diagnostic performance of 99mTc-HMPAO-
labeled autologous leukocyte (99mTc-HMPAO-WBC) scintigraphy in patients 
with suspected infections of cardiovascular implantable electronic devices 
(CIED). Background: Early, definite recognition of CIED infections 
combined with accurate localization and quantification of disease burden is a 
prerequisite for optimal treatment strategies. Methods All 63 consecutive 
patients underwent clinical examination, blood chemistry, microbiology and 
echography of the cardiac region/venous pathway of the device. Final 
diagnosis of infection was established in 32/63 patients, in 23/32 by 
microbiology. Results: 99mTc-HMPAO-WBC SPECT/CT had 94% sensitivity 
for both detection and localization of CIED-associated infection. SPECT/CT 
imaging had a definite added diagnostic value over both planar and stand-
alone SPECT. Pocket infection was often associated with lead(s) 
involvement; the intracardiac portion of the lead(s) more frequently exhibited 
99mTc-HMPAO-WBC accumulation and presented the highest rate of 
complications, infectious endocarditis and septic embolism. Two false-
negative cases and no false positive results were observed. None of the 
patients with negative 99mTc-HMPAO-WBC scintigraphy develop CIED 
infection during follow-up until 12 months. Echography of the cardiac 
region/venous pathway of the device had 90% specificity, but low sensitivity 
(81%, when considering only intracardiac lead(s) infection). The Duke 
criteria had 31% sensitivity for the “definite” category (100% specificity) and 
81% for the “definite+possible” categories (77% specificity). Conclusions: 
99mTc-HMPAO-WBC scintigraphy enabled to confirm the presence of CIED-
associated infection, to define the extent of device involvement, and to detect 
associated complications. Moreover, 99mTc-HMPAO-WBC scintigraphy 
reliably excluded device-associated infection during a febrile episode and 
sepsis, with 95% negative predictive value. 
  







Use of cardiovascular implantable electronic devices (CIED) has increased 
significantly over the last decade due to growing evidence of improved 
quality of life and survival among certain groups of patient (1); such devices 
include permanent pacemakers (PM), the implantable 
cardioverter/defibrillators (ICD), and cardiac resynchronization therapy 
devices. Associated complications, particularly infections, have risen 
disproportionally higher than the growth of newly implanted devices (2). The 
rate of CIED infections varies widely between 1% and 7% (3), with 
significant morbidity and mortality especially in case of delayed diagnosis 
(4). Therefore, strategies to facilitate early diagnosis are crucial for favorable 
clinical outcome.  
Diagnostic workup of CIED infections is problematic, since patients can 
present with a variety of manifestations including subtle signs of systemic or 
local infection (5). The decision whether to medically treat or to remove the 
device represents a further crucial point, also because it implies evaluation of 
response to antimicrobial therapy and selection of the optimal time to re-
implant (6).  
 Final diagnosis of CIED infection is generally based on 
microbiological tests (blood cultures and culture of material from exposed 
sites of implantation) and ultrasound evaluation of the cardiac region (either 
transthoracic and transesophageal) and of the venous pathway of the device. 
The above tests constitute the basis for defining the patients' likelihood to 
have CIED according to the Duke criteria (7). However, in case of CIED 
infections the Duke criteria, originally developed for the diagnosis of 
infectious endocarditis, may be inadequate; even with the addition of clinical 
parameters (8), the possibility remains high of missing the presence and/or 
underestimating the extent of infection (5). 
Evidence is growing that positron emission tomography co-registered with 
computed tomography using 18F-labelled fluorodeoxyglucose ([18F]FDG 
PET/CT) improves the diagnosis of CIED infections (9-11). On the other 
hand, in the era of high spatial resolution hybrid systems for single photon 
emission tomography co-registered with computed tomography (SPECT/CT), 
scintigraphy with radiolabeled autologous leukocytes represents a valuable 
option for imaging patients with suspected CIED infections, as already 
demonstrated in a number of other clinical conditions such as native and 
prosthetic valve endocarditis (12). These functional imaging modalities are 
based on the ability to detect and localize metabolically active cells, such as 
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those involved in inflammation and infection. By following the pattern of 
radiolabeled leukocyte accumulation over time and by using well-defined 
interpretation criteria (13), it is possible to discriminate active infection from 
inflammatory changes (e.g., post-surgical changes, foreign body reactions) 
and to define the extent of active infection.  
In this study we investigated the diagnostic performances of 
radiolabeled leukocyte scintigraphy in suspected CIED infection, by 
evaluating with 99mTc-hexamethypropylene amine oxime labeled autologous 
leukocytes (99mTc-HMPAO-WBC) SPECT/CT all consecutive patients 
referred to the Division of Cardiology or Infectious Diseases of our hospital 
because of such condition.  
 
Material and methods 
 
Study design and patient population 
 
Between June 2007 and June 2011 a total of 63 consecutive patients (47 men 
and 16 women with mean age 68.6±13.9 years, median age 70, range 27-87) 
were referred for scintigraphy with radiolabeled autologous leukocytes 
(99mTc-HMPAO-WBC), recording both planar and SPECT/CT acquisitions 
and results were retrospectively evaluated. All patients provided informed 
consent to the procedure. Patients workout consisted of clinical examination, 
blood chemistry including WBC counts, C-reactive protein, erythrocyte 
sedimentation rate, acute phase proteins, electrophoresis, urine-analysis, 
transthoracic and transesophageal echocardiography (TTE and TEE, 
respectively), and ultrasound evaluation of the venous pathway. Three sets of 
peripheral venous blood samples were obtained for cultures, including at 
least one aerobic and one anaerobic (14). Scintigraphy was performed in all 
cases of unconfirmed diagnosis of CIED-infection at the end of the described 
conventional procedures. After 99mTc-HMPAO-WBC, treatment was decided 
on the basis of the degree of certainty of the CIED infection diagnosis as 
results of conventional tests and clinical guidelines: 35 patients were treated 
with either device extraction followed by antimicrobial therapy as previously 
described (15) , 9 patients with antimicrobial therapy alone, 11 patients with 
other disease-specific surgical procedures. Eight patients received no 
treatment. Results of 99mTc-HMPAO-WBC was not used to guide the final 
decision on the management of patients when a high clinical suspicion of 
CIED-infection based on either a diagnostic echocardiography (n=7) or a 
positive blood-culture (n=12) was present since these patients underwent 
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device extraction followed by antimicrobial therapy (see Figure 3.1). In cases 
of antimicrobial therapy alone or no treatment, clinical follow-up of at least 
12 months was available for final classification. All 9 patients undergoing 
antimicrobial therapy alone repeat 99mTc-HMPAO-WBC scintigraphy at the 
end of the standard antimicrobial therapy. A total of 75 exams were therefore 
performed, 63 baseline and 12 follow-up studies; in particular, 9 patients had 
repeat studies (6 with one follow-up scan 6 months apart, 3 with two follow-




Figure 3.1 – Schematic representation of the clinical management of patients included in the 
study according to the final diagnosis of CIED-related infection (left panel) or exclusion of 
CIED-related infection (right panel). BC = blood culture; ECHO = echocardiography.  
 
 
 The main clinical features of patients and type of devices implanted 
are reported in Table 3.1.  
Final diagnosis of CIED-associated infection was established in 32/63 
patients (see Table 3.2); in 23 of these 32 patients diagnosis was confirmed 
by microbiology after extraction of the device. In the remaining 9/32 cases 
the diagnosis was obtained with clinical follow-up of at least 12 months 
based on negative finding at clinical examination, sequential blood tests, 
TTE/TEE, ultrasound evaluation of the venous pathway and 99mTc-HMPAO-
WBC scintigraphy following antimicrobial treatment.   
 Staphylococcus spp. was the microorganism more frequently 
responsible for CIED-associated infection (12/32), followed by Streptococcus 
spp. (8/32), Enterococcus spp. (3/32), Enterobacteriaceae spp., Micrococcus 
and Candida (2 each); P. aeruginosa, Acinetobacter baumanni, Propionibacter 
Acnes were identified in 1 patient each.  
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 Infection occurred most frequently early after implant (6/8 of patients 
evaluated <1 month and 5/13 cases evaluated 1-3 months after implantation). 
Semi-late and late infections were observed in 8/18 and in 13/22 patients, 
respectively (see Table 1). Nineteen out of the 32 infections occurred after 
the second implantation procedure. 
 
Table 3.1 – Type of cardiac devices and main clinical features of the patients included in the 
study (PM = pace-maker; ICD = implantable cardioverter defibrillator; ESR = erythrocyte 
sedimentation rate; CRP = C-reactive protein). 
 
Type of device single-




































































































 49/63 (77%) 42/63 (67%) 29/63 (46%)   
Microbiological 
results 
 Positive Negative   
 Blood culture 28/63 (44%) 37/63 (56%)*   





















       
         - 
   
 
* during antibiotic therapy in 8/16 patients 
** extraction was performed in a total of 35 patients including 11 resulting without 
CIED associated infection; 9/32 patients with CIED infection did not undergo 
extraction 
 
Radiolabeling and acquisition protocol 
 
Autologous radiolabelled WBCs were prepared according to the EANM 
Guidelines for labeling leukocytes with 99mTc-HMPAO (16, 17). 
Radiolabelling efficiency was always between 70-85%;viability of the 
radiolabelled leukocytes was always evaluated by the Tripan blue exclusion 
test before reinfusion. Radiolabelling of leukocytes with  99mTc was preferred 
over the radiolabelling with 111In for both radiation safety (0.017 mSv/MBq 
with a recommended administered activity of 185-370 Mbq for 99mTc versus 
0.59 mSv/MBq with a recommended administered activity of 10-18.5 Mbq 
for 111In) (13,18) and  imaging quality when performing SPECT/CT. 
 Whole body and spot planar images were obtained after 30 minutes, 
then 4-6 (early images) and 20-24 hours (delayed images) after reinfusion of 
370-555 MBq of 99mTc-HMPAO-WBC. SPECT/CT of the chest was 
performed in all patients at 6 hours and repeated at 24 hours in case of 
negative or doubtful imaging at 6 hours. Images were acquired using a dual-
head, variable-angle SPECT/CT gamma camera (Hawkeye and Discovery 
670, GE Healthcare) as previously reported (12). Both CT-attenuation 
corrected and non-corrected SPECT images were evaluated in the coronal, 
transaxial, and sagittal planes, as well as in tridimensional maximum 
intensity projection (MIP) cine mode. Matching pairs of x-ray transmission 
and radionuclide emission images were fused using the Xeleris software, and 






All images were re-evaluated, independently, by two experienced nuclear 
physicians aware of the patients’ clinical history and of the results of prior 
conventional imaging. Images were first visual inspected to exclude 
misregistration between the SPECT and the CT components. Thereafter, for 
all sets of images the presence and location of any focus of abnormal 
radioactivity accumulation indicating infection was evaluated. The 
scintigraphic studies were classified as negative when no sites of abnormal 
uptake were observed in the SPECT/CT images, or positive for infection 
when at least one focus of abnormal uptake characterized by time-dependent 
increase in radioactivity between early and delayed images was observed 
(13). When present, focal uptake indicating infection was further classified 
as: a) isolated pocket infection; b) isolated lead infection at either the 
intravascular or the intracardiac portion of the lead; c) pocket and lead 
infection (either intravascular or intracardiac portion); d) concomitant 





Results of 99mTc-HMPAO-WBC scintigraphy were correlated with those of 
ultrasonography (echocardiography + soft tissue/venous ultrasound), with the 
Duke criteria classification and with final microbiological or clinical 
diagnosis. Furthermore, the ability to identify concomitant endocarditis as 
well septic emboli was considered, in order to assess the ability of 99mTc -
HMPAO-WBC scintigraphy to define disease burden.  
For the site-based analysis, results of the planar, stand-alone SPECT and 
SPECT/CT images were compared. Stand-alone SPECT and SPECT/CT 
were considered to have a definite added value when they provided data that 
could not be obtained from planar imaging concerning the presence of 
infection or its precise location. The contribution of SPECT/CT was 
considered with special attention to the possibility of anatomically localizing 




All values are expressed as median and range, as customary for 
nonparametric data. The Pearson’s χ2 test was employed for comparing 
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nominal data between groups. The interobserver agreement was determined 
and expressed in a weighted kappa which corrects for agreement by chance. 
The higher the kappa, the higher the agreement, with a maximum of 1.0:  <0 
= no agreement, 0.0–0.19 = poor agreement, 0.20–0.39 = fair agreement, 
0.40–0.59 = moderate agreement, 0.60–0.79 = substantial agreement, 0.80–
1.00 = almost perfect agreement (19). In case of disagreement between the 
two observers a final consensus reading was performed. Sensitivity, 
specificity, accuracy, positive predictive value and negative predictive values 
of echocardiography, Duke’s criteria and 99mTc-HMPAO-WBC planar, stand-
alone SPECT, and SPECT/CT imaging were calculated based on the final 





99mTc-HMPAO-WBC scintigraphy in patients with CIED related infections 
 
By adopting the interpretation criteria described above for scintigraphic 
detection of infection evaluating the best-performing imaging, i.e., 
SPECT/CT, it was possible to classify all the scans as either frankly positive 
or frankly negative, therefore without any equivocal result. The kappa value 
for interobserver agreement was 0.951 (95% CI; 0.909–1.000).  
The 99mTc-HMPAO-WBC scans were totally negative in 22/63 cases. At least 
one area with focal accumulation of the radiolabeled leukocytes was detected 
in the remaining 41 patients.  
99mTc-HMPAO-WBC scintigraphy was true positive in 30/32 patients with 
final diagnosis of CIED-associated infection (94%). The two false negative 
scans were observed in patients with CIED infections caused by Candida and 
Enterococcus (final diagnosis obtained by culture of the leads). One of these 
two patients also had false negative echocardiography and was classified as 
“rejected” infection according to the Duke criteria; the second false-negative 
scintigraphy case was true positive at echocardiography and classified as 
“definite” infection according to the Duke criteria. Both the latter patients 
were under antimicrobial therapy at the time of scintigraphy. There were no 
false positive scans for CIED infection. Figure 3.2 shows an example of 
positive 99mTc-HMPAO-WBC scintigraphy for infection localized at the 
pocket. Figures 3.3 and Figure 3.4 show the scintigrafic pattern of  infection 







Figure 3.2 - (A) 99mTc-HMPAO-WBC scintigraphy in a patient with localized pocket 
infection, with transaxial slices shown at different levels (CT sections in upper panel, 
corresponding fused SPECT/CT sections in lower panel). Obvious focal accumulation of 






Figure 3.3 - (A) 99mTc-HMPAO-WBC scintigraphy in a patient with clinically ascertained 
pocket infection with transaxial slices shown at different levels (CT sections in upper panel, 
corresponding fused SPECT/CT sections in lower panel). Obvious focal accumulation of 
radiolabelled leukocytes involving both the pocket and the intravascular portion of the lead. 






Figure 3.4 - 99mTc-HMPAO-WBC scintigraphy in a patient with suspected CIED infection. 
Obvious focal accumulation of radiolabelled leukocytes at the heart region in the SPECT 
coronal (A left panel) and transaxial images (B left panel); fused SPECT/CT sections exactly 
localized the focus of infection at the intracardiac lead (right panels). CT images are shown 
in middle panels. 
 
 
SPECT/CT acquisition provided higher accuracy both for detecting infection 
and for localizing 99mTc-HMPAO-WBC accumulation at any portion of the 
device, the heart valves or other non-cardiac sites of infection in the thoracic 
and mediastinal space. SPECT/CT acquisitions changed the final 
classification of the scan from negative to positive for CIED-associated 
infection in 15/32 of the cases as compared to the standard planar and 9/32 as 
compared SPECT-alone acquisition (χ² = 4.5, p = 0.03, Table 3.3). It should 
also be noted that no false positive findings due to artifacts were detected in 
both the attenuation-corrected and the non-attenuation corrected images. 
Table 3.4 summarizes the results of 99mTc-HMPAO-WBC scintigraphy 
(considering the best nuclear imaging technique i.e. SPECT/CT), of 
echocardiography and of classification according to Duke criteria in the cases 
with final diagnosis of CIED infection. Table 3.5 correlates the results of 
99mTc-HMPAO-WBC scintigraphy with the results of echocardiography and 
with the Duke classification, stratifying the patients according to the site of 
radiolabeled leukocyte accumulation, as follows: at the pocket, at the 
intravascular and/or intracardiac portion of the lead(s), at both the pocket and 
the lead(s). Sites of 99mTc-HMPAO-WBC accumulation consistent with 
additional infections (n=38) are also indicated.  
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Particular attention was paid to identification of concomitant infectious 
endocarditis (6 cases, see Figure 3.5) and distant septic embolism 
(osteomyelitis n= 6, vascular graft infection and lung infection n= 4 each, 
spetic embolism in the spleen n= 1). Septic embolism causing ophtalmitis or 
cerebral infection (one case each), detected by CT, remained undiagnosed on 





Figure 3.5 - 99mTc-HMPAO-WBC coronal images (A) and transaxial images at different 
levels (B and C) in a patient with CIED presenting with positive blood culture and fever 
three months after mitral valve replacement. SPECT images (left panels) depict focal 
accumulation of 99mTc-HMPAO-WBC at both the intracardiac leads (A and B) and the mitral 
valve mechanical prosthesis (C). SPECT/CT images are shown at right panels and CT 
images in middle panels. 
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for other sites 
of infection 
Planar images 15/32 11/32 6/32 12/32 36/43* 12/18† 3/6 9/15 7/15 
SPECT 21/32 9/32 2/32 21/32 42/43 13/18† 4/6 13/15 11/15 
SPECT/CT 30/32 - 2/32 30/32 43/43 15/18† 6/6 15/15 15/15 
 
* Including 5 false positive cases due to sternal osteomyelitis and mediastinitis 
†  Including 3 false negative cases due to ophtalmitis and cerebral infection 
 
 
Table 3.3b: Diagnostic performances of 99mTc-HMPAO-WBC planar, SPECT and SPECT/CT acquisitions for the diagnosis of CIED-associated 
infection. 
 








53.1%         
(40.2%-65.6%) 
83.9%            
(72%-91.5%) 
68.3%    
(55.2%-79.1%) 
77.3%            
(64.7%-86.5%) 




71.9%         
(58.9%-82.1%) 
96.8%         
(87.9%-99.4%) 
84.1%    
(72.3%-91.7%) 
95.8%            
(86.6%-99%) 




93.7%         
(83.9%-98%) 
100%          
(92.8%-100%) 
96.8%             
(88%-99.4%) 
100%             
(92.8%-100%) 
93.9%              
(84.1%-98.1%) 
 
* planar images versus SPECT images χ² = 0.4, p = 0.5; planar images versus SPECT/CT images χ² = 3.5, p = 0.06, by McNemar test 
#






Table 3.4: Results of 99mTc-HMPAO-WBC scintigraphy, echocardiography and Duke criteria according to the final diagnosis of CIED infection or no 
infection for all the exams performed at baseline (by McNemar test 99mTc-HMPAO-WBC images versus echocardiography χ² = 2.6, p = 0.1; 99mTc-HMPAO-
WBCimages versus Duke Criteria considering as positive for IE the only “Definite” category χ² = 20, p < 0.001  and versus Duke Criteria considering as 














Positive 30/32 0/31 93.7%    
(83.9%-98%) 
100%     
(92.8%-100%) 
96.8%             
(88%-99.4%) 
100%     
(92.8%-100%) 
93.9%       
(84.1%-98.1%) Negative 2/32 31/31 
Echocardiography 
Positive 20/32 4/31 62.5%    
(49.4%-74.1%) 
87.1%    
(75.7%-93.8%) 
74.6%          
(61.8%-84.4%) 
83.3%    
(71.4%-91.1%) 
69.2%       
(56.2%-79.9% Negative 12/32 27/31 
Duke Criteria 
Definite 10/32 0/31 31.3%*  (20.5%-44.3%) 
100%*    
(92.8%-100%) 
65.1%*        
(51.9%-76.4%) 
100%*   
(92.8%-100%) 
58.5%*     
(45.4%-70.5%) 
Possible 16/32 8/31 81.3%
#         
(69%-89.6%) 
74.2%#    
(61.4%-84%) 
52.4%#        
(65.2%-86.9%) 
76.5%#   
(63.8%-85.9%) 
79.3%#     (66.9%-
88.1%) 
Rejected 6/32 23/31      
 
* Considering as positive for IE the only “Definite” category 
#













Table 3.5: Results of 99mTc-HMPAO-WBC scintigraphy, echocardiography and Duke criteria according to the final diagnosis for all the exams 
























accumulation 1 1 18*
†
 2 2 4* 2 15 
Echo 
pos   14‡ 2  2 2 3 
neg 1 1 8‡  2 2  12 
Duke 
criteria 
Definite    8 3  
Possible   13 3 3 
Rejected 1   2 2 12 
* with concomitant IE and/or extracardiac localization for a total of 6 cases* and  15 cases † 
















Blood cultures were positive in only 28/63 of the patients (16/32 of the cases 
with confirmed CIED infection); 28/35 of the blood-culture negative patients 
with CIED infection were under antimicrobial treatment at the time of 
assessment. All the 5 cases of CIED infection with positive blood culture and 
negative TEE and intact pocket, had a true positive 99mTc-HMPAO-WBC 
SPECT/CT examination. 
99mTc-HMPAO-WBC SPECT/CT ruled out device involvement during a 
febrile episode and sepsis (20/63 with positive blood culture), correctly 
excluding the presence of device involvement in 31/63 of cases.  
 
 
99mTc-HMPAO-WBC scintigraphy in patients without CIED infections 
 
As to the 11 baseline scans showing focal accumulation of radiolabeled 
leukocytes in patients without CIED infection, scintigraphy actually detected 
alternative sites of infection occurring in the patients (with sensitivity and 
specificity of 93% and 91%, respectively, Table 3.6). These patients was 
subsequently treated according to standard procedures as indicated for the 
each clinical condition and none of them, including patients with positive 
blood culture, developed CIED infection during follow-up. 
 
Table 3 6: results of the 99mTc-HMPAO-WBC scintigraphy in patients with suspected CIED 
infection where scintigraphy actually detected alternative sites of infection. 
 
Type of infections  
osteomyelitis* 5 
vascular graft infection 2 
mediastinitis 2 
lung infection 2 
cholecystitis 2 
 
* including two spondilodiscitis 
 
Follow-up studies  
 
Follow-up studies performed 6-9 months after the baseline scintigraphy 
showed the disappearance of all the sites of radiolabeled leukocyte 
accumulation in 7/9 patients, thus allowing to discontinue antimicrobial 
treatment in these patients. In the remaining 2 patients 99mTc-HMPAO-WBC 
positivity resulted in prolonged medical treatment, that was stopped only 
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after normalization of a third 99mTc-HMPAO-WBC scintigraphy performed 6 





Infections of CIEDs are associated with significant morbidity and high death 
rate, particularly in presence of endovascular infection (20%) (6, 20). The 
incremental cost for managing CIED infection has been estimated to be about 
$ 28,676 to $ 53,349 (21), nearly half of this amount being due to intensive 
care procedures (4). Furthermore, device replacement procedures that are 
periodically necessary for battery depletion or for upgrading are associated 
with infection rates higher than those occurring after initial implantation (3).  
Early, definite recognition of CIED infection combined with accurate 
localization and quantification of disease burden could provide a rational 
basis for adopting optimal treatment strategies, that have so far not been 
sufficiently defined.  
In this work we evaluated a consecutive series of patients in whom the 
suspicion of CIED infection had been raised on clinical ground. All patients 
underwent 99mTc-HMPAO-WBC scintigraphy with the purpose of validating 
the use of this procedure to confirm CIED infection and to define disease 
burden, the final diagnosis being obtained either by microbiology in 23/32 or 
with clinical follow-up of at least 12 months in the remaining cases.  
99mTc-HMPAO-WBC scintigraphy had 94% sensitivity and no false positive 
results were found, thus confirming the validity of the interpretation criteria 
adopted (increasing radiolabeled leukocyte recruitment over time at infection 
sites) as a diagnostic parameter enhancing specificity (16). Conversely, the 
two false negative cases of 99mTc-HMPAO-WBC scintigraphy observed in 
our series were most likely due to infection caused by low-leukocyte 
recruiting microorganisms (22-24) as are the Candida spp. and Enterococcus 
spp. strains isolated in the two patients with confirmed CIED infection in 
whom 99mTc-HMPAO-WBC scintigraphy was negative. Therefore, when 
infections sustained by such microorganisms are suspected discontinuation of 
antimicrobial treatment should be considered to enhance diagnostic 
performances of  99mTc-HMPAO-WBC scintigraphy.  
The 99mTc-HMPAO-WBC SPECT/CT images aided not only in diagnosing 
infection, but also in defining the infection burden, in particular by 
distinguishing patients with infection limited to either the pocket or the 
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lead(s) from patients with more severe infection involving both the pocket 
and the lead(s), or other sites of infection in some patients.  
The intracardiac portion of the lead(s) was the site more frequently exhibiting 
radiolabeled WBC accumulation (n=18); these cases were also more 
frequently associated with complications such as either infectious 
endocarditis (n=6) and/or septic embolism (n=15). The higher prevalence of 
infection of the intracardiac portion of the lead(s) over the surgical pocket is 
consistent with the relatively high prevalence of semi-late and late infections 
in our patients' population, similarly to data reported in literature due to 
slowly progressing, implant-related infection (25). Indeed, localized pocket 
infection was found in just one of our patients, while in all the other cases 
infection of the pocket was associated with lead(s)' involvement. An 
important feature of 99mTc-HMPAO-WBC scintigraphy is therefore its unique 
ability, shared only with PET/CT, to detect all sites of infection with a single 
examination, considering the frequent underestimation of the infection 
burden based on clinical signs alone (26). 
As customary in case of suspected CIED-associated infection, all patients 
included in this study underwent echography of the cardiac region and of the 
venous pathway of the device as a first-line diagnostic test. In this group of 
patients, echocardiography had high specificity (90%), but relatively low 
sensitivity for diagnosing CIECD infection (63%). The echocardiographic 
finding of vegetations at the distal part of the lead typical for infection (27) 
was detected in 9/32 patients with confirmed infection. On the other hand, in 
4/31 patients who were eventually classified as not having infection, a lead-
associated mass, possibly of thrombotic nature, was also detected, in line 
with a previous report (28). Moreover, in 12/32 patients with final diagnosis 
of CIED infection TEE failed to visualize a mass adherent to the intracardiac 
lead, thus confirming that a negative echocardiography does not exclude lead 
infection (29). In 6 out of these 12 cases with negative echocardiography, 
99mTc-HMPAO-WBC SPECT/CT detected infection, which was localized 
either at the intravascular portion of the lead(s) and/or at the surgical pocket 
(Table 4). Therefore, when considering the echocardiographic findings in 
patients with intracardiac infection (n=26), sensitivity increased to 81%. 
Sensitivity of the Duke criteria was 31% for the patients classified in the 
“definite” category (with 100% specificity), increasing to 81% when 
considering both the “definite” and the “possible” categories (with 74% 
specificity). This relatively low sensitivity is not surprising, since the Duke 
criteria have originally been developed for infectious endocarditis and that 
several of the minor Duke criteria are not applicable in this setting.  
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The results obtained in this study demonstrate that SPECT/CT imaging with 
radiolabeled leukocytes in patients with suspected CIED infection increases 
the detection rate of infection and allows accurate assessment of disease 
burden.  In patients with left-ventricular-assist device and valve infections 
radiolabeled leukocyte SPECT/CT has been shown to determine the precise 
anatomic location and extension of a suspected infection, thus impacting on 
patients’ management (12, 30). High diagnostic accuracy in such condition 
has been observed also with the use of PET/CT with [18F]FDG, particularly 
for ruling out involvement of the devices during febrile episodes (31) or for 
defining the embolic burden in presence of ascertained infection (32). A more 
recent report encourages the use of [18F]FDG PET/CT also in case of early 
device infection (10). However, despite its high resolution, this technique is 
still limited by the lack of a suitable infection-specific radiopharmaceutical. 
In fact, the enhanced glucose consumption that causes increased [18F]FDG 
uptake at infectious sites (for the presence of activated leukocytes, monocyte-
macrophages (33, 34), and CD4+ T-lymphocytes (35)), can also occur in a 
number of non-infectious, inflammatory conditions (36) and in post-surgical 
changes (37). 
The higher specificity of 99mTc-HMPAO-WBC scintigraphy observed in our 
study when employing SPECT/CT imaging (with the associated better spatial 
resolution than planar and stand-alone SPECT) enabled to precisely define 
the disease burden, therefore allowing patients risk stratification and 
decision-making. In fact, similarly as observed with [18F]FDG PET/CT, a 
negative scan has consistently been associated with a favourable clinical 
outcome when antimicrobial therapy alone is initiated. Indeed, a negative 
99mTc-HMPAO-WBC SPECT/CT might be used as a guide to clinicians for 
choosing the most suitable treatment, i.e., conservative treatment 
(antimicrobic agents alone, or removal of just the generator) versus full 
hardware extraction. Despite leukocyte imaging is a relative more complex 
procedure as compared to [18F]FDG PET/CT both in terms of 
radiopharmaceutical preparation that include blood manipulation, and 
imaging acquisition that require multiple scans at different time points , we 
believe that when differentiation between active infection and inflammation 
is crucial, 99mTc-HMPAO-WBC should be considered the method of choice.  
In conclusion, 99mTc-HMPAO-WBC scintigraphy with SPECT/CT 
acquisition of the chest in patients with high clinical suspicion of CIED 
infection enabled to confirm the presence of infection, to define the extent of 
device involvement, and to detect associated complications such as infectious 
endocarditis and septic embolism. In addition, 99mTc-HMPAO-WBC 
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scintigraphy was helpful to exclude the presence of device infection during a 
febrile episode and sepsis, with 95% negative predictive value. 
Demonstration of the impact of functional imaging on the overall healthcare 
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Purpose: In this study we evaluated the diagnostic performance of 99mTc-
HMPAO-leukocyte scintigraphy (WBC) in a consecutive series of 55 patients 
(46 men and 9 women, mean age 71±9 yrs, range 50-88 yrs) with suspected 
late and low-grade late vascular prosthesis infections (VPI)  comparing 
moreover the diagnostic accuracy of WBC to other radiological imaging. 
Methods: All patients suspected to have VPI underwent clinical examination, 
blood tests, microbiology, US and CT and were classified according to 
Fitzgerald. Final diagnosis of VPI was established in 47/55 patients, with 
microbiological confirmation after surgical removal of the prosthesis in 
36/47. In the 11 patients presenting major contraindications for surgery, the 
final diagnosis was based on microbiology and clinical follow-up of at least 
18 months. Results: 99mTc-HMPAO-WBC planar, SPECT and SPECT/CT 
imaging identified VPI in 43/47 patients (16 of these showed also extra-VPI).  
In the remaining 8 patients without VPI different sites of infections were 
found. Using SPECT/CT images we obtained a significant reduction of the 
false positive findings in 37% of patients (sensitivity and specificity 100% 
versus 85.1% and 62.5% of SPECT stand-alone). Sensitivity and specificity 
were 34% and 75% for US, 48.9% and 83.3% for CT and 68.1% and 62.5% 
for Fitzgerald classification. Perioperative mortality was 5.5%, mid-term 
mortality 12%, and long term-mortality was 27%. Survival rates were similar 
in patients treated with surgery and antimicrobial therapy as compared to 
patients treated with antimicrobial therapy alone (61% versus 63%), while 
infection eradication at 12 months was significantly higher when surgery was 
performed (83.3% versus 45.5%). Conclusions: 99mTc-HMPAO-WBC 
SPECT/CT is useful to detect, localize and define the extent of graft infection 
in patients with late and low-grade late VPI with inconclusive radiological 
findings. 99mTc-HMPAO-WBC SPECT/CT might be used to optimize 







Prosthetic graft infections are uncommon complications of vascular surgical 
procedures that are reported in up to 6% of cases  [1]. However, infection 
rates vary significantly according to location of the vascular bypass, being 
less than 1% in case of aorto-iliac graft, increasing to about 2% in case of 
aorto-femoral bypass, and to 6% in case of infra-inguinal bypass [2, 3].  
 While in presence of early infection (i.e., earlier than 4 months after 
graft implantation), and in case of infections of the femoral component the 
clinical presentation may be straightforward, intracavitary graft infection 
often presents with nonspecific signs and may appear up to 10 years after 
surgery. Indeed, late infections (i.e., all infections appearing over 4 months 
after surgery) are less frequently characterized by fever as compared with the 
early form [4], and patients may present with general malaise. These patients 
are more likely to present with complications, such as false aneurysm, 
intermittent lumbar pain, or an intermittent fistula that can result in 
gastrointestinal bleeding in case of aortic localization, hydronephrosis, or 
osteomyelitis [5]. From a microbiological standpoint, blood culture is 
positive in approximately 35% of the cases, higher in aortic and early VPI [4] 
since bacteria adhering to the vascular graft are organized in a biofilm, 
confining to a quiescent state [6, 7]. Such nonspecific presentation makes the 
diagnosis and treatment of these infections a real challenge, and success of 
surgical intervention is closely dependent on an early diagnosis.  
 Polymicrobial etiology is often present [4, 8] with similar distribution 
of bacteria for early and late infection and for aortic or peripheral 
localization, except for an increased incidence of  Staphylococci spp in 
peripheral VPIs [4, 9]. Even though rates vary in different reported series, the 
predominance of Staphylococcus spp is invariable [4, 8]. Enterococcus spp 
and Gram-negative bacilli being less predominant [2].  
 Based on the experience with infection of orthopedic prosthetic 
implants [10, 11] and of endocarditis associated with cardiovascular 
implantable electronic devices [12], several classification systems have been 
developed to facilitate the diagnosis of VPI [2], taking into account 
significant  clinical, biological, microbiological, and radiological data. The 
routine approach to the diagnosis of VPI is often somewhat ad hoc and can 
vary from centre to centre [2]. In general, contrast-enhanced computerized 
tomography (CT) is the technique of choice for the diagnosis of infection and 
its complications. CT has over 95% sensitivity, and specificity around 85% 
when the criteria of perigraft fluid, perigraft soft tissue attenuation, ectopic 
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gas, pseudoaneurysm, or focal bowel wall thickening are considered [13]. 
However, in the immediate postoperative period and in case of late/chronic 
infection the sensitivity of CT decreases to 55%  due to the drawback of 
differentiating between the stigmas of VPI and signs of usual posteoperative 
outcome [13, 14-20]. Furthermore, the frequently impaired renal function of 
these patients does not always allow injecting iodinated contrast agents. 
Doppler ultrasonography (US) may prove useful in case of peripheral bypass 
[21], but the absence of periprosthetic fluid collections on US does not 
invariably rule out VPI [4]. Finally, magnetic resonance angiography did not 
prove superior to CT for diagnosins early VPI [22, 23]. 
 
99mTc-HPMAO-labeled autologous leukocyte (99mTc-HPMAO-WBC) 
scintigraphy has shown clear advantages over other methods [20]. Single 
photon emission tomography co-registered with computed tomography 
(SPECT/CT) has further enhanced the specificity of 99mTc-HPMAO-WBC 
scintigraphy [24-26] both by decreasing false positive findings and by 
improving the characterization of pathological foci of radiolabeled leukocyte 
accumulation. However, the clinical application of this diagnostic approach is 
still limited.  
In this study we investigated the diagnostic performances of radiolabeled 
leukocyte scintigraphy in patients with suspected VPI or suspected infection 
of abdominal aneurysmatic dilatation. All patients, referred to the Divisions 
of Vascular Surgery, or Infectious Diseases of Pisa hospital with inconclusive 
diagnosis after first-line diagnostic tests (clinical examination, ultrasound and 
contrast-enhanced CT), were evaluated with 99mTc-HMPAO-leukocyte 
SPECT/CT. 
 




Between 2005 and 2011, 55 patients (46 men and 9 women, mean age 71±9 
yrs, range 50-88 yrs) were referred for 99mTc-HMPAO-WBC scintigraphy 
because of suspected VPI. Thirty-seven patients had aortic graft replacement 
(aorto-aortic n=6, aorto-iliac n=20, aorto-femoral n=11), 2/55 had vascular 
prosthesis of iliac-femoral vessels, 16/55 had peripheral by passes using 
synthetic grafts, and 3/55 had carotid Dacron patches; there were a total of 58 
vascular grafts, since 3 patients had more than one vascular graft. The mean 
interval between surgery and symptoms was 52±74 months (range 0-372 
months), suspicion of VPI being raised within 1 month post-surgery in 6/55 
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cases and between 1 to 3 months in 10/55. In 12/55 cases late VPI was 
suspected and very late account for 27/55. The main clinical features of 
patients, including significant comorbidities, are reported in Table 4.1. 
 Infection was suspected based on clinical examination and on blood 
tests including WBC counts, C-reactive protein, erythrocyte sedimentation 
rate, and at least three sets of blood cultures from a peripheral vein (at least 
one aerobic and one anaerobic) [27]. US and contrast-enhanced CT were 
performed in all patients.  
 Clinical signs and symptoms including the presence of fever, shaking 
chills, inflammatory or disjoined scar, serous and purulent discharge, 
superinfected lymphocele, local pain, and radiological results were 
considered to stratify patients according to Fitzgerald classification [2] (see 
below) before 99mTc-HMPAO WBC baseline scintigraphy. In all patients, 
scintigraphy was performed within 24 hrs from the clinical request. 
 Final diagnosis of VPI was established in 47/55 patients, 
microbiological confirmation being obtained after surgical removal of the 
prosthesis in 36/47. In the remaining 11/47 patients, all presenting with major 
contraindications for surgery, the final diagnosis was obtained either by 
blood culture or by culture of infected fluid. Therefore, all such patients were 
treated with antimicrobial agents and clinically followed for at least 18 
months. Sequential US, contrast-enhanced CT and 99mTc-HMPAO-WBC 
scintigraphy to monitor antimicrobial treatment were performed. During 
follow-up, 99mTc-HMPAO-WBC scintigraphy (n=18) was performed in case 
of negative clinical examination, no symptoms/signs of persistent infection, 
negative blood tests, negative echocardiography and negative blood cultures. 
Therefore, a total of 73 scans were available for the final analysis. 
 Staphylococcus spp. was the microorganism more frequently 
responsible for the infection (12/47), followed by Candida (10/47), 
Streptococcus spp. and Escherichia Coli (5/47 each), and finally Aspergillus, 
P. aeruginosa and Salmonella spp. (2 cases each). Polymicrobial etiology 
was found in the other 9/47 patients.  
 Infection occurred most frequently in carotid patches (3/3), aorto-
aortic grafts (6/6) and iliac-femoral grafts (2/2), followed by aorto-iliac 
(18/20), aorto-femoral prosthesis (8/11) and femoro-popliteal-tibial (10/16). 







Duplex Ultrasound  
 
Color-coded duplex ultrasound (AU5; Esaote Biomedica, Genoa, Italy) 
included the vascular region of the graft. Cross-sectional views were recorded 
with an abdominal phased-array transducer (2.5–3.5 MHz) to visualize 
pseudoaneurysms, sustained gas, anechoic fluid collections, abscess [28] 
using color Doppler and power Doppler US imaging. Spectral Doppler 
waveform analysis was made of the detected leaks. 
 
CT scanning  
 
Whole-body CT scanning included the thorax, abdomen and aorto-
iliofemoral tract. Unenhanced scan, followed by acquisitions in the arterial 
phase after intravenous iodinated contrast administration (120 mL) with a 
flow rate of 3 to 4 mL/s. (delay calculated by bolus test) and delayed phases 
(80- to 100-second delay), using 3-mm collimation and 1-mm reconstruction 
spacing with the single-row equipment or 2.5-mm collimation and a 1.25-mm 
reconstruction interval with the multidetector scanner (Light Speed Plus; GE 
Medical Systems) was performed. Images were processed with a dedicated 
software package on an independent workstation (Advantage Windows 3.1 or 
4.1; Sun Microsystems, Mountain View, CA, USA) to generate multiplanar 
reformations, maximum intensity projections, and volume renderings. The 
following findings were considered predictive for VPI: presence of 
aortoenteric fistula, pseudo-aneurysm, intergraft thrombus, hydronephrosis, 
perigraftic fluid, perigraft air, perigraft soft tissue attenuation, focal bowel 




According to Fitzgerald criteria [4], a patient was considered positive or VPI 
if fulfilling at least two criteria among the following: i) positive intra-
operative samples and/or blood cultures; ii) local or general clinical signs 
related to the infection of a vascular site (fever, shaking chills, severe sepsis, 
septic or hemhorrhagic shock due to an aorto-digestive fistula or to 
anastomotic rupture of the bypass, local pain, erythema, local swelling, 
suppurative fistula, abscess, lack of vascular material integration); iii) 
biological or radiological signs related to the vascular site (C-reactive protein 
> 10 mg/L, hyperleucocytosis > 10,000/mm3, presence or persistence of 




99mTc-HMPAO-WBC radiolabeling, imaging and data interpretation 
 
Autologous radiolabelled WBCs were prepared according to the EANM 
Guidelines for the labeling of leukocytes with 99mTc-HMPAO [29, 30]. 
Radiolabelling efficiency was always between 70-85%, and viability of the 
radiolabelled leukocytes was always tested by the Trypan blue exclusion test 
before reinfusion. 
 Whole body and spot planar images were obtained after 30 minutes, 
then 2 or 4-6 (delayed images) and 20-24 hours (late images) after reinfusion 
of 370-555 MBq of 99mTc-HMPAO-WBC. Images at 2 hrs were acquired in 
patients with aorto-aortic, aorto-iliac, aorto-femoral grafts whereas images at 
4-6 hrs were registered in case of iliac-femoral peripheral by passes and 
carotid Dacron patches. SPECT/CT of the region of interest was performed in 
all patients at 2 or 4-6 hours and repeated at 24 hours in case of negative or 
doubtful imaging at delayed images. Images were acquired using a dual-head, 
variable-angle SPECT/CT gamma camera (Hawkeye and Discovery ST, GE 
Healthcare). The low-dose CT transmission scan was acquired for 16 seconds 
over 220° for each transaxial slice. The full FOV consisting of 40 slices was 
completed in 10 minutes. The transmission data were reconstructed using 
filtered back-projection to produce cross-sectional images. Resolution of the 
CT scan was 2.2 mm and localization images were produced with a 4.5-mm 
pixel size, similar to the nuclear medicine emission images. The CT scans 
were reconstructed into a 256×256 matrix. The SPECT component of the 
same FOV was acquired using a 128×128 matrix, 360° rotation, 6° angle 
step, and 40/60-sec-per-frame acquisition time at 2-4 and at 24 hours, 
respectively. Both CT-attenuation corrected and non-corrected SPECT 
images were evaluated in the coronal, transaxial, and sagittal planes, as well 
as in tridimensional maximum intensity projection (MIP) cine mode. 
Matching pairs of x-ray transmission and radionuclide emission images were 
fused using the Xeleris software, and hybrid images of overlying 
transmission and emission data were generated. 
All scintigraphic images were evaluated, independently, by two 
experienced nuclear medicine physicians aware of the patients’ clinical 
history and of the results of prior conventional imaging, by reviewing the 
planar scans and the SPECT/CT images, with regard to the presence and 
location of any focus of abnormal radioactivity accumulation indicating 
infection. Preliminary analysis of the SPECT/CT images included visual 
inspection to exclude misregistration between the SPECT and the CT 
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components. The scintigraphic studies were classified as negative when no 
sites of abnormal uptake were observed in the SPECT/CT images, or positive 
for infection when at least one focal abnormal accumulation, characterized by 
time-dependent increase in radioactivity from early to delayed images, was 
observed [31]. When present, focal accumulation indicating infection was 
further classified as pertaining to the vascular grafts and/or to extra-prosthetis 
sites (extra-VPI). Positive scans were categorized as follow: a) isolated VPI; 




In 36 patients with VPI, combined radical surgical explantation and 
antimicrobial therapy were carried out, the surgical procedure being 
performed within 72 hours from scintigraphy. The surgical procedure 
consisted in debridement of the infected prosthesis with in situ replacement 
using homograft (n=17) or with an autologous vein (n=13). Complete 
removal of the infected prosthesis followed by immediate vascular 
reconstruction with axillo-bifemoral bypass was performed in 2 patients, 
whereas rifampicin-bounded dacron prosthesis was used in the other 4 cases. 
Table 4.2 reports the specific surgical treatment for all patients based on the 
site of the prosthesis. Eleven of the patients with VPI (8 aorto-iliac-femoral 
and 3 periferal femoro-popliteal-tibial prosthesis) underwent conservative 
medical therapy alone, because of major contraindications to surgery. The 
remaining 8 patients without VPI were treated with disease-specific medical 
and surgical procedures, according to standard procedures as indicated for 




Results of 99mTc-HMPAO-WBC scintigraphy were correlated with those of 
US/CT, blood culture, and Fitzgerald classification (the latter only for the 
baseline scans). The ability to detect or to exclude the presence of VPI was 
based on the final microbiological or clinical diagnosis. Furthermore, the 
ability to identify peri-prosthetic infections as well as alternative cause of 
infections were considered, in order to assess the ability of 99mTc-HMPAO-
WBC scintigraphy to exclude VPI. 
For site-based analysis, results of the planar, stand-alone SPECT and 
SPECT/CT images were compared. Stand-alone SPECT and SPECT/CT 
were considered contributory when they provided data that could not be 
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obtained from the assessment of planar images concerning the presence of 
infection or its precise location. The contribution of SPECT/CT was 




Table 4.1 – Type of vascular prosthesis and main clinical features of the patients included in the study (CAD =; BPCO =; ESR = erythrocyte 























Risk factors Diabetes Renal failure CAD BPCO Hyperthension Long term 
corticoid use 
Recent major surgery 





     









































(dyspesia, pain, fatigue, 
weight loss)  
21/55 (38%) 
 
Blood tests ESR PCR Leukocytosis     
 22/55 (40%) 18/55 (33%) 17/55 (31%)     
Microbiological 
results 
 Positive Negative     
 Blood 
culture* 
16/55 (29%) 39/55 (71%)     
* during antibiotic therapy in 33/55 patients 
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Table 4.2: Type of surgical treatment for patients with VPI and infection of abdominal aneurysmatic dilatation.  
 
Site of the vascular prosthesis Type of surgical treatment 
carotid patch (n=3) autogenous veins (n=3) 
aorto-aortic prostheis (n=6) homograft (n=5) 
orthotopic rifampicin-bounded dacron graft (n=1)  
aorto-iliac prosthesis (n=14) axillo-bifemoral bypass (n=2) 
homograft (n=9) 
orthotopic rifampicin-bounded dacron graft (n=3) 
aorto-femoral (n= 4) autogenous veins (n=2) 
homograft (n=2) 
iliac-femoral (n=2) autogenous veins (n=2) 






the exact site of infection, particularly for vessels and the heart region. 
Interpretation of the images obtained at 2-4 and 24 hours were also 
compared, to define the most suitable protocol to image patients.  
For each patients we recorded the type of surgical treatment of VPI 
after considering the results of 99mTc-HMPAO-WBC scintigraphy. We also 
evaluated peri-operative and long-term mortality of such surgical treatments, 
as well as infection eradication at 1 year both for patients treated with 
removal of the surgical graft followed by antimicrobial therapy and for 
patients treated with antimicrobial therapy alone. VPI eradication was 
defined in case of negative clinical examination, negative blood tests 
(including microbiology), negative US/CT, and negative 99mTc-HMPAO-




All values are expressed as median and range, as customary for 
nonparametric data. The Pearson’s χ2 test was employed for comparing 
parametric data between groups. Sensitivity and specificity of US, CT, the 
Fitzgerald classification and 99mTc-HMPAO-WBC planar, stand-alone 
SPECT and SPECT/CT imaging were calculated based on the final diagnosis 




99mTc-HMPAO-WBC scintigraphy was positive in all the patients referred for 
the baseline scan, confirming VPI in 47/55 patients. Positive scans identified 
isolated VPI 27/47 patients. VPI and extra-VPI infection was detected in 
16/47 patients, with local complications of VPI represented by involvement 
of perivascular graft tissues in the majority of the cases (n=7) and/or fistulas 
(n=5); VPI and distant sites of infections were detected in 4 patients. No case 
of isolated extra-VPI was detected. 
In the remaining 8/55 basal scans showing focal accumulation of 
labeled leukocytes in patients without VPI, scintigraphy detected alternative 
sites of infections in all such patients. In particular, osteomyelitis was 
detected in 4 cases, inflammatory bowel disease in 3, whereas the last case 
had infection of an artero-venous fistula for hemodialysis access. These 
patients with alternative causes of infection were therefore treated according 
to standard procedures, as indicated for the each clinical condition. None of 
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the 8/55 patients with a negative 99mTc-HMPAO-WBC developed infection 
during follow-up. 
 
Diagnostic performances of 99mTc-HMPAO-WBC scintigraphy versus US, 
CT and Fitzgerald classification 
 
US was positive for VPI in 16/47 patients (33% sensitivity in the 
whole population, but 68% for peripheral VPI; specificity 69%). Contrast-
enhanced CT was positive in 26/55 patients, being true-positive in 23/47 
cases of VPI. Whereas, CT was inconclusive in 15/47 cases. Major CT 
findings were peri-graft fluid and collections (n=14), pseudoaneurysms 
(n=19) and peri-graft gas bubbles (n=9), focal bowel wall thickening (n=4), 
increased soft tissue between the graft and surrounding wrap (n=2), 
disruption of the aneurysmal wrap (n=1).  
According to Fitzgerald classification, our patients were classified as positive 
for VPI in 35/55 (32 true positives, 3 false positives), and negative for VPI in 
20/55 (15 true negatives, 5 false negatives). 
Table 4.3 summarizes the results of 99mTc-HMPAO-WBC scintigraphy, of 
US and contrast-enhanced CT and of stratification according to Fitzgerald 
classification in the cases with final diagnosis of VIP infection. Table 4.4 
directly compares the results of 99mTc-HMPAO-WBC scintigraphy and 
contrast-enhanced CT according to the type of VPI (i.e., early versus late). 
Blood cultures were positive in only 16/55 patients, 14 out of such 16 cases 
with confirmed VPI; however, 29/39 of the blood-culture negative patients 
were under antimicrobial treatment at the time of assessment.  
 
99mTc-HMPAO-WBC scintigraphy and patients’ clinical management  
In 36 patients with positive 99mTc-HMPAO-WBC scintigraphy for 
VPI, combined radical surgical explantation and antimicrobial therapy were 
carried out. In 34/36 patients demonstration at 99mTc-HMPAO-WBC 
scintigraphy of infection of the whole vascular prosthesis resulted in 
complete removal of the infected prosthesis. The 2 patients in whom 
accumulation of radiolabelled leukocytes limited only at the distal portion of 
the aorto-iliac grafts was detected, were treated with partial removal and 
replacement of the prosthesis; follow-up demonstrated eradication of 
infection in both cases.  
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In patients undergoing combined surgical and medical treatment 
perioperative mortality was 5.5%, mid-term mortality (within 1 month) was 
12% (all deaths being associated with infective complications), and long 
term-mortality was 27% (mainly unrelated to infection). Survival rate was 
61%, whereas the rate of infection eradication at 12 months was 83.3%.  
Eleven of the patients with VPI (8 aorto-iliac-femoral and 3 periferal 
femoro-popliteal-tibial prosthesis) underwent conservative medical therapy 
alone, because of major contraindications to surgery. In these patients 
infection was sustained by Staphylococcus spp, Candida in 3/11 each, 
Escherichia Coli and Aspergillus in 1 case each; the other 3 VPI was of 
polymicrobial origin. Follow-up examination performed in these patients 6-9 
months after the baseline scan showed the disappearance of the pathologic 
accumulation of radiolabelled leukocytes in only 3/11 cases. In 2/8 of the 
remaining patients medical therapy was discontinued after normalization 
observed in a third 99mTc-HMPAO-WBC scan (at 6 months), whereas the 
other 6 patients had persistent abnormal scintigraphy despite the prolonged 
medical treatment; Survival rates of these patients treated with antimicrobial 
therapy alone was 63% and the corresponding infection eradication rate was 
45.5%.  
Four major contributions of 99mTc-HMPAO-WBC scintigraphy on 
patients’ management have been identified: i) saving the prosthesis after 
identification of an alternative site of infection; ii) identifying VPI and 
concomitant distant sites of infections; iii) selecting the most suitable surgical 
timing; iv) aiding in the selection of the optimal surgical planning (complete 
versus partial prosthesis removal).  
  
Comparison of 99mTc-HMPAO-WBC planar, stand-alone SPECT and 
SPECT/CT images 
 
Table 4.5 compares the results of scintigraphic findings based on 
interpretation of planar, stand-alone SPECT and SPECT/CT images. 
SPECT/CT acquisition provided higher accuracy both for the detection of 
infection and for localization of 99mTc-HMPAO-WBC accumulation at 
specific portions of the graft, distinguishing soft tissue and cutaneous 
involvement from infection localized at the vascular prosthesis. Additionally, 
SPECT/CT allowed to recognize false positive results at planar imaging 
(n=9) as well as at stand-alone SPECT imaging (n=7), by identifying either 
blood-pool activity in the vascular bed and in the bone marrow (vertebral 
bodies) and/or nonspecific radioactivity accumulation in the bowel. Overall, 
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SPECT/CT imaging changed the final classification of the scan from negative 
to positive for infection in 14/57 cases as compared to planar imaging and in 
9/57 cases as compared to stand-alone SPECT imaging. Figures 4.1, 4.2, 4.3 





Table 4.3: Results of 99mTc-HMPAO-WBC scintigraphy, US, contrast-enhanced CT and the Fitzgerald classification according to the final diagnosis of VPI, 
other concomitant infections or no infection for all the exams performed at baseline. By McNemar test 99mTc-HMPAO WBC SPECT/CT performed significantly 
better as compared to US( χ² = 25.48, p < 0.0001), contrast-enhanced TC (χ² = 16.33, p < 0.0001) and Fitzgerald classification (χ² = 8, p = 0.004). 
 
 
Table 4.4: Results of 99mTc-HMPAO-WBC scintigraphy and contrast-enhanced CT for all the exams performed at baseline, classified according to the time of 
suspected VPI onset. 
 Very early VP (n=6) Early VP (n=10) Late VP (n=12) Very late VP (n=27) 
 
99mTc-HMPAO-WBC 
















positive (n=26) 4 1 5 2 4 0 10 0 
non diagnostic (n=19) 1 0 2 1 3 1 9 2 





















Negative 0/47 0/8 








(8.1%-29.1%) Negative 31/47 6/8 
TC 









(8.7%-30.6%) Negative 9/47 1/8 
Non-
diagnostic 15/47 4/8 
Fitzgerald 
classification 









(14.7%-38.8%) Negative 15/47 5/8 
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Table 4.5: Results of 99mTc-HMPAO-WBC planar, SPECT and SPECT/CT acquisitions in the 55 patients evaluated with a baseline scintigraphy for suspected 
VPI. (SPECT images versus planar images χ² = 1.8, p = 0.179; SPECT/CT images versus planar images χ² = 3.26, p = 0.07 and SPECT/CT versus SPECT  images 




*including  4 FP results due to bowel and bone marrow uptake, soft tissue and cutaneous infections 
** including 9 FN results because of overlapping of the abdominal aorta and bone marrow-uptake at the vertebral bodies 
# all 9 inconclusive findings because of the lack on anatomical landmarks  





































images 40/55* 0/55 15/55** 20/47 0/15 4/8 5/8 4/8 
76.6%       
(62.9%-96.5%) 
50%                 
(36.5%-63.6%) 
72.7%        
(58.8%-83.5%) 
90%          
(78.2%-96.1%) 
26.7%     
(16.1%-40.6%) 
SPECT 43/55$ 9/55# 3/47 23/47 8/15 5/8 8/8 5/8 85.1%      (72.4%-92.8%) 
62.5%              
(48.4%-74.9%) 
81.8%       
(68.6%-90.5%) 
93%          
(81.9%-97.8%) 
41.7%     
(28.8%-55.7%) 
SPECT/

















Figure 4.1: 99mTc-HMPAO-WBC scintigraphy in a patient with suspected late infection of an 
aorto-bisiliac vascular prosthesis presenting with cellulitis and erysipelas of the left lower leg 
and fever. Blood culture was negative and swab culture isolate Enterobacter sakazakii and 
Escherichia Coli. Anterior (left panel) and posterior (right panel) planar images of the 
abdominal region at 30 min and 2 hrs at baseline (A) and follow-up studies (C). Coronal and 
transaxial slices: CT (left panel) and corresponding fused SPECT/CT sections (right panel) at 
baseline (B) and follow-up studies (D). Baseline planar images show increased WBC 
accumulation at the level of L1-L3 corresponding to vascular graft in the SPECT/CT images. 
The patient was first treated with antimicrobial therapy and repeated 99mTc-HMPAO-WBC 
scintigraphy that showed persistence of uptake at the vascular prosthesis, less intense as 
compared to baseline. After the follow-up study, the patient was treated with debridement of 
the prosthesis with in situ replacement with autologous femoral veins and microbiology 







Figure 4.2: 99mTc-HMPAO-WBC scintigraphy in a patient with suspected late infection of 
right iliac-femoral and femoro-popliteal vascular prosthesis. The patient presented a peri-
prosthetic collection extending surrounding the whole prosthesis and negative blood culture. 
(A) Anterior (left panel) and posterior (right panel) planar images of the region extending 
from the iliac crest to the knee at 30 min and 4 hrs, showing increased WBC uptake at the 
inguinal region. (B) Coronal and transaxial slices (emission images in left panel, 
corresponding CT sections in the middle panel and fused SPECT/CT sections in right panel) 
localized the focal accumulation of radiolabelled leukocytes at the vascular graft, at both the 
iliac and the femoral portions. Microbiology confirms infection sustained by poly-microbial 





       
Figure 4.3: 99mTc-HMPAO-WBC scintigraphy in a patient with suspected very early 
infection of aorto-bifemoral vascular prosthesis. The patient presented a left lower limb 
lymphedema, lymphocele with isolation of Enterococcus faecalis at microbiology of the 
aspirate. Transaxial slices at different levels (emission images in left panel, corresponding 
CT sections in the middle panel and fused SPECT/CT sections in right panel) showing 
multiple sites of radiolabelled leukocytes uptake at the vascular graft at the femoral left 
branch (A), at the intestine (B and C) and at the right lung/costal pleura (D). Microbiology 
after debridement of the prosthesis with in situ replacement with homograft confirms 







Figure 4.4: 99mTc-HMPAO-WBC scintigraphy basal (left panel) and follow-up studies at 6 (middle panel) and 12 months (right panel) in a patient with suspected 
late infection of aorto-bisiliac vascular prosthesis. The patient presented fever, positive blood culture for Methicillin-resistant Staphylococcus Aureus and CT 
finding of 20mm pseudoaneurysm at the left iliac anastomosis. Coronal (A) and transaxial emission images (left panel), corresponding CT sections (middle panel) 
and fused SPECT/CT sections (right panel) at different levels (B, C, D) showing WBC uptake at the distal portion of the prosthesis, at the level of the left iliac 
branch extending into muscles and soft tissue very intense at baseline (right panel), decreasing both in intensity and extension at the first follow-up scan (middle 






VPI are associated with significant morbidity, including major amputation [4, 
19, 32] and death. Overall cost of VPI combined medical and surgical 
treatment as well as of associated morbidities in the US has estimated to 
amount annually to 720,000,000 US $ [33]. Furthermore, reinfection after 
abdominal aortic graft re-implantation remains a risk, particularly during 
treatment of an extra-anatomic bypass graft infection [34]. The success of 
surgical treatment is closely dependent on early diagnosis, which however 
may be hampered by nonspecific presentation such as in case of low-grade 
late infections. Indeed, in this condition as in the case of very early 
infections, sensitivity of contrast-enhanced CT, that is considered the 
imaging method of choice for VPI diagnosis, significantly decreases [17]. 
Therefore, search for alternative imaging modalities is needed to expedite 
diagnosis.  
In this study we evaluated a consecutive series of patients with 
suspected VPI that remained unconfirmed after standard diagnostic tests, 
including blood chemistry, US and contrast-enhanced CT. All patients 
underwent 99mTc-HMPAO-WBC scintigraphy with the purpose of confirming 
or excluding VPI. VPI was eventually confirmed in 47/55 of the patients, 
being mainly represented by low grade late VPI (51%). Most of the 
infections were sustained by Staphylococcus spp. (26%). Patients were 
treated either with combined radical surgical explantation and antimicrobial 
therapy (36/47 patients) or with conservative medical treatment alone (11/47 
patients) in case of major contraindications for surgery.  
99mTc-HMPAO-WBC scintigraphy identified isolated VPI in 57% 
patients, and VPI associated with extra-VPI in 43% of the cases, including 
distant site of infections. No cases of isolated extra-VPI were detected. No 
false positive or false negative results were observed, irrespective of the 
strain of sustaining microrganisms or of concomitant administration of 
antimicrobial agents. High specificity was achieved even when scintigraphy 
was performed within few months after surgery, in line with previous 
findings [35]. Furthermore, 99mTc-HMPAO-WBC scintigraphy excluded VPI 
and identified instead alternative sites of infection (such as osteomyelitis, 
inflammatory bowel disease and infection of a hemodialysis fistula). An 
important advantage of SPECT/CT imaging was the resulting significant 
reduction of the false positive findings in 37% of patients as compared to 
stand-alone SPECT (i.e., vascular pool, nonspecific abdominal 
accumulation), accurate characterization of the site and extension of 
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abnormal accumulation, even in presence of post-surgical distortions and in 
complex anatomical sites, supporting previous similar findings [26]. 
Therefore, SPECT/CT further enhanced the high values of sensitivity (82-
100%) and specificity (85-100%) already reported in the literature for 99mTc-
HMPAO-WBC scintigraphy in patients with suspected VPI.  
Sub-optimal diagnostic performance of contrast-enhanced CT in this 
series of patients with predominant very late infections is not surprising. In 
fact, it is well known that CT might fail to distinguish the stigmas of 
periprosthetic infection from normal postoperative changes [16, 17] and 
might be false-negative in chronic low-grade infections [36]. Indeed, in our 
patients more than 80% of the inconclusive findings at CT were found in case 
of late and very late infection.  
From a surgical perspective, major contributions of 99mTc-HMPAO-
WBC scintigraphy on patients’ management have been identified. In fact, 
based on 99mTc-HMPAO-WBC imaging, patients with VPI without major 
surgical contraindications were treated within 72 hours with a surgical 
approach that include the information of 99mTc-HMPAO-WBC scintigraphy. 
Therefore, while in 34/36 patients complete debridement of infected tissues, 
complete exeresis of the prosthesis and adjacent arterial area maintaining or 
restoring the arterial flux was performed, the 2 cases with accumulation of 
radiolabelled leukocytes limited only at the proximal portion of the aorto-
iliac graft were treated with partial removal and replacement of the 
prosthesis. Infection eradication was obtained in both such cases. 
Furthermore, in the patients with concomitant distant sites of infections at 
99mTc-HMPAO-WBC scintigraphy, treatment was multimodal and included 
treatment for the VPI followed by surgical debridement and long-lasting 
antimicrobial therapy.  
Perioperative mortality of our patients was 6%, higher in the group 
with aorto-iliac VPI. Despite explantation of the graft and reperfusion of the 
area is considered the gold standard for treatment of an infected prosthetic 
graft [37] to avoid infection chronicization [38] we observed similar survival 
rates in patients treated with combined surgical and medical treatment as 
compared to those treated with conservative medical treatment alone (61% 
versus 63%). However, infection eradication at 12 months was significantly 
higher in VPI patients treated with combined surgical and medical treatment 
as compared to patients treated with conservative medical treatment alone 
(83.3% versus 45%). In patients with persistent infection, the 99mTc-
HMPAO-WBC follow-up scans clearly depicted the sites of persistent 
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infection, thus demonstrating the reliability of this imaging modality when 
used to monitor treatment response.  
Therefore, we believe that our results constitute the basis for a more 
extensive application of 99mTc-HMPAO-WBC not only for the diagnosis of 
VPI or to exclude graft involvement, but for providing to the surgeon 
complementary information useful for the choice of alternative surgical 
procedures, such as complete or partial graft preservation in high-risk 
patients in whom conventional management is precluded because of severe 
co-morbid illness or a hostile abdomen. Furthermore, 99mTc-HMPAO-WBC 
scintigraphy enables to monitor response to antimicrobial treatment, by 
distinguishing patients who respond favourably from those who require 




99mTc-HMPAO-WBC scintigraphy with SPECT/CT acquisition in 
patients with clinical suspicion of VPI enabled to confirm the presence of 
infection and to define the extent of graft infection, thus impacting on 
subsequent planning of surgical management. In addition, 99mTc-HMPAO-
WBC scintigraphy was helpful in identifying concomitant distant sites of 
infection, in excluding graft infection during a febrile episode and sepsis and 
in monitoring response to antimicrobial treatment.  
Our results demonstrated that 99mTc-HMPAO-WBC scintigraphy with 
SPECT/CT acquisition is to be considered in patients with suspected VPI and 
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There is no consensus yet on the best protocol for planar image acquisition 
and interpretation of radiolabelled white blood cell (WBC) scintigraphy. This 
may account for differences in reported diagnostic accuracy amongst 
different centers. Here we report the results of a multicentre retrospectively 
study performed by analysing 235 WBC scans divided in 2 groups. First 
group (105 patients) acquired with a fixed-time acquisition protocol and 
second group (130 patients) acquired with a time-decay corrected acquisition 
protocol. Image interpretation was performed on planar images both 
qualitatively and semi-quantitatively. Three different blind readers analysed 
the images. 
Results showed that the most accurate imaging acquisition protocol is to 
acquire images at 3-4h and at 20-24h in time mode with acquisition times 
corrected for isotope decay. When using this protocol, visual analysis leads to 
high sensitivity and specificity for diagnosis of infection. Semi-quantitative 
analysis might be used in doubtful cases, using no cut-off for the percentage 
of increase in radiolabelled WBC over time, as a criteria to define a positive 
scan. 
 



























The use of 99mTc-HMPAO or 111In-oxine labelled white blood cells (WBC) is 
still considered the gold standard nuclear imaging technique to diagnose 
infections in the bone and soft tissue, except for spondylodiscitis [1, 2]. For 
acute osteomyelitis and for prosthetic joint infections, reported diagnostic 
accuracy is approximately 90% [3-5]. However, there are also various reports 
that mention lower rates for sensitivity and specificity. These differences in 
diagnostic accuracy reported for WBC scintigraphy may be related to 
different image acquisition protocols and different interpretation criteria [6, 
7]. To strengthen the clinical use of WBC scintigraphy, procedures and 
protocols are being standardized throughout the world. To this aim, the recent 
published guidelines by the Infection Committee of the European Association 
of Nuclear Medicine (EANM) provide indications, practical aspects, quality 
controls and safety procedures of this technique [8, 9]. Guidelines that 
describe the correct image acquisition and interpretation criteria for labelled 
WBC are also under preparation. Accurate acquisition protocols and 
interpretation criteria require knowledge of the normal radiolabelled WBC 
biodistribution (ie. blood and bone marrow) and pathological variants of 
WBC localization in different tissues and organs [2]. The general agreement 
for osteo-muscular infections and soft tissue infections is that at least two 
imaging time points are necessary, delayed (3-4 h after re-injection) and late 
(20-24 h). Early imaging (30 min-1 h after re-injection), which may be a 
surrogate for bone marrow uptake, is optional. Image interpretation can be 
made qualitatively (visual) or semi-quantitatively (calculation). In case of 
doubtful planar images with suspected bone marrow expansion, bone marrow 
imaging with 99mTc-colloids is currently performed to reduce the false 
positive rate [5, 10]. For exact localization of the infection SPECT/CT may 
have added value [11]. 
In this article, we retrospectively compared in a large series of 99mTc-
HMPAO-WBC planar scintigraphies in different types of infections, two 
different acquisition protocols (time decay corrected versus fixed-time 
acquisition) and two different interpretation criteria (visual versus semi-
quantitative evaluation), to determine which is the best combination to obtain 
the highest diagnostic accuracy for infection versus sterile inflammation. The 
hypothesis is that a sterile inflammation will not show an increase focal 
uptake with time, differently from an infection, and that this trend of 
increase/decrease in time is better detectable by acquiring time decay 







This is a retrospective study analysing patients that were referred for 
scintigraphy with 99mTc-HMPAO labelled WBC from January 2009 to 
December 2011, in three University centers (University Medical Center 
Groningen, University of Pisa Medical School, and Sapienza University of 
Rome). Ethic Committee approved the study in all centers. We therefore 
analyzed 235 patients with suspected osteomyelitis suspected prosthesis 
infection and suspected soft tissue infection as shown in Table 5.1. Infection 
was suspected based on clinical examination, blood tests (including WBC 
counts, C-reactive protein, erythrocyte sedimentation rate, acute phase 
proteins), urine-analysis, three sets of blood cultures including at least one 
aerobic and one anaerobic from a peripheral vein [12], and/or conventional 
radiology, e.g. plain X-ray, ultrasound and/or contrast-enhanced computed 
tomography (CT).  
Final diagnosis of an infection or exclusion of an infection was defined on 
the basis of pathological, microbiological, or clinical diagnosis, with clinical 
follow-up of more than 6 months for all patients. Overall, 109 patients were 
diagnosed with an infection and 126 were negative for infection (see Table 
5.2). 
 
99mTc-HMPAO WBC preparation and imaging protocol  
 
Preparation and labelling of WBC were performed according to the 
guidelines for the labelling of leukocytes with 99mTc-HMPAO from the 
European Association of Nuclear Medicine [13]. Radiolabelling efficiency 
was always between 70-85%. 
In 105 patients, we used the fixed-time (FT) acquisition protocol by acquiring 
planar delayed and late images for 600 seconds each. In 130 patients, we 
used the time-decay corrected (TDC) acquisition protocol by acquiring planar 
(static) images at 30 min-1 h (optional “early images”, 100-200 sec), at 3-4 h 
(“delayed images”, 133-300 sec) and at 20-24 h (“late images”, 951-2396 
sec) after reinjection of 370-555 MBq 99mTc-HMPAO labelled WBC (see 




Table 5.1 Patient characteristics (n = 235) 
 
Age 
     Mean 
     Median 
     Range 







     Female 




Type of suspected infection 
     Osteomyelitis 
     Hip prosthesis 
     Knee prosthesis 
     Shoulder prosthesis 








     WBC counts  
             Increased 
             Normal 
     C-reactive protein 
             Increased 
             Normal 
     Erythrocyte Sedimentation Rate 
             Increased 













Table 5. 2 Final diagnosis in all patients and divided in the two groups studied with fixed 
time acquisition (FT) and time-decay corrected acquisition (TDC). 
 
 
Diagnosis n (%) FT (%) TDC (%) 
Infection 
    Osteomyelitis 
    Infected hip prosthesis 
    Infected knee prosthesis 
    Infected shoulder prosthesis 
    Soft tissue infection 
    Total 
 









































time (seconds) if early 
images were acquired 
for 100 seconds 
Corrected acquisition 
time (seconds) if early 
images were acquired 
for 200 seconds 
1.5 119 238 
2 126 252 
Delayed images 2.5 133 267 
3 141 283 
3.5 150 300 
19.5 951 1902 
20 1007 2015 
Late images 20.5 1067 2135 
21 1131 2262 
21.5 1198 2396 
 
 
All images (128×128 matrix size or 256x256 matrix size depending on 
centers) were acquired on a SPECT gamma camera system (Siemens Symbia 
T, Siemens Medical Systems (Groningen), Hawkeye, GE Healthcare (Pisa) or 
SkyLight, Philips (Rome)) equipped with low-energy high resolution 
collimators with energy window centred at the 140 keV photo-peak of 99mTc 
using a width of 20%.  
All images were displayed and analysed using the same workstation (Osiris), 
to avoid differences in display of different camera systems. TDC images 
were displayed in number of counts, using the same intensity scale both for 
delayed and late images, thereby avoiding operator-bias in changing the 
intensity scale. This is essential when interpreting time-decay corrected 
images but it is not possible when images are acquired with a fixed-time 
protocol. Therefore, FT images were displayed in % of maximum counts as 
they usually appear in automatic mode on both Siemens, GE and Philips 
workstations.  
SPECT/CT was performed for precise location of the infectious focus. In 
these cases, the low-dose CT transmission scan was acquired for 16 seconds 
over 220° for each transaxial slice. The full FOV consisting of 40 slices was 
completed in 10 minutes. The transmission data were reconstructed using 
filtered back-projection to produce cross-sectional images. Resolution of the 
CT scan was 2.2 mm and localization images were produced with a 4.5-mm 
pixel size, similar to the nuclear medicine emission images. The CT scans 
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were reconstructed into a 256×256 matrix. The SPECT component of the 
same FOV was acquired using a 128×128 matrix, 360° rotation, 6° angle 
step, and 40/60-sec-per-frame acquisition time at 4 and at 24 hours, 
respectively. Both CT-attenuation corrected and non-corrected SPECT 
images were evaluated in the coronal, transaxial, and sagittal planes, as well 
as in three-dimensional maximum intensity projection (MIP) cine mode. 
Matching pairs of x-ray transmission and radionuclide emission images were 
fused using the Xeleris workstation (Pisa), and hybrid images of overlying 
transmission and emission data were generated. 
 
Visual and semi-quantitative image interpretation 
 
The planar scintigraphic images were visually analysed separately by two 
experienced nuclear medicine physicians (PE, AG); in case of disagreement 
by the two observers a third reader (AS) reviewed the images and his 
decision was considered as for the final classification. The studies were 
classified (a) “negative for infection” if no uptake was seen in both delayed 
and late planar images or when the uptake was the same or decreasing in 
time, and (b) “positive for infection” when at least one focus of abnormal 
uptake characterized by time-dependent increase in radioactivity or increase 
in size from delayed to late planar images was observed. In some positive 
patients with peripheral osteomyelitis, when differential diagnosis between 
bone and soft tissue involvement was not ascertained at planar images, we 
did perform SPECT/CT for exact localization. 
The visual analysis was performed using the same criteria for the non-decay 
corrected and the decay corrected images. For semi-quantitative analysis, in 
all images a ROI was drawn over the area suspected for infection and copied 
to presumed normal reference tissue (e.g. anterior-superior iliac crest, 
unaffected contralateral bone, etc.) The mean counts per pixel in these ROIs 
were recorded to calculate Target/Background (T/B) ratios both in delayed 
and late images. When the T/B was similar or decreased with time the scan 
was considered negative for infection; when the T/B increased with time, the 
scan was considered positive. Images were classified using different 
thresholds of increase of T/B ratio over time: ≤ 5, ≤10, ≤ 20, and ≤ 25 %. 
 
Data analysis and statistics 
 
Results of 99mTc-HMPAO-WBC scintigraphy were correlated with those of 
conventional radiologic imaging and with the final microbiological, 
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pathological or clinical diagnosis. For each patient results of visual and semi-
quantitative interpretation were compared to the final diagnosis. Semi-
quantitative analysis using < 5, < 10, < 20, and < 25% of increase in time, 
were calculated.  
All values are expressed as median and range, as customary for 
nonparametric data. Comparison of the two groups for clinical and 
demographic factors was performed by Pearson’s χ2. The readers inter-
observer agreement rates were also evaluated and expressed in weighted 
kappa which corrects for agreement by chance. The sensitivity, specificity, 
diagnostic accuracy, negative predictive value and positive predictive value 
were calculated and differences between groups compared by Chi-squared 
test. All statistical evaluations were performed using the STATA Statistical 
Software package, Release 10-2010 (STATA Corporation, College Station, 





No significant difference in age distribution or any other clinical parameters 
between the two groups was observed. 
By adopting the interpretation criteria described above for scintigraphic 
detection of infection, it was possible to classify all the scans as either frankly 
positive or frankly negative, therefore without any equivocal result. 99mTc-
HMPAO-WBC scans were totally negative in 121 cases (47/105 FT 
acquisition and 74/130 TDC acquisition; p=ns). At least one abnormal area 
with focal accumulation of the radiolabelled leukocytes with increase of 
radioactivity over time, or size, was detected in the remaining 114 patients 
(58/105 FT acquisition and 56/130 TDC acquisition; p=ns). Table 5.4 shows 
the results of 99mTc-HMPAO-WBC at visual analysis, in all patients and 
according to the specific clinical indication. Overall, TDC acquired images, 
as compared to the FT acquired images, showed comparable sensitivity 
(94.1% versus 94.8%; p=ns) and NPV (96.3% versus 93.3%; p=ns), but 
better specificity (100% versus 89.4%; p=0.006), accuracy (97.7% versus 
92.4%; p=0.05) and PPV (100% versus 91.6%; p=0.05). Figures 5.1 shows 
examples of positive and negative radiolabelled WBC scan at the visual 
analysis. Even though numbers vary according to the specific clinical 
indication, the better performances for the TDC acquired images at the visual 
analysis are invariable with the exception of soft tissue infections (Table 5.4).  
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For the semi-quantitative analysis we found best accuracy, sensitivity and 
NPV when considering any percentage of increase of radioactivity in the 
suspected lesion over time, for both FT and TDC acquired images. By 
contrast, specificity and PPV increase by increasing the threshold of 
percentage increase (Table 5.5).  
Furthermore, accuracy, specificity and PPV are generally higher in the semi-
quantitative analysis when images are acquired with FT method, whereas 
sensitivity and NPV are higher when images are acquired with TDC method 
(Table 5.6). This is particularly true for osteomyelitis and hip prosthesis, but 
not for soft tissue infections and knee prosthesis. Figure 5.2 provides 
examples of visual and semi-quantitative interpretation of images. 
Inter-observer agreement rates for the interpretation of 99mTc-HMPAO-WBC 
images were higher for TDC acquired images as compared to the FT acquired 
images (lack of consensus in 11% and 19% of cases, respectively, with the 
lower agreement for hip and knee prosthesis infections).  
The rate of concordance between the visual and the semi-quantitative 
analysis was better considering any % of increase of radioactivity in time and 
for the TDC images (200/235) either considering all patients together or 
considering osteomyelitis and prosthetic infections alone. In case of soft 
tissue infection, the best agreement was obtained comparing the visual and 
the semi-quantitative analysis considering 5% of increase of radioactivity in 
time (always better for the TDC images).  
 
 
Figure 5.1: 99mTc-HMPAO-WBC scintigraphy in patients with suspected bone and knee 
prosthesis infections acquired after 4h (delayed images) and 20h (late images) with either 
fixed time acquisition modality (left and middle panels) or time-decay corrected modality 
(right panels). In all cases the visual analysis correctly diagnosed osteomyelitis (left panel), 
aseptic bone marrow expansion (middle panel) and right knee infected prosthesis vs non-




Table 5.4: Results of qualitative (visual) analysis of 99mTc-HMPAO-WBC scintigraphy as 
compared to final diagnosis 
 
 
Visual vs final diagnosis 
 
 
Osteomyelitis Prosthesis hip Prosthesis knee Soft tissue Total 
 
 
FT TDC FT TDC FT TDC FT TDC FT TDC 
TP 23 11 7 14 15 14 7 9 55* 48 
TN 23 20 10 29 8 25 1 5 42 79 
FP 2 0 1 0 2 0 0 0 5 0 
FN 1 0 1 1 1 1 0 1 3 3 
Sensitivity 96% 100% 87% 93% 94% 93% 100% 90% 95% 94% 
Specificity 92% 100% 91% 100% 80% 100%# 100% 100% 89% 100%# 
Accuracy 94% 100% 89% 98% 88% 98%# 100% 93% 92% 98%# 
PPV 92% 100% 87% 100% 88% 100%# 100% 100% 92% 100%# 
NPV 96% 100% 90% 93% 89% 93% 100% 83% 93% 96% 
TP, TN, FP and FN are numbers of patients. FT = fixed time acquisition, TDC = time-decay 
corrected acquisition. *includes 3 cases of shoulder prosthesis. # p<0.05 versus FT. 
 
 
Table 5.5: Results of semi-quantitative analysis of 99mTc-HMPAO-WBC scintigraphy 














FT TDC FT TDC FT TDC FT TDC FT TDC 
TP 56 48 46 38 41 34 30 24 26 18 
TN 34 59 40 65 45 69 45 69 45 69 
FP 13 20 6 15 2 10 2 10 2 10 
FN 2 3 13 12 17 17 28 27 32 33 
Sensitivity 97% 94% 78% 76% 71% 67% 52% 47% 45% 35% 
Specificity 72% 75% 87% 81% 96% 87% 96% 87% 93% 87% 
Accuracy 86% 82% 82% 79% 82% 79% 71% 72% 68% 67% 
PPV 81% 70% 87% 72%# 95% 77%# 94% 71%# 96% 64%# 
NPV 94% 95% 75% 84% 73% 80% 62% 72% 58% 68% 
TP, TN, FP and FN are numbers of patients. FT = fixed time acquisition, TDC = time-decay 







Table 5.6: Results of semi-quantitative analysis of  99mTc-HMPAO-WBC scintigraphy, 
defined for each specific indication and compared to final diagnosis, specified for both 
acquisition protocols 
 
 Semi-quantitative vs final diagnosis (any T/B increase) 
 Osteomyelitis Prosthesis hip Prosthesis knee Soft tissue 
 
 
FT TDC FT TDC FT TDC FT TDC 
TP 23 11 7 14 16 14 7 9 
TN 23 17 9 20 6 17 1 5 
FP 2 3 2 9 4 8 0 0 
FN 1 0 1 1 0 1 0 1 
Sensitivity 96% 100% 88% 93% 100% 93% 100% 90% 
Specificity 92% 85% 82% 69% 60% 68% 100% 100% 
Accuracy 94% 90% 84% 77% 85% 78% 100% 93% 
PPV 92% 79% 78% 61% 80% 64%# 100% 100% 
NPV 96% 100% 90% 95% 100% 94% 100% 83% 
TP, TN, FP and FN are numbers of patients. FT = fixed time acquisition, TDC = time-decay 




Figure 5.2: 99mTc-HMPAO-WBC scintigraphy in two different patients with suspected low 
grade infection of the right hip prosthesis acquired after 4h (upper panels) and 20h (lower 
panels) with either fixed time acquisition modality (left panels) or time-decay corrected 
modality (right panels). Images A and B at visual analysis were judged negative and semi-
quantitative analysis showed a stable T/B over time (equivocal for infection). After 
prosthesis removal microbiology showed the presence of infection. Images C and D at visual 
analysis were judged negative and semi-quantitative analysis showed a stable T/B over time 
(equivocal for infection). After prosthesis removal microbiology confirmed the absence of 
infection. These two examples highlights how TDC acquisition allows accurate and easier 





It is commonly accepted that WBC images are visually classified as (i) 
negative if no uptake or a decrease in uptake from delayed to late images is 
present, (ii) positive when uptake is seen in both delayed and late images 
with increase in activity or size in time, and (iii) equivocal when uptake in 
delayed and late images is the same or slightly decreasing. However, a 
general criticism to the visual analysis is that it is strictly operator dependent 
and that the final results may differ significantly when images are acquired 
and displayed, using  
different ways with different contrast and background. Acquisition protocols 
are variable. Some author acquire, early, delayed and late images, with a 
fixed constant time for all images; others acquire all images with a fixed 
number of counts, but both methods are not corrected for isotope decay, are 
influenced by variations of background activity and are operator dependent. 
To reduce variability some authors suggest, after acquisition, to display 
images equalizing bone marrow activity, as reference. However, also bone 
marrow activity may change in time, therefore this modality of displaying 
images does not improve accuracy and is limited to expert readers and some 
regions of the body with a good bone-marrow activity. We suggest here to 
acquire images at different time points with different acquisition times, 
starting from a settled amount of time in the early images and deriving the 
corresponding acquisition time for delayed and late images by correction due 
to isotope decay (as shown in Table 5.3). As a result, delayed and late images 
have the same counting statistics of early images and comparison is possible 
reducing the operator bias [14-16]. It is of course mandatory to display all 
images with same intensity scale in counts units and not in percentage of max 
counts per pixels that is another common display error. If images are 
correctly acquired and displayed, they are operator independent, 
reproducible, comparable and easy to interpret. 
We used the same software system (Osirix) for all patients, in order to avoid 
differences in display of different software systems between the centers. 
However, we want to state that all data are reproducible on all three systems 
(GE, Philips and Siemens) by displaying images in count units with the same 
intensity scale. 
Semi-quantitative analysis may also be helpful when visual interpretation is 
doubtful. Regions of interest (ROIs) can be drawn over the part of the 
presumed infected focus, copied to presumed normal reference tissue (e.g. 
anterior-superior iliac crest, contralateral bone), and target-to-background 
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(T/B) ratios can be calculated. However, location of ROIs in lesion and 
reference tissue is operator dependent. Additionally, the level of significance 
of the T/B ratios is arbitrarily decided and no studies have yet defined the 
threshold of increase of radiolabelled WBC over time to be considered 
positive.  
In this study, we retrospectively compared two different acquisition protocols 
for planar images (TDC vs. FT) and two different interpretation criteria 
(visually vs. semi-quantitatively) to determine the criteria that allow highest 
diagnostic performances.  
Best results were obtained with TDC acquired images and visual analysis for 
bone associated infections but not for soft tissue infections. Despite statistical 
significance is reached only when considering the whole group of patients, 
for each bone indication a consistent improvement of the diagnostic 
performances was always achieved by acquiring TDC images. The add value 
of the TDC acquisition is more evident in patients with bone and prosthetic 
infections, hereby potentially limiting the need for bone marrow imaging 
with colloids. The FT acquired images possibly have an advantage in term of 
sensitivity, but lead to a significant drop in specificity and diagnostic 
accuracy. On the other hand, when soft tissue infections were considered, the 
advantage of TDC acquisition was not evident. This may have several 
explanations. First, there might be different kinetics of migration of 
radiolabelled WBC in bones and soft tissues. Additionally, soft tissue 
infections includes muscular, brain, abdominal, heart, lung or dermal 
infections, thus being a very heterogeneous group with possible different 
behavior in terms of leukocyte recruitment and may need “ad hoc” 
interpretation criteria as already demonstrated for dermal filler infections and 
dermal infections in diabetic foot [14, 15]. In our study the 7 cases of soft 
tissue infections acquired with FT modality were mainly muscular infections, 
whereas the 10 soft tissue infections acquired with TDC modality were all 
dermal infections and this difference may account for the different accuracy 
in our results. 
Overall, the main advantage of TDC acquisition protocol is represented by 
the absence of operator interference and bias, that, by contrast, can strongly 
affect the results of FT acquired images. In this study there was little but 
significant difference in global diagnostic accuracy between FT and TDC 
acquired images (92.4% versus 97.7%; p<0.05) but we should consider that 
readers were experts also in FT acquired images. Indeed we can expect that a 
lower diagnostic accuracy of FT acquired images can be observed for less 
expert readers thus being TDC acquired images even more relevant.   
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Our results indicate that any percentage of radioactivity increase over time 
leads to high sensitivity (Table 5.5). Increasing the threshold to i.e. 20% 
radioactivity increase over time improves specificity, but lowers sensitivity.  
The threshold of the percentage of T/B increase over time may be affected by 
several parameters such as the type of infection (acute versus chronic), the 
type of disease (osteomyelitis versus soft tissue infections), the sustaining 
microorganisms and the presence of concomitant antimicrobial treatment. 
Since all these factors can significantly modify the intensity and the pattern 
of radiolabelled WBC over time, further studies are warrant to give clinical 
validation to this approach.  
Another point of discussion is the placement of the ROIs, which can differ 
between operators (contralateral, bone marrow, etc.). Despite a recent study 
from our group showed that the contralateral region is the most accurate for 
positioning the ROI for the background semi-quantitative calculation [17], in 
this study it was not possible to apply this criteria and background ROIs were 
positioned either on ipsilateral bone marrow or muscle when contralateral 
bone marrow was not available.   
To better localize the site and extent of infection, SPECT/CT images may be 
used. If sequential SPECT images are acquired, acquisition times for SPECT 
can also be normalized according to isotope decay using the same decay 
formula shown in Table 5.3. SPECT/CT is invaluable to better identify the 
site and delineate the extent of 99mTc-HMPAO-WBC uptake (i.e. bone or soft 
tissue) as compared to the planar and stand-alone SPECT images due to the 
easy identification of either blood-pool activity at the vascular bed or at bone 
marrow or e.g. non specific accumulation of 99mTc-HMPAO in the bowel. In 
this study, however, SPECT/CT was not used for diagnosing infection but for 
determining its extent in positive planar images. 
The role of SPECT/CT has been established for soft tissue infections [15] and 
endocarditis, cardiac devices, vascular prosthesis infections [11] and diabetic 
foot [18] when the need of anatomical landmarks is relevant. However, in 
some circumstances attention should be paid since intense uptake of the 
radiolabelled WBC localized close to the bone may lead to false positive 
results for osteomyelitis (see Figure 5.3).  
When evaluating bone/prosthesis infection and soft tissue infections, whole 
body imaging is mostly not necessary. However, such images allowed the 
check for the normal biodistribution of the radiolabelled autologous 
leukocytes and also the detection of distant sites of infection when suspected. 






Figure 5.3: Planar images of feet of a patient with a suspected osteomyelitis consequent to a 
fracture of the calcaneus bone with a cutaneous wound. At 30 min post-injection (first image, 
“early image”) image was acquired for 100 sec/frame (61,269 counts) (A). At 3 hrs post-
injection (“delayed image”, 2.5 hrs after first image) image was acquired for 133 sec/frame 
(52,274 counts) (B). At 20 hrs post-injection (“late image”, 19.5 hrs after first image) image 
was acquired for 951 sec/frame (52,212 counts) (C) showing evident decrease of activity at 
visual analysis, sign of no osteomyelitis. At 3 hrs semi-quantitative analysis showed T/B=2.2 
and at 20 hrs T/B=1.8 confirming a decrease with time, sign of no infection but just wound 
inflammation. The SPECT/CT at 20 hrs (D-G) however, does not allow to clearly identify 
the origin of uptake (cutaneous vs bone surface), thus being the visual analysis of planar 
imaging more accurate. Patient was operated to remove the bone fragment and no sign of 




When having a suspicion of a prosthetic joint infection or osteomyelitis, 
WBC scintigraphy should be performed by acquiring images at least at two 
time points, one at 3-4 hours (delayed images) and one at 20-24 hours (late 
images). Early images (at 30min-1h post-injection) may also be performed to 
have an early map of bone marrow distribution, but are not strictly necessary.  
The most reproducible and accurate acquisition protocol in musculoskeletal 
infections is using time-decay corrected acquisitions.  
Images must then be displayed using the same intensity scale in count units 
and not in percentage of max counts per pixel.  
158 
 
When these methodological considerations are fulfilled, visual analysis of 
images is operator-independent and is enough for high diagnostic accuracy of 
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The potential of indium-111 labelled diethylene- triaminepentaacetic  acid  
a,o-bis(biocytinamide) (111In-DTPA-Biotin) as a specific tracer in nuclear 
medicine imaging of vertebral osteomyelitis has been shown in a large series 
of consecutive patients. Biocytin is known to serve as a biotin source for a 
number of different microorganisms and quantitative studies on 
staphylococci indicated that on a molar basis biocytin seemed to have an 
activity equal to that of biotin. In this study, we evaluated the possibility of 
an illicit transport of 111In-DTPA-Biotin in cultures of Staphylococcus 
aureus on continued incubation for 24 h. Radiolabelled biocytin was 
prepared as described earlier and the stability and radiochemical purity was 
assessed in vitro for 24 h after labelling. Our data seem to demonstrate a 





Staphylococcus aureus is the bacterium most frequently isolated (55–80%) in 
infections (especially in spondilo- discitis), followed by coagulase-negative 
staphylococcus and enterobacteriaceae (Salmonella spp., Escherichia coli, 
Klebsiella spp.) [1–5]. Several radiopharmaceuticals have been developed for 
the scintigraphic imaging of infection/inflammation [6,7], aiming in 
particular at discriminating infection from ster- ile inflammation. However, 
none of the agents nowadays available are completely infection-specific. 
Indium-111 labelled diethylenetriaminepentaacetic acid a,o-
bis(biocytinamide)   (111In-DTPA-Biotin)   has   been used in a two-step 
approach to infection imaging (the avidin/111In-DTPA-Biotin  technique)  [8–
12];  neverthe- less, the potential of radiolabelled biotin as an infec- tion-
imaging agent per se has already been shown in an experimental animal 
model of infection using  biotin labelled with fluorine-18 [13] and in a large 
series of consecutive patients with vertebral osteomyelitis using 111In-DTPA-
Biotin [14,15]. A possible  pathophysiologic basis for such an observation is 
that biotin accumulates at the sites of infection not only because of passive 
local dif- fusion on account of abnormally increased capillary perme- ability, 
but also because of some incorporation of the radiolabelled agent into the 
bacteria; this consideration is based on the ascertained function of biotin 
itself as a growth factor for several bacteria (including staphylococ- ci) [16–
19]. Such early observations emphasize the need to take into account several 
parameters when evaluating the    biotin    requirement    of    staphylococci    
(especially S. aureus). In particular, attention must be paid to avoid the 
inhibitory effect  of  biotin  excess  on  the  synthesis of the transport system; 
furthermore, it should be con- sidered that some bacterial strains that require 
biotin for growth, can actually synthesize such a compound starting from the 
constituents of the culture medium. The aim of this study, to further validate 
the clinical relevance of labelled biotin, particularly in spine infec- tion, was 
to assess the extent, stability and mechanism of 111In-DTPA-Biotin 
incorporation by S. aureus on contin- ued incubation for 24 h in simply saline 










One milligram of DTPA-Biotin,  purchased  from  Sigma (St Louis, 
Missouri, USA), was diluted in 20 ml of sterile acetate buffer 0.05 mol/l, pH 
5.5. Aliquots  containing 500 mg/ml of DTPA-Biotin were then prepared and 
stored at 41C for subsequent labelling with indium-111. Just before use, each 
500 mg aliquot of DTPA-Biotin was labelled with  111 MBq  of  111In-
chloride  (Mallinckrodt Inc., St Louis, Missouri, USA) by incubation at room 
tem- perature for 15 min; labelling  efficiency  was  assessed by instant  thin-
layer  chromatography-silica  gel  (Pall, New York, USA) using bicarbonate  
buffer  0.05 mol/l  as the mobile phase. In this chromatographic system, 111In- 
chloride remains at the origin, whereas 111In-DTPA-Biotin migrates with the 
solvent with an RF of 0.7. Radioactivity in the chromatographic strips was 
measured both by counting with a g-counter and by imaging with a phos- 
phor  imager  (Perkin-Elmer,  Monza,  Milan,  Italy). 
 
Microorganisms and growth conditions 
Clinical isolates of S. aureus supplied by the Infection Disease Unit of the 
University Hospital of Pisa were inoculated into vials containing 50 ml of 
Mu¨ller–Hinton broth (Biomerieux, Bagno a Ripoli, Firenze, Italy) and stored 
overnight at 351C in a rotating incubator (Bactec 9240; Becton Dickinson, 
Franklin Lakes, New Jersey, USA).  Microbial growth was quantified by 
sequential dilutions and subcultures on selective agar plates (Mannitol Salt 
Agar; Becton Dickinson), and also tested on permissive agar plates 
(Chocolate Agar; Becton Dickinson) as a con- trol for contaminating bacteria 




Suspensions of S. aureus were washed twice with saline, resuspended in 
distilled water and standardized turbidi- metrically so that each suspension 
tube would contain 4 x 1010  colony-forming units per millilitre equivalent to 
0.2 mg of dry cells per millilitre. A total of 84 incubation tubes were prepared 
for each experiment: 61 tubes with viable bacteria and 21 tubes with killed 
staphylococci (boiled for 20 min). Viable microorganisms were incu- bated at 
37 and 41#C  for  different  incubation  times (30 min,  1,  2,  4,  6,  and  24 
h)  with  200 ml  of  both  a 3.5 nmol/l   (approximately   4 ng/ml)   111In-
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DTPA-Biotin solution in sterile saline (corresponding to 0.7 pmol of 
radiolabelled biotin per tube, or 0.8 ng of the compound) and a 3.5 mmol/l 
(approximately 4 mg/ml) 111In-DTPA- Biotin solution. To explore possible 
active uptake, in one set of experiments, 0.01 mol/l glucose was added to the 
viable staphylococci incubation tubes. The viable count of staphylococci was 
also monitored for all time periods by the standard-agar plating technique. At 
the end of the incubation, microorganisms were recovered by centrifugation 
at 4500 g for 10 min. The bacterial pellets were washed three times with 1 ml 
of sterile saline to remove free 111In-DTPA-Biotin, and radio- activity 
retained in the bacterial pellet was measured in a well-type gamma-counter 
(LKB Wallac, Turku, Finland). Background radioactivity possibly because of 
adsorption onto the incubation tubes was assessed using 111In-DTPA- Biotin 
in sterile saline, without microorganisms, in the same incubation times and 
conditions described above. Radioactive counts were used to determine the 
amount of 111In- DTPA-Biotin incorporated by bacterial suspensions, ex- 
pressed as nanograms of 111In-DTPA-Biotin per milligram of dry cells. The 
experiments were carried out using sets of 3–6 tubes per incubation time and 
condition, and the results reported here represent the average of two separate 




Radiochemical purity and stability of 111In-DTPA-Biotin 
 
Radiolabelling efficiency was  consistently greater than 99% in all the 
experiments performed (n = 4). Stability of 111In-DTPA-Biotin, assessed by 
evaluating radioche- mical purity at 2, 4, 6 and 24 h after labelling, was 
remark- ably high with radiochemical purity greater than 99% at all time 
points up to 24 h of incubation at room tempera- ture in the labelling reaction 
mixture (Fig. 6.1), which depicts a typical output of phosphor-imager 
analysis. Agree- ment between the strip cut-and-count technique and 




After thorough washing, the residual radioactivity because of 111In-DTPA-
Biotin adsorbed to the incubation tubes without adding bacteria was always 
much less than 0.005% of the total added radiolabelled biotin. No 
radioactivity was found associated with the bacterial pellet at all incubation 
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times and conditions in the experiments performed with the lower 
concentration of 111In-DTPA-Biotin (3.5 nmol/l, data not shown). 
In contrast, in the experiments performed with the higher concentration (3.5 




Figure 6.1: Radiopharmaceutical stability of indium-111 labelled 
diethylenetriaminepentaacetic acid a,o-bis(biocytinmaide) (111In-DTPA-Biotin) in vitro. 
Chromatographic strips images generate on a phosphor screen at different time points.  
 
viable S. aureus was observed, with an incorporation curve rising until 6 h of 
incubation and then plateauing until 24 h at approxi- mately 0.95 ng/mg of 
dry cells (corresponding to approxi- mately 0.86 pmol); the addition of 
glucose did not change such a time-pattern of incorporation (data not shown). 
Similarly, the incorporation curves obtained when in- cubating at 41°C were 
nearly identical to those obtained at 37°C (Fig. 6.2). The count of viable cells 
was found to be constant over the 24 h of incubation. In contrast, the 
microorganisms  killed  by  boiling  for 20 min showed an incorporation 
pattern characterized by the continuous rise of the curve, with values that 
were significantly higher than those observed with viable staphylococci (P = 
0.02). In particular, the incorporation  of 111In-DTPA-Biotin by the killed 
bacteria at 6 and 24 h was approximately two-fold and four-fold the 




Little  is  known  about  the  conditions  that  affect  the accumulation of 
native biotin into S. aureus. Hugo and Davidson [20] observed that S. aureus 
growing under limited biotin supply (if compared with the standard glucose 
meat-infusion broth, Müller–Hinton broth) slight- ly reduced their growth 
rate. Biotin transport into bacterial cells has been extensively investigated in 
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Lactobacillus by Waller and Lichstein [21], who showed that biotin transport 
occurred by two mechanisms: one process was dependent on temperature, pH 
and active cellular metabolism (Michaelis–Menten constant of 31.5 nmol/l), 
whereas the other one was inde- pendent of these. 
.  
 
Figure 6.2: Comparison of the time-pattern of indium-111 labelled 
diethylenetriaminepentaacetic acid a,o-bis(biocytinamide) (111In-DTPA- Biotin) uptake by 
suspensions of Staphylococcus aureus (S.A) in different experimental conditions. Each point 
represents the mean ± 1 SD of two independent experiments with triplicate tubes. 
 
 
According to Rogers and Lichstein [22,23], the apparent Km for 
active transport of 14C-biotin in yeast cultures of Saccaromyces cerevisiae 
was 0.03 nmol/l and the presence of glucose caused a 13-fold increase in the 
amount of biotin uptake after 30 min of incubation: 13 ng (0.05 nmol) versus 
0.99 ng (0.004 nmol) of d-biotin (20 ng/ml) per milligram of dry cells. These 
investigators evaluated the inhibition of the active transport system of 14C-
biotin in yeast cells grown in biotin excess (25 ng/ml, 100 nmol/l) medium, 
and they observed a mild uptake of biotin (less than 10 ng of biotin/mg of dry 
cells), with many features suggesting passive diffusion. 
The possibility that biotin and biocytin could have, on a molar basis, 
the same activity [24] prompted us to evaluate the possible occurrence of an 




Nevertheless, there is still some contradictory evidence about the 
specific portion of biotin’s structure affecting its ability to be taken up by 
bacterial cells; Prakash and Eisenberg [25] showed that the ureido ring of 
biotin must be intact for its uptake by bacteria, and that modifying the side 
chain does not reduce its uptake, whereas Gretler et al. [18] suggested that 
modifications of the side chain of biotin could reduce its transport across cell 
membranes. 
We evaluated the 111In-DTPA-Biotin incorporation into viable and 
killed S. aureus over the 24 h of incubation in a growth-limiting medium 
consisting of saline, but added with two different levels (4 ng/ml and 4 
mg/ml, respec- tively) of radiolabelled biotin. Viable S. aureus cells show a 
slight uptake of radiolabelled biocytin (0.2 ng/mg of dry cells) as early as 
after 1 h of incubation in a medium containing excess (4 mg/ml) of 
radiolabelled biocytin, with a mechanism independent of glucose and 
temperature. 111In-DTPA-Biotin has two biotin carboxyl groups joined to the 
DTPA through an amide bond and two intact ureido rings. Our data are 
consistent with the hypothesis that modifications of only the side chain 
(leaving the ureido rings intact) do not affect the uptake of 111In- DTPA-
Biotin. 
The effect of the absence of glucose and temperature on radiolabelled 
DTPA-biotin uptake suggests that there is passive diffusion of approximately 
0.2 pmol of labelled biocytin from the surrounding fluid into viable S. aureus, 
similar to that shown in the yeast cells grown in biotin excess medium (that 
still exhibited an ability to take up 4 pmol of 14C-biotin even in the absence 
of glucose). On continued incubation for 24 h, the 111In-DTPA-Biotin 
intracellular  content  reaches  a  steady  state  level  of 0.95 ng (or 0.86 
nmol) per milligram of dry cells within 6 h. The viable cell count and the 
level of incorporated 111In-DTPA-Biotin then remain constant, suggesting 
that there is a stable association of 111In-DTPA-Biotin with the cells. Several 
factors might be responsible for the saturation kinetics of this process. For 
instance, cells might be capable of taking up radiolabelled biotin by a 
mediated carrier transport system displaying saturation kinetics,  or  
alternatively,  synthesis  of  the  transport system might be inhibited in such 
aging cells. Further- more, some saturation of the outer binding sites for 
111In- Biotin in the absence of growth might occur as well. 
On the other hand, killed staphylococci show a substan- tially higher 
uptake of 111In-DTPA-Biotin, continuing for 24 h apparently without 
saturation. This finding supports the hypothesis that radiolabelled biocytin is 
normally able to pass the viable cell membrane probably through a faci- 
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litated diffusion process displaying a saturation kinetic pattern; on the 
contrary, 111In-DTPA-Biotin can freely enter into the cells if the membrane 
has been damaged (killed staphylococci). Nevertheless, whichever is the 
mechanism of 111In-DTPA-Biotin uptake under the con- ditions described 
here, it seems to be a passive process in which the radiolabelled biotin is 
presumably taken from the environment and stored, rather than destroyed by 
nonproliferating living organisms Further research is in progress to elucidate 
the fraction of 111In-DTPA-Biotin that remains in the  membrane  and the 
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Objectives Biocytin analogues labelled with indium-111, yttrium-90 and 
lutetium-177 have shown their effectiveness in the imaging of 
infections/inflammation in patients with osteomyelitis and function as 
efficient tools in pretargeted antibody-guided radioimmunotherapy. In this 
study, the labelling of a biocytin analogue coupled with DOTA     (1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid), namely, r-BHD, with 
gallium-68 (68Ga) was optimized, and the quality and stability of the 
preparations were assessed for clinical use. Materials and methods Synthesis 
of 68Ga-r-BHD was carried out by heating a fraction of the 68Ge/68Ga eluate 
in a reactor containing the biocytin analogue with the appropriate buffer. The 
influence of the precursor amount (from 2.5 to 140 nmol), the pH of the 
reaction (from 2 to 5.5) and the buffer species (1.5 mol/l sodium acetate, 1.5 
mol/l sodium formate, 4.5 mol/l HEPES) on radiochemical yield and 
radiochemical purity was assessed. Studies on stability and binding to avidin 
(Av) were also conducted in different media. Results  Under the best 
labelling condition (56 nmol of precursor, 3.8 pH, sodium formate buffer) 
synthesis of 68Ga-r-BHD resulted in a yield of 64±3% (not decay corrected). 
Radiochemical purity was around 95% because a 68Ga-coordinated 
sulphoxide form of the ligand was detected as a by-product of the reaction 
(68Ga-r-SBHD). The by-product was identified and characterized by liquid 
chromatography–electrospray ionization tandem mass spectrometry. At the 
natural 1:4 Av/68Ga-r-BHD molar ratio, affinity results were 62±2 and 
80±2% in saline and human serum, respectively. Stability of 68Ga-r-BHD and 
of the radiotracer/Av complex remains almost constant over 180 min. 68Ga-r-










4yl]pentanoic acid) is a natural vitamin that acts as a coenzyme in the 
metabolism of fatty acids, isoleucine and valine and plays a role in 
gluconeogenesis. Biotin has a strong binding affinity for avidin (Av) and 
streptavidin, and this binding property can be exploited to develop tracers 
for a number of applications on the basis of a pretargeting concept. Biocytin 
is an amide derived from the condensation between the biotin carbo- xylic 
moiety and the amino acid L-lysine that acts as a biotin source for a 
number of different microorganisms in vitro. For this reason an indium-111 
(111In)-labelled DTPA-biocytin analogue [111In -diethylenetriaminepen- 
taacetic acid a,o-bis(biocytinamide)] has been used along with preinjection 
of Av or per se as an infection/ inflammation imaging agent and has 
shown its effective- ness in a large number of patients with vertebral 
osteomyelitis [1–3]. Recently, the infection specificity of 111In –DTPA-
biocytin with respect to inflammation was postulated [4]. Nevertheless,  
DTPA-biocytin adducts show relatively low stability in human serum 
mainly because of the susceptibility to hydrolysis of the amide bond 
between biotin and the L-lysine linked to the chelating moiety by the 
serum biotinidase [5,6]. More- over, in recent years, the use of DTPA itself 
as a chelator of metal radionuclides in bioconjugate molecules has been 
replaced by the use of macrocyclic chelating agents such as 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), providing 
kinetically more stable complexes in human serum [7,8]. Both chemical 
drawbacks were overcome by Sabatino et al. [9], who reported the 
preparation of a CO-reduced N-aminoexylbiotinamido derivative 
conjugated to DOTA (r-BHD). This biocytin analogue showed improved 
stability in human serum and retained a high binding affinity for Av r-BHD, 
labelled with yttrium-90 (90Y) and lutetium-177 (177Lu), was used in a 
number of clinical studies to facilitate efficient pretargeted antibody guided 
radioimmunotherapy (PAGRIT) [10,11]. PET has shown a large number of 
advantages with respect to single photon emission tomography in terms of 
spatial resolution and target background ratio. However, even if the 
labelling of r-BHD with a positron emitter radionuclide such as 68Ga 
could improve the imaging of both inflammation/infection and the 
pretargeting approach, limited data are available for the preparation and 
quality assessment of the 68Ga-labelled r-BHD biocytin analogue [12]. 
The present study aimed at optimizing the radiolabelling of the biocytin 
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r-BHD derivative with the positron emitter 68Ga radionuclide in order to 
yield a well-characterized product of high purity. Herein, the effect of 
some reaction parameters such as precursor and buffer amounts, buffer 
species  and  the stabilizers  used  on  the  radiochemical  yield  (RCY)  and 
radiochemical purity (RCP) was investigated. Further, a full set of  analyse  
was developed in order to achieve a pharmaceutical grade of the preparation 
and allow its safe use in clinical trials.  
 
Materials and methods 
 
Reagents and instrumentation 
 
4-(2-hydroxyethyl)-1-piperazineethanesulphonic acid (HEPES), sodium 
acetate, sodium formate, Av (Mw 66 kDa), biotin and gallium(III) chloride 
(purity > 99.999%) were purchased from Sigma-Aldrich (Milan, Italy). A 
3 mg/ml solution of r-BHD (ST2210-DP) was obtained from Sigma-Tau 
(Pomezia, Italy). A 1850 MBq IGG100 68Ge/68Gagenerator and a 
Modular Lab automatic synthesizer were purchased from Eckert & Ziegler 
(Berlin, Germany). Metal-free hydrochloric acid (0.1 mol/l) was purchased 
from Carlo Erba (Milan, Italy), whereas 10 ml of disposable 95% ethanol, 
0.9% sodium chloride and injectable water solu- tions were purchased 
from SALF (Bergamo, Italy) and B. Braun (Milano, Italy). Human albumin 
solution (20%) was obtained from Kedrion Biopharmaceuticals (Lucca, 
Italy). All reagents were used without further purification. When needed, 
milliQ water (resistivity 18.2 MO·cm) was used for preparing reagent 
solutions. Radiochemical and chemical analyses were carried out by 
ultrahigh-performance liquid chromatography (UHPLC) using an Acquity 
system with a binary solvent, a BEH C-18 1.7-mm column (2.1 x 150 mm) 
and autosampler manager modules (Waters, Milan, Italy). The instrument was 
equipped with an Acquity TUV detector (Waters) and a Herm LB 500 
radiochemical detector (Berthold Technologies, Milan, Italy). RCP was 
also assessed by thin-layer chromatography (TLC) using an AR 2000 
Imaging Scanner device (Bioscan, Washington, District of Columbia, USA). 
Liquid chromatography-electrospray ionization tandem mass spectrometry 
(LC-ESI-MS) was performed using an Ultimate 3000 HPLC 
chromatographic system (Dionex, Sunnyvale, California, USA) equipped 
with a Luna C-18 100-A  column (4.6x50 mm; Phenomenex, Bologna, 
177 
 
Italy). The eluted samples were analysed using an LTQ Orbitrap XL 
instrument (Thermo Scientific, Waltham, Massachu- setts, USA) equipped 
with an electronspray ion source. The pH of the samples was assessed using 
a pH 213 Microprocessor pH-meter (Hanna Instruments, Milan, Italy). For 
the stability and Av affinity studies, samples were prepared using 10 kDa 
molecular weight cut-off Amicon Ultra-4 centrifugal filter devices 
(Millipore, Milan, Italy) and centrifuged at 6000 RCF for 60 min using an 
SL16 centrifuge (Thermo Fisher, Milan, Italy). All the activity measures 
described in this study were performed using an Aktivimeter ISOMED 
2000 dose calibrator (MED Nuklear-Medizintechnik, Dresden, Germany). 
 
Radiosynthesis of 68Ga--r-BHD 
 
The radiolabelling of Ga-r-BHD was performed with a Modular Lab 
synthesizer using the fractionating method as already described by 
Decristoforo et al. [13] for the radiolabelling of Ga-DOTATATE. The 
software sequence was modified to allow the operator to manually select 
the eluate fraction to be collected, obtaining more than 80% of the Ga 
activity in an B2 ml 0.1 mol/l HCl fraction. The selected fraction was 
transferred into a reactor vial containing varying amounts of a 1 mg/ml r-
BHD water solution (corresponding to a range from 2.5 to 140 nmol) and 
varying amounts of different buffer solutions in order to study the effect of 
the pH (ranging from 2 to 5.5) and the buffer species (1.5 mol/l sodium 
formate, 1.5mol/l sodium acetate, 4.5 mol/l HEPES solutions) on the RCY 
and RCP. The mixture was heated to 1001C for 5 min and then passed 
through a light C-18 cartridge (Waters) preconditioned manually with 3 
ml of a 50% EtOH solution and 3 ml of a 0.9%  sodium  chloride  solution. 
The product  was retained in the cartridge,  and the solution was collected 
separately in order to measure the pH of the reaction precisely. Ga-r-BHD 
was eluted with 0.5-1 ml of a 50% ethanol solution and diluted with 8 ml 
of a 0.9% sodium chloride solution. Before being collected into the final vial 
the solution was passed through a sterile 0.22 mm filter (Waters). In the 
second step of the experiments, varying amounts of EtOH (50, 100 and 200 
ml) were directly added to the reactor before the labelling reaction in order 
to assess the effect of the radical scavenger on the RCP. The synthesis time 
was about 14 min and every preparation was performed in triplicate. None 
of the radiochemical yields reported in the results of this study are 
corrected for decay and are referred to the radioactivity of Ga-r-BHD at 
the end of synthesis with respect to the total 68Ga activity eluted from 
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the generator. The yield was calculated considering the RCP obtained 
from UHPLC analyses. Preparation of free 68Ga3+ and the 68Ga-
hydrolysed product as a reference standard. 
To develop a reliable set of quality controls and to identify the 
chromatographic peaks during the analyses, free 68Ga3+ was obtained 
directly by collecting a 100 ml aliquot (B10 MBq) of the 0.1 mol/l HCl 
generator eluate. 68Ga-hydrolysed products were obtained at varying pH 
values (5,7 and 10) by adding varying aliquots of a 1 mol/l NaOH solution 
to 100 ml of the generator eluate. All the mixtures were incubated for 5 
min at room temperature. 
 
Synthesis of natGa-r-BHD as a reference standard 
 
A measure of 12.40 mg of GaCl3 (70 nmol) was dissolved in 1.8 ml of 0.1 
mol/l HCl, and then a solution of 170 ml of 1.5 mol/l sodium formate 
containing 50 mg (70 nmol) of r-BHD was added to obtain a solution of pH 
3. The mixture was heated for 10 min at 1001C on a heater block and then 
passed through a C-18 cartridge (precondi- tioned with 3 ml of a 50% 
EtOH solution and 3 ml of a 0.9% sodium chloride solution). The products 




Quality control of the natGa-r-BHD solution as performed by LC–ESI-MS. 
The  chromatographic part was carried out with a constant 0.2-ml/min flow 
using a 0.2% formic acid–water solution (A) and a 0.2% formic acid- 
acetonitrile (ACN) solution (B) as the mobile phase, with the following 
gradient: 0-9 min, 6-8% B; 9-12 min, 8% B; 12–15 min, 8–15% B; and 
finally 15-24 min, 15% B. Analysis was carried out by ESI-MS using the 
following parameters: source voltage of 3.3 kV and capillary and tube lens 
voltages of 13 and 85 V, respectively. The source was heated at 2751C with 
a 20 sheath gas flow rate and five sweep gas flow rate. The acquisition 
was carried out by full mass spectroscopy in the FT mode (R’s = 60 000). 
Quality controls on every radioactive preparation were performed  by  
chromatographic methods. UHPLC was the preferred procedure; however, 
as this technology is not routinely available in every laboratory, a radio-
TLC method was also applied. The UHPLC analyses were carried out at a 
flow rate of 0.35 ml/min using ACN and a 0.1% v/v trifluoroacetic acid-
water solution as the mobile phase, with the following gradient: 0-3 min, 6-
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8% ACN and 4–5 min, 8–15% ACN. The wavelength of the ultraviolet 
detector was set to 220 nm and the column temperature was fixed at 301C. 
To verify the effectiveness of the purification through  the C-18 cartridge, 
the UHPLC analysis was carried out both on the crude product of the 
reaction and on the final product. The identity of the products was 
confirmed by coinjection of the natGa-r-BHD standard or by injection of 
the free 68Ga3+ or the 68Ga -hydrolysed products obtained as described 
before. A 100 ppm r-BHD solution was also used to determine the retention  
time of the free ligand. The RCP of 68Ga-r-BHD solutions was also 
assessed by TLC with RP-18F plates (Merck, Whitehouse Station, New 
Jersey, USA) as the stationary phase and a solution with 97% 0.1 mol/l 
sodium citrate and 3% 1 mol/l HCl as the mobile phase. 
As various buffers were used and their eligibility for human use is, in 
some cases, debated, the presence of buffer residues in the final 68Ga-r-
BHD solutions was assessed by a second UHPLC analysis under the 
following  conditions: use BEH C-18 1.7mm column (2.1 x 150 mm), 0.35 
ml/min flow rate using ACN and a 17 mmol/l H3PO4 water solution (pH 
2.5) as the mobile phase, with a gradient of 0–15% ACN from 0 to 15 
min, and an ultraviolet detector set at  210 nm. The sterility and absence of 
bacterial endotoxins were tested for according to European Pharmacopeia 
standards. 
 
Stability of 68Ga -r-BHD 
 
For stability studies, 68Ga-r-BHD was synthesized by reacting 56 
nmol of the precursor at pH 3.8 obtained using sodium formate as the 
buffer. Different aliquots of the 68Ga-r-BHD solution (0.75 ml, 45 MBq) 
were alter- natively mixed with 0.75 ml of a 0.9% NaCl, 4% human 
albumin (pH = 7) or healthy human serum solution. The mixtures were 
incubated at 371C, and after 10, 30, 60, 120 and 180 min, a 10 ml 
aliquot of each solution was injected into the UHPLC. Analyses were 




Avidin binding reactions 
 
To obtain 68Ga-r-BHD to Av molar ratios of 2:1, 4:1, 8:1, 16:1 and 
32:1, a fixed amount of 68Ga-labelled r-BHD solution (1.4 nmol, 13 
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MBq) was added to 1.5 ml of a 0.9% NaCl solution or to healthy 
human serum containing decreasing amounts of Av. For separating the 
activity bound to Av from the bulk solution, the mixtures were incubated 
at 371C for 5 min and centrifuged using Amicon Ultra-4 devices. The 
top and bottom parts of the Amicon were measured using a dose 
calibrator. The amount of Ga-r-BHD that aspecifically bound to the filter 
membrane was evaluated by incubating and centrifuging aliquots of the 
radiotracer under the same conditions described above but in the absence 




A 100-fold molar excess of natural biotin was added to 1.5 ml of a 0.9% 
NaCl solution or human serum containing 0.35 nmol of Av solution. The 
mixture was incubated at 371C for 5 min and an aliquot of Ga-r-BHD  
solution (1.4 nmol, 13 MBq) was added. Thereafter, the solutions were 
freshly incubated for 5 min and then centrifuged in an Amicon Ultra-4 
centrifuge. The top and bottom parts were measured in a dose calibrator.  
 
Stability of the avidin/ Ga-r-BHD complex 
 
Solutions containing  an aliquot of Ga-labelled  r-BHD (1.4 nmol,  13 
MBq) and Av in a 4:1 molar ratio were incubated in Amicon Ultra-4 
devices with 1.5 ml of a 0.9% NaCl solution or human serum at 371C for 
0, 30, 60, 120 and 180 min, respectively. After incubation, centrifuga- 
tion was performed on the Amicon Ultra-4 centrifuge and the top and 
bottom parts were measured using a dose calibrator. All tests were 




Radiosynthesis of 68Ga-r-BHD 
 
Figure 7.1a shows the dependence of the radiolabelling yield on the 
precursor amount. Although the highest yield was obtained with 140 nmol 
of precursor (68±1%), a substantial plateau was observed at 56 nmol of r-
BHD, corresponding to a 64±3% RCY. Therefore, this amount was used 
in the subsequent labelling reactions, being considered a good compromise 
between high yield and high specific activity. Figure 7.1b shows the 
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dependence of the RCY on the pH and on different buffer species. On 
using sodium acetate buffer, the best yield was 58±2% and was achieved 
at a pH of 4.6. Both sodium formate and HEPES buffers gave better RCY 
values than did sodium acetate, although the best results were obtained 
at different pH values (64±3% RCY at pH 3.8 and 64±4% RCY at pH 




RCP and chemical purity of the product were assessed by UHPLC before 
and after the final purification through the C-18 cartridge. A comparison 
of the two chromatograms of a typical preparation is shown in Fig. 7 .2 
and the following retention times can be observed: free 68Ga3+,1.14 min; 
68Ga-hydrolysed products, 1.35 min; 68Ga-r-SBHD, 3.33 min; and 68Ga-r-
BHD, 6.80 min. When the radiosynthesis was performed under the best 
conditions (56 nmol of r-BHD, pH = 3.8, sodium formate buffer), but 
in the absence of EtOH as a stabilizer, an RCP of 95±1% was 
achieved. The addition of varying amounts of EtOH to the reactor 
before the labelling has a strong impact on the RCP of the preparation 
and also affects the RCY. The best conditions were found when 50 ml of 
EtOH was added to the reactor. In this case RCP was improved to 98% and 
RCY was comparable to that achieved under the same reaction 
conditions but in the absence of EtOH (64%). If a higher amount of 
EtOH was added, the RCY markedly decreased to 45% (100 ml) and 8% 
(200 ml). Radio-TLC analyses were carried out on the final solutions  only  
and the following  Rf values were obtained: 68Ga -r-BHD and 68Ga -r-
SBHD, 0.0-0.2; free 68Ga3+ and hydrolysed products, 0.9-1.0. The 
amount of free ligands was under the limit of detection (0.1 mg/ml) 
despite the total amount used for the labelling. The second set of 
UHPLC analyses for determining the amount of buffers in the final 
solutions gave the following results: 20±5 mg/ml (Rt = 1.2 min) for 
HEPES, 36±4 mg/ml (Rt = 1.3 min) for sodium formate and 33±3 mg/ml 






Figure 7.1: (a) 68Ga-r-BHD radiochemical yield as a function of precursor amount 
(sodium formate buffer, pH = 3.8). (b) 68Ga-r-BHD radiochemical yield as a function of 












Figure 7.2: UHPLC chromatogram (radiochemical detector) of a typical 68Ga-r-BHD 
preparation before (a) and after (b) purification through a C-18 cartridge 
 
 
Stability of 68Ga-r-BHD 
 
Stability of 68Ga-r-BHD in different media is shown in Fig. 7 . 3a. 
Considering the fact that the initial RCP was 95±1%, a high stability of 
the radiotracer in 0.9% NaCl and albumin solutions can be observed 
within the assessed time. In addition, after 180 min at 37°C the 
percentage of 68Ga bound to the r-BHD analogue remained greater 
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than 94±1 and 93±1% for 0.9% NaCl and albumin solutions, 
respectively. The stability in human serum is slightly lower (a decrease 
from 95±1 to 90±1% after 180 min was observed) and it was likely 
because of the presence of serum enzymes, proteins and metal 
competitors in the solution. 
 
Binding to avidin and blocking experiments 
 
Results of the study on 68Ga-r-BHD affinity for decreasing amounts of Av in 
a 0.9% NaCl solution and in healthy human serum are shown in Fig. 7.3b. In 
the 0.9% NaCl solution, when the molar ratio between r-BHD and Av was 2:1, 
the amount of radiotracer bound to Av was about 70%; however, at the 
natural 4:1 molar ratio, it decreased to about 62%. These results are 
comparable to the findings obtained for 90Y-r-BHD by Sabatino et al. [9]. In 
human serum, the amount of radiotracer bound to Av was notably higher than 
that in saline and was about 95 and 80% for 2:1 and 4:1 molar ratios, 
respectively. For all the calculations, the average percentage of radiotracer that 
aspecifically bound to the Amicon was subtracted by the amount measured 
in the top part of the device. In the blocking experiments performed by 
adding a 100-fold excess of natural biotin for saturating the Av binding 
sites, the percentages of 68Ga-r-BHD still binding Av were about 5 and 20% 
for the 0.9% NaCl solution and human serum, respectively. 
 
Stability of the avidin/68Ga-r-BHD complex 
 
Stability of the Av/68Ga-r-BHD complex in the 0.9% NaCl solution and in 
human serum is shown in Fig. 7 . 3c. The study was conducted using a 
1:4 Av/r-BHD molar ratio. In both media the stability of the complex 
remains almost constant for the duration of the study. In the 0.9% NaCl 
solution, the amount of 68Ga-r-BHD bound to Av started from 62% and 
decreased to about 54% after 180 min. For the experiments performed 
in human serum the percentage started from 80% and decreased to about 




The labelling of r-BHD with a positron emitter radionuclide such as 68Ga 
can potentially lead to an improvement both in the localization of small 
foci of avidinated cells in the pretargeting approach and in the per-se 
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injection of the radiotracer as an infection/inflammation imaging agent. 
Moreover, 68Ga is produced by means of a 68Ge/68Ga generator from the 
long-lived parent 68Ga (t1/2 = 270 days) and can also be utilized in 
facilities without a cyclotron in situ. 68Ge/68Ga generators are widely used 
in many nuclear medicine departments nowadays and 68Ga labelled 
radiopharmaceuticals are recognized as effective tools for clinical trials 
[14,15]. 
The 68Ga –DOTA-biocytin analogue was prepared using a commercial 
automatic synthesizer. Similar to the proce- dure adopted for the synthesis 
of 68Ga labelled somatostatin analogues already described in the literature 
[13,16], a fraction of the 68Ge /68Ga generator eluate was transferred into 
a reactor and labelled with bioconju-gates at high temperature for 3-10 min 
in the presence of a buffer. On the basis of this procedure, synthesis of 68Ga-
r-BHD was optimized for pH, buffer species and precursor amount in order 
to obtain the most reliable and highest yielding procedure. The feasibility of 
labelling biotin analogues with 68Ga has already been explored by Bloom et 
al. [17]. In their study three analogues linked to DOTA by different alkyland 
polyethylenglycol chains were manually labelled with 68Ga for monitoring 
the graft survival during islet transplantation. However, these derivatives 
are still in a preclinical phase of evaluation [18]. In contrast, the use of the 
r-BHD analogue labelled with 90Y and 177Lu has already been reported in 
a large number of human applications [10,11]. 
In our study, the labelling yield of the reaction between 68Ga3+ and 2.5-
140 nmol of the DOTA-conjugated biocytin analogue r-BHD was 
investigated (Fig. 7 .1a). As the RCY did not markedly improve when 
more than 56 nmol of the ligand was reacted, we decided to use this 
amount for the rest of the study. Using 56 nmol of r-BHD and starting 
from 962 MBq of 68Ga(III), the specific activity was 11 MBq/nmol. These 
results can be compared with the results obtained by Bloom and colleagues 
on the labelling of DOTA-pegylated biocytin analogues. In their study, the 
plateau of 68Ga3+ incorporation was reached at 10 nmol, but chemical 
concentration/purification of the 68Ga eluate through an anion exchange 
cartridge was performed instead of simple fractionation [17]. 
68Ga3+ incorporation in r-BHD was also notably influenced by the pH 
of the reaction and by the nature of the buffer used during labelling. In 
an analogue study on the radiosynthesis of 68Ga -DOTATOC, Bauwens 
et al. [19] reported that the use of HEPES, sodium acetate and 
sodium succinate as buffering agents yielded comparable results. 
However, the researchers concluded that only sodium acetate should 
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be applied in clinical 68Ga-DOTATOC labelling as it is the only buffer 
among the three to be recognized as a substance for pharmaceutical and 
human use in the European legislation. Herein, the RCY and RCP 
obtained using 1.5 mol/l sodium acetate were compared with those 
obtained with 4.5 mol/l HEPES and 1.5 mol/l sodium formate, and an 
B10% higher RCY was achieved when both HEPES and sodium formate 
were used instead of sodium acetate (Fig. 7.1b). It appears complicated 
to explain this difference because both thermodynamic and kinetic 
factors may influence the trend of the reaction, and the constants for all 
the processes are not available yet. Reasoning on the mechanism, we 
suppose that the 68Ga3+ in solution is rapidly coordinated by the donor 
atoms of the buffers and then these complexes are slowly converted to 
the DOTA bioconjugates during heating. As the constant for forma- tion 
for Ga–acetate complexes (log K = 3.68) is almost two orders of 
magnitude greater than that for Ga–HEPES (log K = 1.99), we surmised 
that the conversion to Ga-r- BHD is better promoted starting from the 
HEPES complexes than from the acetate ones [20,21]. Thermo- dynamic 
data for Ga-formate complex formation are not available; hence, a direct 
comparison between acetate and formate buffers is not yet possible. 
However, it is likely to suppose analogous reasons for the higher RCY 
compared with that for HEPES when formate instead of acetate is used, 
as the log K values of the metal-formate complexes (i.e. 90Y or 177Lu) are 
normally two to three orders of magnitude lower than the log K values of 
the corresponding metal-acetate complexes [22]. As the use of sodium 
formate or HEPES as an additive for injectable prepara- tions is not 
universally accepted, a UHPLC method for assessing the buffer amount 
was developed. The amount of residues detected in the final solutions 
was very low when compared with the reported LD50 sodium acetate, 
3530 mg/kg (mouse); sodium formate, 11200 mg/kg (mouse); HEPES, 316 
mg/kg (quail). However, as a really concen- trated HEPES solution was 
needed to buffer the reaction solution to the optimal pH, we decided to 
use sodium formate for the rest of the study. 
In contrast to that reported in the study by Blom et al. [17], in which 
purification after a labelling reaction was not considered necessary, we 
observed considerable improvement in the RCP after purification by solid 
phase extraction of the crude labelled Ga-r-BHD solution through the C-18 
cartridge, as demonstrated by UHPLC analysis. However, as shown in Fig. 
7.2b, it was not possible to achieve an RCP of greater than 95% as a 
radioactive by-product (Rt = 3.33 min) was still present in the solution after 
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purification by solid phase extraction. The LC-ESI-MS analysis of the natGa-
r-BHD preparation allowed the separation of the impurity and the acquisition 
of its mass spectra. The m/z pattern was ascribed to the 68Ga-coordinated r-
BHD sulphoxide. Although the formation of D-biotin and L-biotin 
sulphoxides as intermediate products of the biotin oxidation to the sulphone 
was already reported [23], the UHPLC analysis of the r-BHD ligand did not 
show the presence of by-products in the solution. Hence, the formation of D-
CO-reduced and L-CO-reduced N-aminoexyl sulphoxide biotinamido-DOTA 
(r-SBHD) by oxidation of r-BHD was supposed to occur during the 
labelling reactions. Structures of 68Ga-r- BHD and 68Ga-r-SBHD are 
shown in Fig. 7.4. In addition, under the best reaction conditions (56 
nmol r-BHD, pH = 3.8, sodium formate buffer) it was not possible to 
fully eliminate this byproduct from the final solution, and the best RCP 
achieved was 95%. In contrast to that reported on the preparation of 68Ga-
labelled somatostatin analogues [24], the use of HEPES as buffer did 
not significantly improve the RCP of 68Ga-r-BHD preparations, as the 
results are comparable to those obtained using sodium formate and 
acetate. 
Biotin sulphoxide is a product of the catabolic pathway of biotin in 
mammals and is commonly found in urine and plasma of rats, pigs and 
humans [25–28]. However, 68Ga-r-SBHD may affect image quality because 
of its possible metabolization by liver or kidney enzymes. In our study, the 
formation of 68Ga-r-SBHD was partially avoided by adding 50 ml of 
EtOH to the reaction solution [29]. The use of different antioxidants such 
as sodium ascorbate, selenomethionine or sodium thiosulphate is currently 
under investigation in our laboratory.  
Because of the short half-life of 68Ga, the stability of 68Ga-r-BHD was 
assessed by UHPLC after a maximum of 180 min from preparation. As 
shown in Fig. 7.3a, when the preparation was mixed with a 0.9% NaCl or a 
4% albumin solution, 68Ga (III) remained almost completely in the 
coordinated form during the assessment period, whereas the RCP 
decreases to 90±1% after 180 min when tested in human serum. Under this 
condition, the activity dissociated from 68Ga-r-BHD corresponded to about 
6.2% and could be attributed to 68Ga-hydrolysed by-products obtained under 
physiological conditions (UHPLC-ob- served retention time was 1.35 
min). The formation of these by-products can be because of the 
suboptimal properties of DOTA chelator in the context of 68Ga a 
coordination with respect to larger cations such as 90Y or 177Lu. 
Decomplexation and transchelation from DOTA to competitor serum 
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proteins, such as transferrin, can bring about rapid hydrolysis of 68Ga 
a(III) at human serum pH. 
As radiolabelled biocytin analogues were used in clinical trials not only 
per se but also coupled with a preinjection of Av [2,3,10,11], we tested 
the binding of 68Ga-r-BHD and Av at varying Av/radiotracer molar ratios 
and for the specificity of the bindings itself. The studies were conducted in 
a 0.9% NaCl solution and in healthy human serum to mimic the 
behaviour of the Ga-r-BHD in vivo (Fig. 7.3b). At the natural 1:4 molar 
ratio, 62±2% of Ga-r-BHD was bound to Av in saline, whereas the 
percentage was 80±2% in serum. Comparing these findings, we 
concluded that some proteins present in high concentra- tion in human 
serum, such as albumin or transferrin, can aspecifically bind Ga-r-BHD 
and de-facto decrease the calculated 4:1 radiotracer/Av molar ratio. As a 
result, an increase in the radioactivity amount measured in the top part 
of the Amicon devices in serum with respect to saline solution was 
found. The contribution of these proteins to the total activity with 
respect to Av itself is evaluated to be around 20%. This conclusion is 
also supported by the experiments performed with a 100-fold excess of 
natural biotin, in which a percentage of only 5% 68Ga-r-BHD bound to 
Av was found in the 0.9% NaCl solution, whereas the percentage in 
serum remained around 20%. The amount of 68Ga-r-BHD bound to Av 
remained almost constant over 180 min from the incubation both in 




The feasibility of labelling a reduced biocytin derivative coupled with DOTA, 
namely, r-BHD, with 68Ga has been investigated in depth. The safety of the 
preparation has been assessed and the products obtained have been 
characterized by developing a complete set of quality controls. The high 
affinity of 68Ga -r-BHD to Av and the stability of both the 68Ga-r-BHD/Av 
complex and 68Ga-r-BHD itself make the radiopharmaceutical suitable for 
acquiring PET images. 68Ga-r-BHD per se or with preinjection of Av appears 





Figure 7.3: (a) Stability of Ga-r-BHD in different media at 37°C (56 nmol of r- BHD, 
sodium formate buffer, pH = 3.8). (b) Percentage of 68Ga-r-BHD bound to Av as a function 
of the r-BHD/Av molar ratio in different media. (c) Stability of the Ga-r-BHD/Av complex 
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Conclusions and future perspectives 
 
In conclusion, we demonstrate that the use of 99mTc-HMPAO-WBC 
scintigraphy is beneficial in patients with a high clinical probability of 
infected endocarditis and suspected infections of cardiovascular implantable 
electronic devices or vascular grafts. The main indications of 99mTc-HMPAO-
WBC scintigraphy are the confirmation of diagnosis in doubtful 
circumstances, defining the extent of device involvement, and the detection 
of associated complications and septic embolisms, thus potentially 
determining treatment strategy. SPECT/CT combined technology is preferred 
to visulaize infection by 99mTc-HMPAO-WBCs, confirming or excluding the 
diagnosis of infection. In addition, 99mTc-HMPAO-WBC scintigraphy might 
be used to monitor the response to antimicrobial treatment. Whole-body 
images followed by additional planar spot and SPECT/CT images allow to 
detect distant sites of septic embolism,  constituting an invaluable aid of this 
scintigraphic procedure in the management of patients with IE, CIED or VPI. 
The next step to complete the process of validation of scintigraphy 
with 99mTc-HMPAO-WBC is to introduce this diagnostic procedure within 
the clinical guideline. To this aim, within the European Association of 
Nuclear Medicine (EANM) we have started the discussion together with the 
European Society of Cardiology, Thoracic Surgery and Vascular Surgery 
trying to design the most suitable diagnostic clinical algoritm that include 
99mTc-HMPAO-WBC and [18F]FDG PET/CT. Indeed, the first results of this 
collaboration will soon be published containing a proposed diagnostic flow-
chart for patients with endocarditis and suspected vascular graft infections. 
The proposed diagnostic flow-chart are shown in Figure 8.1, 8.2 and 8.3.   
Before completing the clinical validation of 99mTc-HMPAO-WBCs 
SPECT/CT and [18F]FDG PET/CT it is still need to identify advantages and 
limitations of each diagnostic technique. To this regard a well designed 
multicentre prospective clinical trial, that will compare the diagnostic 
performances of each method using the final microbiological and histological 
diagnosis as gold standard, will provide the answer to these open questions. 
Such clinical trial will also give the possibility to better investigate and 
understand which paramether can significantly affect the scintigraphic results 
as the type of microorganism, the effect of prolonged antimicrobial teraphy 
with new moleculesactive on biofilm, etc.  
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In addition, continuous efforts are required to make new 
radiopharmaceuticals for PET/CT to image infectious processes. Indeed, 
besides well established limitations, [18F]FDG is the only PET 
radiopharmaceutical commercially available for imaging infections. 
Therefore, the development of efficient radiolabelling procedures of WBCs 
with long-lived positron emitter isotopes and labelling new small molecules 
specific for bacterial imaging, will represent a fundamental step to further 
increase the use of molecular imaging in all patients suffering from 
infections. In this view we are preparing the first clinical application of 68Ga-
DOTA-Biotin in human with the aim of defining the biodistribution 
proprieties and the diagnostic performances of this new radiopharmaceutical. 
Furthermore, we are also working at the possible development of new biotin-
derivatives suitable for the radiolabelling with 99mTc-pertecnetate that, in case 
of success, will allow cheaper and wider use.    
When suitable PET radiopharmaceuticals will be available, this will 
eventually translate in improvements in the diagnosis and management of 
infectious diseases. In addition, it would also open new perspective for 
investigating a promising hybrid technology where PET is combined with 
MRI (PET/MRI). Indeed, nearly a decade after the introduction of PET/CT, 
combined PET/MRI systems have become available first in the pre-clinical 
settings and subsequently for clinical applications. PET/MRI scanners have 
been technically developed ahead of detailed considerations for many 
important pratical issues including clinical applications that would benefit 
exclusively from simultaneous imaging acquisition or dual-modality imaging 
probes, as in the case of heart and vessels. One of the great advantage of MRI 
over CT is its excellent soft-tissue contrast in combination with high spatial 
resolution along with absence of radiation burden. Therefore the use of 
PET/MRI in combination with specific infection tracking 
radiopharmaceuticals could significantly improve the sensitivity and 
specificity for diagnosing inflammatory and infectious, allowing more 
accurate assessment of sites of infection/inflammation as weel as of their 
extent rather than PET-CT expecially in case of soft tissues, cardiac and 
vascular structures. Furthermore, multiparametric and functional imaging 
such as dynamic contrast enhancement (DCE), diffusion weighted imaging 
(DWI) and spectroscopy as well as  combined new paramagnetic nano-cell-
contrast agent with radiolabelled probes could be used for histological 
characterization of tissues in vivo and could provide more insight into the 
dynamics and characteristics of the inflammatory/infectious processes.  
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The pivotal questions are whether simultaneous PET/MRI may 
provide a competitive advantage over separate clinical examinations and 






Figure 8.1: diagnostic flow-chart for native valve IE proposed by the Infection and 
Inflammation Committee of the European Association of Nuclear Medicine and shared with 
the European Society of Cardiology and the European Society of Clinical Microbiology and 







Figure 8.2: diagnostic flow-chart for prosthetic valve IE proposed by the Infection and 
Inflammation Committee of the European Association of Nuclear Medicine and shared with 




Figure 8.3: diagnostic flow-chart for prosthetic valve IE proposed by the Infection and 
Inflammation Committee of the European Association of Nuclear Medicine and shared with 
the European Society for Vascular Surgery and the European Society of Clinical 





In the beginning of the project, the main indication for imaging of 
infection using scintigraphy with 99mTc-HMPAO radiolabelled 
leukocytes, musculoskeletal infections. In fact, despite the enormous 
potential of the techniques very few patients were referred for the 
evaluation of infections of other tissues or devices.  
In 2005 the first SPECT/CT hybrid scanner (Infinia, GE) was 
introduced in our center followed just after the installation of a PET/CT 
system (Discovery ST, GE). This was the opportunity to start expanding 
our clinical experience in the field of infectious disease. In particular, 
infections of the cardiovascular system were a challenge. There was a 
clinical need of identifying patients with a high probability of infection, 
but undetermined results after a first line clinical management that 
include blood chemistry, echocardiography and blood culture  as well as 
for antimicrobial treatment evaluation during ascertained infection. In 
addition, the widespread use of PET/CT and [18F]FDG have created the 
need of a comparative evaluation of the two procedures. Using 99mTc-
HMPAO radiolabelled leukocytes scintigraphy enhanced specificity is 
expected, whereas a higher sensitivity is expected using [18F]FDG 
PET/CT imaging.  
Therefore, in this work we applied 99mTc-HMPAO radiolabelled 
leukocytes in patients with infective endocarditis (chapter 2). Clinical 
performance of the Duke Endocarditis Service criteria to establish the 
diagnosis of infectious endocarditis can be improved through molecular 
imaging procedures as 99mTc-HMPAO-WBC SPECT. Therefore we 
assessed the value of 99mTc-HMPAO-WBC with SPECT/CT in a cohort 
of 131 patients with suspected IE. No false positive results were found, 
even in patients with early IE, whom were evaluated within the first two 
months after the surgical procedure. Most of the added value from the 
99mTc-HMPAO-WBC scan for decision-making was seen in patients of 
whom the Duke criteria indicated "possible" IE. The scan was also 
valuable in patients with negative and/or difficult-to-interpret 
echocardiographic findings. Our results demonstrate the ability of 99mTc-
HMPAO-WBC to reduce the rate of misdiagnosed IE, when combined 
with the standard diagnostic tests, (a) in patients with a high clinical 
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probability but inconclusive echocardiographic findings; (b) for the 
differential diagnosis of septic and sterile vegetations detected by 
echocardiography; (c) when echocardiographic, laboratory and clinical 
data are contradictory; (d) to exclude valve infection (especially of a 
prosthetic valve) during febrile episodes, sepsis or post-surgical 
infections. 
Cardiovascular device related infections are discussed in chapter 
3. 99mTc-HMPAO-WBC SPECT/CT had a 94% sensitivity for both 
detection and localization of CIED-associated infection. SPECT/CT 
imaging had a definite added diagnostic value over both planar and 
stand-alone SPECT. Pocket infection was often associated with 
infections of the lead(s).The intracardiac portion of the lead(s) more 
frequently exhibited 99mTc-HMPAO-WBC accumulation and presented 
the highest rate of complications, infectious endocarditis and septic 
embolism. None of the patients with negative 99mTc-HMPAO-WBC 
scintigraphy develop CIED infection during follow-up until after 12 
months. 99mTc-HMPAO-WBC scintigraphy was able to confirm the 
presence of CIED-associated infection, to define the extent of device 
involvement, and to detect associated complications. Moreover, 99mTc-
HMPAO-WBC scintigraphy reliably excluded device-associated 
infection during a febrile episode and sepsis, with a 95% negative 
predictive value. 
Vascular graft prosthesis are discussed in chapter 4. In patients 
with suspected late and low-grade late vascular prosthesis infections 
99mTc-HMPAO-WBC using SPECT/CT demonstrated a significant 
reduction of false positive findings in 37% of patients (sensitivity and 
specificity were both 100% of SPECT/CT versus 85.1% and 62.5% of 
SPECT stand-alone). 99mTc-HMPAO-WBC SPECT/CT is useful to 
detect, localize and define the extent of graft infection in patients with 
late and low-grade late VPI with inconclusive radiological findings. 
99mTc-HMPAO-WBC SPECT/CT might be used to optimize treatment 
decisions. In fact, perioperative mortality was 5.5%, mid-term mortality 
12%, and long term-mortality 27%. Survival rates were similar in 
patients treated with surgery and antimicrobial therapy, as compared to 
patients treated with antimicrobial therapy alone (61% versus 63%), 
while infection eradication at 12 months was significantly higher when 
surgery was performed (83.3% versus 45.5%). 
In addition to these investigations, we tried to established how 
the use of standardized imaging acquisition protocols (Chapter 5) and 
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new, bacterial specific, radiopharmaceuticals may improve the accuracy 
of scintigraphy (Chapter 6 and 7).  
In Chapter 5 we compared the analysis of 99mTc-HMPAO-WBC 
scans in patients using a fixed-time acquisition protocol with a time-
decay corrected acquisition protocol.The most accurate imaging 
acquisition protocol is scanning at 3-4h and at 20-24h after radiolabelled 
leukocyte injection, corrected for isotope decay. When using this 
protocol, visual analysis of the scans leads to high sensitivity and 
specificity for diagnosis of infection. Semi-quantitative analysis might 
be used in doubtful cases, without using a cut-off for the percentage of 
increase in radiolabelled WBC as a criteria to define a positive scan. 
In chapter 6, we evaluated the possibility of an illicit transport of 
indium-111 labelled diethylene- triaminepentaacetic  acid  a,o-
bis(biocytinamide) (111In-DTPA-Biotin), already shown as a specific 
tracer in nuclear medicine imaging of vertebral osteomyelitis. To this 
aim we evaluated 111In-DTPA-Biotin was evaluated in cultures of 
Staphylococcus aureus on continued incubation for 24 h. Our results 
seem to demonstrate the mechanism of 111In-DTPA-Biotin uptake 
seems to be a passive process in which the radiolabelled biotin is 
presumably taken from the environment and stored, rather than 
destroyed by nonproliferating living organisms.  
In Chapter 7 the labelling of a biocytin analogue, coupled to 
DOTA, with gallium-68 (68Ga-r-BHD) was optimized, and the quality 
and stability of the preparations were assessed for clinical use. In 
addition, the influence of the precursor amount (from 2.5 to 140 nmol), 
the pH of the reaction (from 2 to 5.5) and the buffer species (1.5 mol/l 
sodium acetate, 1.5 mol/l sodium formate, 4.5 mol/l HEPES) on 
radiochemical yield and radiochemical purity were assessed. Studies on 
the stability and binding of the 68Ga-DOTA-Biotin to avidin (Av) in 
different media were also conducted. Under the best labelling condition 
(56 nmol of precursor, 3.8 pH, sodium formate buffer) synthesis of 
68Ga-DOTA-Biotin resulted in a yield of 64±3% (not decay corrected). 
Radiochemical purity was around 95% because a 68Ga-coordinated 
sulphoxide form of the ligand was detected as a by-product of the 
reaction (68Ga-r-SBHD). The by-product was identified and 
characterized by liquid chromatography–electrospray ionization tandem 
mass spectrometry. At the natural 1:4 Av/68Ga-r-BHD molar ratio, 
affinity results were 62±2 and 80±2% in saline and human serum, 
respectively. Stability of 68Ga-r-BHD and of the radiotracer/Av complex 
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remains almost constant over 180 min. 68Ga-r-BHD appears to be a good 
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